Contents lists available at ScienceDirect

Progress in Neurobiology

journal homepage: www.elsevier.com/locate/pneurobio

Nanotechnology, nanotoxicology, and neuroscience

Won Hyuk Suh [a], Kenneth S. Suslick [b], Galen D. Stucky [a], Yoo-Hun Suh [c,*]

[a] Department of Chemistry and Biochemistry, Materials Department, University of California, Santa Barbara, CA 93106, USA
[b] Department of Chemistry, School of Chemical Sciences, University of Illinois at Urbana-Champaign, 600 S. Mathews Ave., Urbana, IL 61801, USA
[c] National Creative Research Initiative Center for Alzheimer's Dementia, and Neuroscience Research Institute, Medical Research Center, Department of Pharmacology, College of Medicine, Seoul National University, 28 Yeongeon-dong, Jongno-gu 110-799,South Korea

ABSTRACT

Nanotechnology, which deals with features as small as a 1 billionth of a meter, began to enter into mainstream physical sciences and engineering some 20 years ago. Recent applications of nanoscience include the use of nanoscale materials in electronics, catalysis, and biomedical research. Among these applications, strong interest has been shown to biological processes such as blood coagulation control and multimodal bioimaging, which has brought about a new and exciting research field called nanobiotechnology. Biotechnology, which itself also dates back ∼30 years, involves the manipulation of macroscopic biological systems such as cells and mice in order to understand why and how molecular level mechanisms affect specific biological functions, e.g., the role of APP (amyloid precursor protein) in Alzheimer's disease (AD). This review aims (1) to introduce key concepts and materials from nanotechnology to a non-physical sciences community; (2) to introduce several state-of-the-art examples of current nanotechnology that were either constructed for use in biological systems or that can, in time, be utilized for biomedical research; (3) to provide recent excerpts in nanotoxicology and multifunctional nanoparticle systems (MFNPSs); and (4) to propose areas in neuroscience that may benefit from research at the interface of neurobiologically important systems and nanostructured materials.

© 2008 Elsevier Ltd. All rights reserved.

* Corresponding author. Tel.: +82 2 740 8285; fax: +82 2 745 7996.
E-mail address: yhsuh@snu.ac.kr (Y.-H. Suh).

Abbreviations: 3T3, derived from primary mouse embryonic fibroblast cells, 3-day transfer, inoculum 3×10^5 cells; A-431 (or A431), human epithelial carcinoma cell line; A549, human lung epithelial cell line; Ab, antibody; Aβ, amyloid beta; AD, Alzheimer's disease; ADDL, amyloid β-derived diffusible ligand; AFM, atomic force microscopy; AM, alveolar macrophages; APP, amyloid precursor protein; AsPC-1, human pancreatic cancer, epithelial cell line; A*STAR, Agency for Science Technology and Research; ATP, adenosine triphosphate; BAL, bronchoalveolar lavage; BBB, blood–brain barrier; BD-AM, primary alveolar macrophages from beagle dogs; BEAS-2B, human bronchial epithelial cell lines; BET, Brunauer, Emmett and Teller; β-Gal, β-galactosidase; bipy, 2,2'-Bipyridine; BRL 3A, rat liver derived cell lines; BSA, bovine serum albumin; BV2 (or BV-2), murine brain microglia; C57BL/6, C57 black 6, most common inbred lab mouse; CAT, catalase; CBEN, Center for Biological and Environmental Nanotechnology; CFP, cyan fluorescent protein; CFU, colony forming unit; CNS, central nervous system; CNT, carbon nanotubes; Colon-26 (or Colon 26), murine rectum carcinoma cell line; CREKA, Cys-Arg-Glu-Lys-Ala; CRL8798, normal breast epithelial cell line; CRP, C-reactive protein; DHED, dehydroevodiamine hydrochloride; DLS, dynamic light scattering; DMEM, Dulbecco's Modified Eagle's Medium; DMSO, dimethyl sulfoxide; DNA, deoxyribonucleic acid; DOX, doxorubicin; EC, endothelial cell; EC_{50}, half maximal effective concentration; EGFP, enhanced GFP; EM, electron microscopy; ESEM, environmental SEM; FITC, fluorescein isothiocyanate; FRET, fluorescence resonance energy transfer; GAP-43, growth associated protein-43; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; GPX (GPx or GSH-Px), glutathione peroxidase; GR, glutathione reductase; GSH, glutathione; H&E staining, hematoxylin and eosin staining; HA, hydroxyapatite; HAEC, human aortic endothelial cell; HEK293, human embryonic kidney 293 cells; HeLa, human cervical cancer cell line derived from Henrietta Lacks; HER, human epidermal growth factor receptor; hMSC, human mesenchymal stem cell; HPRT, hypoxanthine–guanine phosphoribosyltransferase; HRTEM, high resolution transmission electron microscope; HT-1080 (or HT1080), human fibrosarcoma cell line; HT-22 (or HT22), mouse hippocampal nerve cell line; IACUC, Institutional Animal Care and Use Committees; IBN, Institute of Bioengineering and Nanotechnology; ICON, International Council on Nanotechnology; ICP-MS, inductively coupled plasma mass spectrometry; IEP, isoelectric point; IMN, immuno-magnetic nanoparticle; ISI, Institute for Scientific Information; IUPAC, International Union of Pure and Applied Chemistry; J774A.1, murine macrophage; Jurkat, human T lymphocyte cell line; K-562 (or K562), human myelogenous leukemia cell line; L929, murine fibroblast; LBNL, Lawrence Berkeley National Laboratory; LDH, lactate dehydrogenase; LD_{50}, lethal dose for 50% of population; LPO, lipid peroxidation; MCF, mesocellular siliceous foam; MCF-7, human breast carcinoma cell line; MCM-41, Mobil Catalytic Material number 41

Contents

1. Introduction to nanomaterials

The science and technology of nanoscale materials has roots as old as chemistry itself, from the formulation of precious metal colloids for medieval stain glass to the Roman's use of cement (Bergna, 1994; Delatte, 2001; Edwards and Thomas, 2007; Faraday, 1847; Sanchez et al., 2003). As a separate field, nanoscience and nanotechnology began to emerge some 20 years ago (Hodes, 2007), and a database search yields more than 500 review articles in this area. For our discussions here, we will focus on materials with domain dimensions below 100 nm (nm = 1 billionth of a meter), e.g. length scales below those observable by simple optical or even confocal microscopy (Fig. 1). For scale, nanosized objects are 100–10,000 times smaller than the size of mammalian cells.

The molecular level contents of neurobiologically important systems are proteins, nucleic acids, lipid bilayers, metal ions, and small molecules, whose sizes are shown schematically in Fig. 1 (lower panel). At this size scale, the most important structural characterization techniques include X-ray crystallography, nuclear magnetic resonance (NMR), scanning, transmission electron microscopy, and optical/fluorescence/confocal microscopy. For instance, the amyloid precursor protein (APP) (Kong et al., 2007; Suh and Checler, 2002) shown as a biomolecule in Fig. 1 (lower panel) is an actual X-ray crystal structure visualized using VMD (visual molecular dynamics) (Humphrey et al., 1996). Compared to this biomolecule, a small molecule such as dehydroevodiamine hydrochloride (DHED) (Ahn et al., 2004; Decker, 2005; Park et al., 1996, 2000; Suh et al., 2005), a potent Alzheimer's disease (AD) candidate therapeutic agent, is much smaller in size. Micron sized nanostructured microspheres are readily endocytosed into the cytosol and can carry nanosized cargo into neurobiologically relevant systems (Suh et al., 2006a,b). In this review, we examine several important nanostructured materials that may interface well with neurobiologically important systems and find use in the neuroscience community.

Fig. 1. The sizes of biologically relevant entities. (Top row above scale bar) From left to right: (a) Potent Alzheimer's disease candidate drug, dehydroevodiamine HCl (DHED) X-ray crystal structure, (b and c) porous metal oxide microspheres being endocytosed by BV2 microglia cell (close-up and low magnification) SEM images, (d and e) SEM and fluorescence micrograph of DHED microcrystals (DHED is blue-green luminscent). (Bottom row below the scale bar) Left to right: Small molecules, such as dopamine, minocycline, mefenamic acid, DHED, and heme, are ~1 nm or smaller. The lipid bilayer is a few nanometers thick. A biomolecule such as a (22 bp) microRNA and a protein is only a few nanometers in size. A single cell or neuron is tens or hundreds of microns in size. Illustration of a human brain which is tens of centimeters in size.

2. Engineered nanomaterials: overview and recent advances

2.1. The first nanoparticles: carbonaceous nanomaterials

Arguably the oldest and easiest nanoparticles to make are of carbon: the use of carbon black from fuel-rich partial combustion for ink, pigment, and tatoos dates back more than 3000 years, but still remains a topic of current research interest (Lee et al., 2006b; Lu and Schuth, 2006; Xia et al., 2006b). The largest modern use of nanophase carbon, by far, is as filler in rubber tires, for which >8 million metric tons are produced each year; roughly another million tons are used as pigments (What is carbon black?). Various synthetic carbon materials exist that have nanometer scale features. Macroporous carbon materials can be created via inverted opal synthesis (colloidal template method) but these materials are usually amorphous (Lee et al., 2006b). Crystalline carbon nanomaterials can be created via high voltage arc electricity, laser ablation, or growth under high temperatures with metal-based precursors or nanoparticles as catalysts (Dai, 2002; Jiao et al., 1996; Satishkumar et al., 1999). In addition, fullerenes (e.g. C_{60}, C_{72}) and carbon nanotubes, either single-walled or multi-walled, can be synthesized in this way (Burghard, 2003; Dai, 2002; Dosa et al., 1999; El Hamaoui et al., 2005; Hayashi et al., 1996; Hu et al., 1999; Iijima, 1991; Iijima et al., 1999; Iyer et al., 2003; Kroto et al., 1985; Lei et al., 2006; Lu et al., 2006; Odom et al., 1998; Rinzler et al., 1998; Sano et al., 2003; Terrones et al., 1997; Thess et al., 1996). These more sophisticated carbon nanomaterials are finding a variety of applications for electronics (Dai, 2002; Odom et al., 1998), catalysis (Kim et al., 2000), chemical sensing (Barone et al., 2005; Heller et al., 2005, 2006; Jeng et al., 2006; Zheng et al., 2003), and cell biology (Carrero-Sanchez et al., 2006; Dumortier et al., 2006; Kam et al., 2004; Yan et al., 2006). The scope of this review limits us from extensively discussing carbon-based nanomaterials; we will, however, cover some newer versions of carbon nanomaterials in Section 3.2.

Interestingly for neuroscience, Silva (2005) recently reviewed a list of fullerene (C_{60}) derivatives studied both *in vitro* and *in vivo* for their neuroprotective ability. The model material responsible for providing neuroprotection is fullerenol which is hydroxyl functionalized fullerene. More recently Yamawaki and Iwai (2006), however, reported the *in vitro* toxicity of fullerenols in human umbilical vein endothelial cells (ECs) that were treated with 1–100 μg/mL concentrations (average diameter 4.7–9.5 nm)

for a day which induced cytotoxic morphological changes as well as showing cytotoxicity via LDH and WST assays in a dose-dependent manner. Eight day chronic treatment (10 μg/mL) also inhibited cell attachment and delayed EC growth. Varying biological effects of a single nanomaterial such as the hydroxy fullerene offers a clear demonstration of extraordinary situations where a single nanomaterial plays both beneficial (neuroprotection) and unfavorable (specific cell toxicity response) roles within a biological system. Choosing, utilizing, and assessing toxicity of any nanostructured material for biomedical applications are not trivial tasks especially for neuroscience applications where biological systems involved in the bioprocesses are more vital functions such as the central nervous systems (CNS) which include the brain and the spinal cord.

Carbon nanotubes, owning to their structural robustness and synthetic versatility, have been utilized in multiple biomedical applications including tissue engineering. Recently, Kotov and co-workers have formulated a nanocomposite matrix comprised mainly of single-walled carbon nanotubes (SWCNT) which was utilized as a growth substrate for murine embryonic neural stem cells (Jan and Kotov, 2007). Differentiation, growth, and biocompatibility reported by the authors supported positive uses of such nanocomposites but a more recent article by Zhu et al. (2007) showed DNA damages (genotoxicity) induced by multi-walled carbon nanotubes (MWCNT) in mouse embryonic stem cells. This additional example clearly demonstrates realistic dilemmas researchers can face while choosing carbon-based as well as other types of nanostructured materials for biomedical uses.

2.2. Porous nanomaterials

Long before the recent interest in nanoscience, the IUPAC divided porous materials and pore size into three categories, microporous (<2 nm), mesoporous (2–50 nm), and macroporous (>50 nm) (Rouquerol et al., 1994; Ying et al., 1999; Zdravkov et al., 2007). There is some confusion, however, in the increasingly popular use of "nanoporous" to describe all three of these categories. Synthesis methods for such materials range from crystal engineering to cooperatively assembled template methods and sol–gel chemistry (Boettcher et al., 2007; Eddaoudi et al., 2001). In this section an overview of the synthetic methods to achieve meso- and macroporosity will be briefly covered.

One of the biggest challenges in porous material synthesis is the precise controlling of the pore size while maintaining overall structure integrity as well as overall size (Alfredsson et al., 1994). Mesoporous materials such as MCM-41 (Beck et al., 1992) and SBA-15 (Zhao et al., 1998a,b), and MCF (Han et al., 2007, 1999; Schmidt-Winkel et al., 1999) have been the most successful porous materials to date and their application in catalysis (Boettcher et al., 2007; Corma, 1997; Ying et al., 1999) has been particularly interesting. Synthesis of mesoporous materials involves the use of a surfactant or block copolymer and a polymerizing inorganic precursor, preferably carried out at a pH near the isoelectric point (IEP) of the inorganic species (Huo et al., 1994). It is a cooperative molecular assembly process (Monnier et al., 1993; Huo et al., 1994) that makes use of all components of the synthesis solution.

Macroporous material syntheses using colloidal template methods have been the focus of recent research. Previously prepared colloidal particles (which can range in size from a few microns down to a few nanometers) are assembled into a "colloidal crystal", a regular array of close packed spheres, dried, and then a matrix-forming material is interspersed into the interstices between the colloidal particles. This initially liquid solution is then solidified (e.g. polymerized through heat or chemical reduction) and the original colloid particles removed by dissolution or pyrolysis, leaving a porous material whose pore size is controlled by the initial colloid. Materials of these kinds are sometimes referred to as inverse opals. Application of such macroporous materials has been in catalysis (Chai et al., 2004; Yoon et al., 2005), photonics (Norris and Vlasov, 2001; Vlasov et al., 2001), and tissue engineering (Liu et al., 2005b; Zhang et al., 2005), depending on the pore size and type of material. The new trend in porous material synthesis is to combine different levels of porosities (e.g. microporosity with macroporosity) or inclusion of porosities into materials whose overall dimensions are sub-micron (Yang et al., 1998; Yoon et al., 2002). The bio-applications of such materials include bioseparation, biosensing, drug delivery, and controlling bioprocesses in blood clotting (Blumen et al., 2007; Lee et al., 2006b; Ostomel et al., 2006a,b).

Briefly we will highlight few advances of porous nanomaterials that were designed and successfully used in several key biological applications. First, on the tissue engineering front, Desai and researchers utilized porous aluminum oxide membranes (prepared via electrochemical etching) as cell growth substrates for osteoblast cells which was a comparison study among several different porous and non-porous aluminum oxides. It turns out that the as-prepared nanoporous Al_2O_3 substrates showed improved attachment and proliferation of osteoblast cells both short-term and long-term compared to other examples (Swan et al., 2005a,b). More recently, Schmuki and co-workers have demonstrated that vertically aligned titanium oxide nanotubes (also prepared via electrochemical etching) can effectively direct the adhesion and proliferation of mammalian cells on anodized porous substrates (Park et al., 2007). The critical factor in the case of mesenchymal stem cells' adhesion, spreading, growth, and differentiation was the diameter of the as-prepared nanotubes which meant that the porosity of the substrate controlled the bioprocesses involved in stem cell biology to a noticeable degree. Adhesion and spreading of the mesenchymal stem cells (MSCs) were impaired which led to reduction of cellular level activity and eventual cell death when the diameter of the nanotubes increased beyond 50 nm. Such a dramatic influence arising from artificially created sub-100 nm size features is a direct testament that nanotechnology can effectively influence biological processes via careful tuning of variables such as size, volume, and surface electronic characteristics. Secondly, work related to blood coagu-lations, Grimes and co-workers showed that the electrochemically produced TiO_2 nanotubes (100 nm diameter with aspect ratio of approximately 1000) can enhance blood clotting rates (Roy et al., 2007). Metal oxide hemostatic agents such as porous zeolites and bioglass (SiO_2–P_2O_5–CaO) have been reported much earlier in time by Stucky and co-workers to effectively enhance the rate of clotting times both *in vitro* and *in vivo* (Ostomel et al., 2006a,b,c). These efforts demonstrated by the Stucky group illustrated that porous metal oxides can play key roles in controlling the bioprocesses involved in the blood clotting cascade. Details involved in Stucky group's work in the field of hemostasis will be provided in a later section within this review.

2.3. Magnetic nanomaterials

Magnetic properties of materials are controlled by temperature, applied field, alignment and relative orientation of the magnetic domains, and electronic spin states (Hyeon, 2003). Additionally, the size of the particles greatly alters magnetic properties (Campbell et al., 1999). As particle size is decreased to the few tens of nanometers, ferromagnetic materials will have only a single magnetic domain, and all magnetic spins within that domain will be aligned, while thermal motion of such particles relative to one another will control the bulk magnetic properties. These materials are referred to as superparamagnetic and are excellent MRI (magnetic resonance imaging) contrast agents (Gupta and Gupta, 2005; Murray et al., 2001; Wang et al., 2001).

Superparamagnetic inorganic oxides (SPIO) such as Fe_3O_4 are proving especially useful in tumor targeting and MRI imaging in biomedical applications (Huh et al., 2005; Jun et al., 2005; Lee et al., 2003; Song et al., 2005). Water-soluble superparamagnetic iron oxide (WSIO) nanoparticles, for instance, can be additionally passivated with cancer targeting agents (e.g. antibodies) and *in vivo* MRI imaging can be done to monitor the circulation and specific attachment to the cancer induced area (Huh et al., 2005). Iron oxides have also been utilized in bioimaging for neuroscience (Atanasijevic et al., 2006; Bulte et al., 2001; Cengelli et al., 2006; Dunning et al., 2004, 2006; Faber et al., 2007; Liu et al., 2007b; Moore et al., 2000; Muldoon et al., 2005; Neuwelt et al., 2007; Petropoulos et al., 1995; Rock et al., 2005; Sykova and Jendelova, 2007; Wadghiri et al., 2003). A recent review by Sykova and Jendelova (2007) highlights the use of labeled SPIO imaging agents for tracking migration and fate of adult stem cells *in vivo* with a focus in the central nervous system. Cell labeling can be done either on the surface of the cell or internalized into the cytoplasm but not the nucleus. The labeling contrast agent is usually comprised of a superparamagnetic core (e.g. Fe_3O_4), a water-soluble protective coat with functionalizable chemical groups (e.g. thiol, carboxylic acid), and a targeting agent (e.g. antibody).

Juillerat and co-workers have studied several different SPIO nanoparticles (both synthesized and commercially available) on their biological effects on brain-derived endothelial cells and microglial cells (Cengelli et al., 2006). Among the coated SPIO's, active uptake was observed in the amine functionalized case which should have a positive surface charge. This observation is in agreement with a previous report by Cheon and co-workers where cationic water-soluble iron oxide nanoparticles were efficiently transported into neural stem cells in comparison to the anionic counterparts (Song et al., 2005). The ideas behind such studies where particle uptake was increased via surface charge modification are two-fold: one is to increase the signal level of MRI and the other to achieve drug or small molecule delivery to specific cells and tissues. Recent researches have shown, however, that cationic surface charges (Xia et al., 2006a) and iron oxide (Pisanic et al., 2007) itself may have detrimental effects on cells so extensive

toxicology experiments should follow any type of *in vitro* and *in vivo* studies utilizing cationic iron oxide nanoparticles where dosage and procedures are carefully tuned and monitored.

Liu et al. (2007a,b) demonstrated the use of modified SPIO nanoparticles that can target cellular mRNAs and detect active transcriptions of specific mRNAs *in vivo* using antisense imaging agents (e.g. phosphorothioate oligodeoxynucleotide) coupled with MRI imaging. This type of research can lead to the development of real-time MRI detection methods where CNS disease models linked to mRNA alteration can be identified. On a slightly different note, Turnbull and Wisniewski, along with their co-workers, used Aβ1–40 peptide modified iron oxide nanoparticles to detect Aβ in transgenic mice *in vivo* (Wadghiri et al., 2003). In summary, magnetic nanomaterials, especially superparamagnetic iron oxides, can be utilized in three distinctive neurological applications which include tracking transplanted cells (e.g. stem cells), identifying transcription efficiencies, and detecting amyloid beta peptides in diseased brains.

2.4. Zeolites and clays

Dramatic responses observed in biomolecules and biomolecular processes involved in interfacial phenomena that involve inorganic surfaces are well demonstrated in biomineralization processes (Zaremba et al., 1996), biomolecular chromatographic separations (Kimura et al., 2004), supported enzyme activities and lifetime (Carrado et al., 2004; Han et al., 2002) and protein folding and denaturation (Charache et al., 1962). Mentioned earlier in Section 2.2, the development of potent wound-dressing materials (blood clotting agents) that are capable of arresting hemorrhage due to traumatic injury is another emerging application using materials chemistry to control bioprocesses (Ellis-Behnke et al., 2006; Fischer et al., 2005; Marris, 2007; Ostomel et al., 2006a) and one of the most effective wound-dressing materials currently available is a nanoporous zeolite called QuikClot® (QC) (Z-Medica). Alam et al. (2005) reported that among several different advanced wound-dressing materials tested using a swine model of fatal femoral injury QC exhibited the highest rates of survival.

The Stucky group has found that the isoelectric points of different inorganic surfaces, as measured in simulated body fluid (SBF), can be used as primary determinants to selectively and in a predictable manner accelerate or inhibit blood coagulation (Baker et al., 2007; Ostomel et al., 2007). One example of the many metal oxides based materials that were investigated was clays. Chemical and physical properties, including variable swelling capacities, particle morphologies, surface charge, and the ability to control the local electrolyte balance through ion exchange are tunable variables available in clay science. In a recent study, it was found that surface charge in SBF for clays such as kaolin correlated very well with the wide range of blood clotting activities of porcine whole blood or plasma (Baker et al., 2007).

Surface charge modulation is not the only way to direct the bioprocesses associated with the blood coagulation cascade as seen in the case of QC where local heating, dehydration, and electrolyte release also contribute to the overall biological process (Baker et al., 2007). Recent studies of the hemostasis properties of high-surface-area porous silica, the Stucky group has shown that the selective variation of window/pore sizes at the sub-50 nm range strongly dictated the rate at which blood clots are formed in human plasma (Baker et al., 2008). This indicates that pore sizes in this size range directly impact the accessibility and diffusion of clotting-promoting proteins to and from the interior surfaces of the porous silica particles. These studies point toward a critical pore size, ≥ 20 nm, at which clotting speed is maximized. Interestingly, this size regime very closely resembles the pore size at which electrochemically prepared porous TiO_2 nanotubes affected mesenchymal stem cell fate as highlighted earlier in this review (Park et al., 2007). Another important capability of such porous metal oxides is that the clotting times of plasma can be even further dramatically reduced by immobilizing selected enzymes within the large pores. This validates the utility of enzyme-immobilized mesoporous silicas in biomedical applications and further expands their possible use in the field of drug delivery systems (Han et al., 1999, 2002; Kim et al., 2006a, 2007b; Luckarift et al., 2004; Tischer and Wedekind, 1999). Porous metal oxides because of their surface chemistry and high internal surface area will allow facile incorporation of proteins in high loading. Fine tuning of nanostructured surfaces including pores and expanded structures to facilitate neurochemicals and important proteins involved in various biological pathways responsible for key neurological functions will prove to be key factors in the development of nanobiotechnology in the field of neuroscience along with the ability to incorporate and release such entities in a controlled fashion.

3. Nano–bio interface and nanotoxicology

3.1. Nano–bio interface

Proteins and nucleic acids have been the focus of many types of research involving nanotechnology (Kim et al., 2006a; Samori and Zuccheri, 2005; Sarikaya et al., 2003; Seeman, 2003; Zhao and Zhang, 2006). A single cell, usually tens of microns in size, is huge compared to a 10 nm nanoparticle (Figs. 1 and 2). In this sense, researchers around the world have been utilizing various inorganic, organic, and composite nanoparticles to study biological processes involved in drug delivery and cellular level bioimaging (Akerman et al., 2002; Allen and Cullis, 2004; Arap et al., 1998; Gref et al., 1994; Martin and Kohli, 2003). Recently, growing number of papers examine the interaction between a protein and a nanoparticle (Klein, 2007; Sui et al., 2005; Taylor et al., 2000). Compared to a 10 nm nanoparticle (Fig. 2), the APP and a small drug molecule (e.g. DHED) is extremely small which makes probing biologically relevant molecules on nanoparticles extremely difficult. In reality, an injected nanoparticle into a living system will have an uncountable number of interactions with the surrounding system regardless of size. Efforts studying the interface between nanostructured materials and biological systems starting with proteins and then the cell will be a key development that will aid in the study of bio-systems relevant to neuroscience, pharmacology, and medicine.

Studying the bio–nano interface is a very different task since there are no simple ways of probing the interaction in real time or *in situ*. On the other hand, nanotoxicology (the examination of bioeffects of nanomaterials) is a rapidly developing field of some direct relevance. Over the past few years, substantial efforts have begun in the study of the toxic effects of nanomaterials on the environment and living systems. For instance, University of California has a focused nanotoxicology program sphere headed by UCLA and UCSB under its UC Toxic Substances Research and Teaching Program (http://www.bren.ucsb.edu/news/press/nanotoxicology.htm; http://www.cnsi.ucla.edu/staticpages/education/nanotox-program). As a city, Berkeley (CA), for the first time in US history, has decided to regulate nanotechnology by law with UC Berkeley and LBNL (Lawrence Berkeley National Laboratory) being involved in many nanotech projects but without any implemented safety related protocols (Berkeley, 2006; Monica et al., 2007). Rice

Fig. 2. Size matters. (a) Compared to a 10 nm nanoparticle, proteins (e.g. APP; X-ray crystal structure obtained from www.pdb.org (Berman et al., 2000), protein ID 2FKL; visualization done by Accelrys Discovery Studio Visualization 1.7 software) and small molecules (e.g. DHED) are small in size and volume. A mammalian cell which is made up of proteins, nucleic acids, and other small to large molecules is thousand times larger in volume and size compared to a 10 nm nanoparticle. (b) Cell membrane incorporating various proteins and a single 10 nm nanoparticle.

University has a center called CBEN (Center for Biological and Environmental Nanotechnology) and an organization called ICON (International Council on Nanotechnology) dedicated to establishing a database for nanotechnology based materials (http://cben.rice.edu/; http://icon.rice.edu). The National Cancer Institute (NCI), not long ago, started a separate institution called NCL (Nanotechnology Characterization Laboratory) headed by a chemist investigating nanomaterials that are below 100 nm on a proposal submission and approval basis (http://ncl.cancer.gov/). Internationally, IBN (Institute of Bioengineering and Nanotechnology) governed by A*STAR (Agency for Science, Technology and Research) in Singapore is an interdisciplinary research park that brings together nanometer scale science with control over biological system (http://www.ibn.a-star.edu.sg/). IBN is headed by a materials scientist which is a sign that the institution has an emphasis more in the materials they make which will help to alleviate transfer of nanotechnology to be implemented in biotechnology.

In essence, a fundamental understanding of nanomaterial toxicology (nanotoxicology) is highly desirable both from the material's stand point as well as from the biological system's point of view. With the increase of commercial products from cosmetics to tennis balls, toxicology evaluations of nanoscale materials should receive greater attention than ever before whether it is the general public, the government, or the personnel involved in the development of nanomaterials (Colvin, 2003; Maynard et al., 2006; Nel et al., 2006; Oberdorster et al., 2005). For the field of neuroscience, the lessons learned from these nanotoxicology studies should help researchers to better choose the type of nanomaterial that can be utilized for studying, for instance, the synaptic plasticity of a neuron. In hopes of doing this, we will review the literature of how nanotoxicology has developed and provide few tables to ease the selection process of materials. With current data, however, it is often difficult to ascertain the toxicity of specific nanomaterials because, as with any small molecule (e.g. pharmaceuticals), toxicity is dose, exposure and pathway dependent. In addition, nanotoxicology studies on animals or cultured cells alone cannot predict in a good manner the effects it might have on human beings.

3.2. Nanotoxicology

Various types of engineered nanomaterials exist now thanks to the extraordinary and highly focused efforts from both industry and academia in recent years. The number of published papers

dealing with just the synthesis of nanostructured materials has grown exponentially (both 2006 and 2007 exceeds 3200 papers) (Fig. 3). Owing to this explosive increase in publications, hundreds of in vitro toxicological studies have been reported (Derfus et al., 2004; Gurr et al., 2005; Oberdorster, 2004; Ramires et al., 2002; Soto et al., 2005; Suh et al., 2006b; Yoshida et al., 2003), as well as numerous reviews and perspectives (Balbus et al., 2007; Borm and Kreyling, 2004; Colvin, 2003; Dobrovolskaia and McNeil, 2007; Garnett and Kallinteri, 2006; Handy and Shaw, 2007; Hardman, 2006; Maynard et al., 2006; Medina et al., 2007; Nel et al., 2006; Oberdorster et al., 2005). In vivo toxicology, on the other hand, which probes toxicity (i.e. LD_{50}, pathology) by inhalation, injection, and oral digestion, involves the test subject to internalize the test sample whether it is a small mice or a large mammal such as a dog or a monkey. It is, however, troublesome to test nanomaterials' toxic effects on whole animals since all of the synthetic engineering (Cushing et al., 2004; Dai, 2002; Huber, 2005; Jeong et al., 2007; Lee et al., 2006b; Lu et al., 2007a; Medintz et al., 2005; Michalet et al., 2005) is done very specifically by individual research groups and proprietary information on synthesis is hard to get especially from the industry. In addition, preparing/conducting/regulating an in vivo test is ethically and administratively challenging and individual research efforts have to work in partnership with the institutional approval organization(s) such as IACUC (Institutional Animal Care and Use Committees).


Fig. 3. Published papers in nanomaterials synthesis papers published in 1970–2007. Number of publications was obtained from ISI Web of Science (one of Thomson Scientific databases and part of Web of Knowledge) using a combination of search terms that represent nanomaterial and synthesis.

3.2.1. In vitro nanotoxicology

The easiest simple solution in assessing nanomaterial toxicology is utilizing various mammalian cells to test for viability or increase/decrease in a designated inherent biological pathway against chosen engineered nanomaterials. For instance, tetrazolium salt based assays (e.g. MTT (Mosmann, 1983) or WST (Ishiyama et al., 1996; Tominaga et al., 1999) are readily available commercially (i.e. Dojindo, Roche) and straightforward to use. Inorganic oxides (Gurr et al., 2005; Ramires et al., 2002; Soto et al., 2005; Suh et al., 2006b; Yoshida et al., 2003) such as TiO_2, SiO_2, Fe_2O_3, carbon-based materials (Jia et al., 2005; Oberdorster, 2004; Sayes et al., 2005; Soto et al., 2005; Zhu et al., 2006) such as nanotubes (Cui et al., 2005a; Donaldson et al., 2006; Garibaldi et al., 2006; Heller et al., 2005; Lam et al., 2004, 2006; Liopo et al., 2006; Manna et al., 2005; Maynard et al., 2004; Monteiro-Riviere et al., 2005; Shvedova et al., 2003; Singh et al., 2006b), C_{60}, and other nanoparticulates (Derfus et al., 2004; Soto et al., 2005; Yoshida et al., 2003) such as semiconductor quantum dots (Chang et al., 2006; Lovric et al., 2005a,b; Tsay and Michalet, 2005; Voura et al., 2004), metal nanoparticles have been evaluated by various research groups (excerpts given as Tables 1–5). The current biggest challenges which have been mentioned in previous papers (Maynard et al., 2006; Nel et al., 2006) might be establishing standard protocols (e.g. particle preparation and growth condition) and producing a reproducible and credible database, such as MSDS (Materials Safety and Data Sheet) for small molecules and effectively linking the toxicological information with physicochemical properties. It is, however, easy to identify a fairly non-cytotoxic material from seriously cytotoxic ones since materials like TiO_2 show very little overall cytotoxicity regardless of method or choice of laboratory (Gurr et al., 2005; Ramires et al., 2002; Soto et al., 2005; Suh et al., 2006b; Yoshida et al., 2003). Of course, there are different results arising from different types of assay conditions, the nature of the nanomaterial synthesis, and differences in physicochemical properties.

Another factor to consider is the fact that all of these nanomaterials are not exposed to a biological system in its pristine state (Fig. 4). Consider the DMEM (Dulbecco's Modified Eagle's Medium) liquid cell media and its contents which contain various inorganic salts, amino acids, vitamins and few other components. At least, six components have molar concentrations over 1 mM while fifteen components (mostly amino acids) have concentrations between 0.1 and 1 mM. On top of this, there is approximately 0.1 M of sodium chloride present and the overall molar concentration of small molecules is approximately 0.2 M (or 2 wt%). And this does not even include the various proteins in the serum that is usually supplemented in 5–10% fractions to the cell media. Realistically, when nanoparticles are added to a biologically relevant liquid medium their surface physicochemical properties will change over time depending on their physical conditions such as temperature (37 °C, the incubation temperature), light, and some form of agitation. In fact, several research groups have investigated adsorption of proteins and small molecules on nanomaterials and their effects on biological activity (Chan et al., 2007; Dutta et al., 2007; Wang, 2005; Wiesner, 2006; Yang et al., 2006b). Adsorption chemistry and physics of small molecules and biomolecules onto metal oxides have traditionally been a research topic in the physical sciences (Campbell, 1997; Diebold, 2003; Freund et al., 1996; Hofer et al., 2001; Lavalley, 1996; Rajh et al., 2002) so expanding on such work should greatly aid in the process of assessing nanomaterial toxicology. For instance, Mrksich and Whitesides (1996) wrote a review which dealt with how cells interact with small molecules adsorbed onto surfaces.

3.2.2. The cell–nanoparticle interface

Eventually, expanding the toxicity studies to mammals should be done but since it is practically impossible to test on a human subject it will be difficult to assess nanomaterials' effects on human beings with just animal studies alone. In addition, as mentioned previously, nanostructured materials will be in contact with some biologically relevant entity once it enters a biological system. This makes any biochemical assay or structural analysis irrelevant just on its own.

Biological effects of nanomaterials with a focus on toxicity have to be addressed since consumer products as well as medical tools increasingly utilize them one way or another (Maynard et al., 2006). Neuroscience has been linked to nanotechnology previously (Silva, 2006) so instead of repeating things from that particular review we would like to focus on biological effects of nanomaterials with a focus on toxicology and excerpts from recent advances that can potentially be beneficial to the neuroscience community. First, we would like to focus on several nanomaterials and show how researchers around the world have tried to assess their toxicity. Fig. 5 shows eight representative schemes of how a cellular organism can be affected by a nanoparticle: the cell–nanoparticle interface.

Reactive oxygen species (ROS) products whether it is inside or outside of the cell can be key factors in nanostructured materials toxicological effects (Nel et al., 2006). Event 1 represents a nanoparticle smaller than a cell (red particle) producing ROS which ultimately will affect cell membrane stability and cell survivability. If this nanoparticle is internalized, ROS production (event 2) (Nel et al., 2006), particle dissolution (event 3) (Borm et al., 2006), and mechanical damage to sub-cellular units (event 4) (Yamamoto et al., 2004) such as the nucleus will be very important events to monitor and analyze. In addition, different functional groups and surface electronics of the nanostructured materials will determine the level of interaction between the nanoparticles and their surroundings (event 5) (Karakoti et al., 2006; Kostarelos et al., 2007). Furthermore, overall size of the particle can play an important role since large particles can potentially induce permanent damage to the cell membrane while small particles can pass through the membrane and do harm inside the cell (event 6) (Yoshida et al., 2003). Non-spherical particles, on the other hand, might have a different biological response compared to the spherical nanoparticles (event 7) (Geng et al., 2007). Dissolution characteristics of the nanomaterials (whether it is outside the cell or inside) can affect the cell in various ways (event 8) (Borm et al., 2006). Limiting the interaction between a nanoparticle and a cell to eight events is an over simplification and the details of actual phenomena that are happening at the interfaces are very difficult to understand. In addition, the size differences among a 1 nm small molecule, a 4 nm protein, and a 10 nm nanoparticle are huge as shown in Fig. 2. Interaction parameters between these three entities coupled with various other molecules, ions, and particles will make the system highly complex (Fig. 4) to account for in a simple manner so applying systems biology (Ideker et al., 2001; Kitano, 2002a,b) approach could be an interesting option as a long-term research project.

On top of these eight nanotoxicology events, nanomaterials interaction with microbial organisms (Moreau et al., 2007) will be an interesting aspect to consider since biologically contaminated nanostructured materials will have detrimental effects on their utilization in biomedical applications (Fig. 6). For instance, mycoplasmas (Razin, 1978; Razin et al., 1998) have a size range below few hundred nanometers and they have become a rising concern in mammalian cell cultures including stem cells (Chen and Chang, 2005; Cobo et al., 2005, 2007; Rottem and Barile, 1993; Simonetti et al., 2007; Ware et al., 2006). If such microbial

Table 1

TiO$_2$ nanotoxicology.

Type	Crystal phase	Size and characteristics	Animal or cell type	Concentration	Assay	Results	Reference
1 Manufactured TiO$_2$	• Anatase • Rutile	• 5–40 nm/1–2 μm aggregate (surf. area = 55 m^2/g) • 2–60 nm/0.5–1.5 μm agg. (surf. area = 125 m^2/g) • Sizing by TEM	• Murine alveolar macrophage (RAW 264.7) • Human alveolar macrophage (THB-1) • Human lung epithelial cell line (A549)	Up to 10 μg/mL	*In vitro* bioassays MTT assay	• RAW 264.7 murine alveolar macrophage cell line EC$_{50}$ (anatase) = 10 μg/mL EC$_{50}$ (rutile) = non-cytotoxic • THB-1 human alveolar macrophage cell line EC$_{50}$ (anatase) = 5 μg/mL EC$_{50}$ (rutile) = non-cytotoxic • A549 human epithelial cell line EC$_{50}$ (anatase) = 1 μg/mL EC$_{50}$ (rutile) = non-cytotoxic • TiO$_2$ can be considered non-cytotoxic compared to Ag, Al$_2$O$_3$, Fe$_2$O$_3$, ZrO$_2$, Si$_3$N$_4$, asbestos, carbon nanoparticles	Soto et al. (2007)
2 Manufactured TiO$_2$	• 80% Anatase (TiO$_2$-1) • Rutile (TiO$_2$-2) • Anatase (TiO$_2$-3)	• 5–100 spherules/0.5–1 μm agg. • 5–15 nm short fibers/0.5–1.5 μm agg. • 5–40 nm spherules/1–5 μm agg. • Sizing by TEM	Murine alveolar macrophage (RAW 264.7)	Up to 10 μg/mL	*In vitro* bioassays MTT assay	• EC$_{50}$ (TiO$_2$-1, 80% anatase) = 10 μg/mL • EC$_{50}$ (TiO$_2$-2, rutile) = non-cytotoxic • EC$_{50}$ (TiO$_2$-3, anatase) = 10 μg/mL • TiO$_2$ can be considered non-cytotoxic compared to Ag, Al$_2$O$_3$, Fe$_2$O$_3$, ZrO$_2$, Si$_3$N$_4$, asbestos, carbon nanoparticles	Soto et al. (2005)
3 • DuPont ultrafine rutile TiO$_2$ (uf-1) • DuPont ultrafine rutile TiO$_2$ (uf-2) • Degussa P25 (uf-3) • DuPont rutile R-100 fine-TiO$_2$ (F-1) • α-Quartz particles	• Rutile • Anatase • 80/20 = Anatase/rutile • Rutile 99%, alumina coat 1% • Crystalline silica	• 2.1–2.9 μm in PBS • 129–382 nm in water • Sizing by DLS • Surface areas: F-1 = 5.8, uf-1 = 18.2, uf-2 = 35.7, uf-3 = 53.0 m^2/g	8-week-old male rats (210–280 g in weight)	• 1 or 5 mg/kg intratracheal instillation • PBS instilled rats were vehicle controls	*In vivo* lung toxicity assessment 1. Bronchoalveolar lavage (BAL) fluid inflammatory marker evaluation 2. Cell proliferation 3. Histopathology	• Toxic ranking: quartz > uf-3 > F-1 = uf-1 = uf-2 • uf-3 anatase/rutile TiO$_2$ particles produced pulmonary inflammation, cytotoxicity and adverse lung tissue effects • Inhaled rutile ultrafine-TiO$_2$ particles are expected to have a low risk potential for producing adverse pulmonary health effects • Cannot assume that all nanoparticle TiO$_2$ are toxic	Warheit et al. (2007)

4 • Nano-sized TiO$_2$ particles (Hangzhou Dayang Nanotechnology) • Fine TiO$_2$ particles (Zhonglian Chemical Medicine)	N/A	• 25 nm • 80 nm • 155 nm • Sizing by TEM	Adult mice (19 ± 2 g in weight)	• 5 g/kg (due to low toxicity) • Single oral administration (OECD Guidelines, No. 420)	*In vivo* 1. Histopathology of the brain, kidneys, liver, and the stomach tissues (hematoxylin–eosin staining) 2. Blood biomarker assay 3. Titanium ICP-MS	• TiO$_2$ particles showed no obvious acute toxicity in two weeks • Female mice liver affected by 25 and 80 nm TiO$_2$ • Hapatic injury observed due to various levels of TiO$_2$ exposure • TiO$_2$ gets retained in the liver, spleen, kidneys, and lung tissues (ICP-MS analysis)	Wang et al. (2007b)
5 Sigma–Aldrich nano-sized or ultrafine TiO$_2$ (UF-TiO$_2$)	99% TiO$_2$ but no crystal phase given	Sub-100 nm	Human B-cell lymphoblastoid cell line (WIL2-NS)	• 0, 26, 65 and 130 µg/mL • 6, 24, 48 h	*In vitro* bioassays 1. MTT assay 2. Population growth assay 3. Apoptosis assay (flow cytometry) 4. Cytokinesis-block micronucleus assay 5. Comet assay 6. HPRT gene mutation assay	• Significant decreases in viability were seen in the MTT assay at higher doses (130 µg/mL) • UF-TiO$_2$ can cause genotoxicity and cytotoxicity in cultured human cells.	Wang et al. (2007a)
6 • Pigment-grade TiO$_2$ • Nanoscale TiO$_2$ rods • Nanoscale TiO$_2$ dots • Quartz	• Rutile • Anatase • Anatase • Crystalline silica	• 300 nm (6 m^2/g) • 92–233 nm × 20–35 nm (26.5 m^2/g) • 5.8–6.1 nm spheres (169.4 m^2/g) • 1–3 µm (4 m^2/g) • TEM sizing	• 8-week-old rats (240–255 g in weight) • Lung parenchymal cells of rat	• 1 or 5 mg/kg intratracheal instillation • PBS instilled rats were vehicle controls	*In vivo* pulmonary bioassays 1. Bronchoalveolar lavage (BAL) fluid inflammatory marker evaluation 2. Cell proliferation 3. Histopathology	• No significant lung toxicity difference observed for TiO$_2$ nanorods and nanodots • Results not in line with previous studies which link increased surface area to being more toxic • Further study required to address particle size and surface area effects on lung toxicity	Warheit et al. (2006)
7 Sigma Titanium dioxide (TiO$_2$)	N/A	N/A	• Human whole blood cultures from four non-smoking healthy donors	• 1, 2, 3, 5, 7.5 and 10 µM • Sterile DMSO stock solution • Dilution in water	*In vitro* bioassays • Blood examination (oxidative stress markers) 1. Glutathione peroxidae (GSH-Px) 2. Glutathione reductase (GR) 3. Catalase (CAT) 4. Superoxide dismutase (SOD) 5. Sister chromatid exchange (SCE) 6. Micronuclei (MN)	• DNA damage by oxidative stress observed • GSH-Px, GR, CAT, SOD activity decrease • Sister-chromatid exchanges (SCEs) and micronuclei (MN) frequency increase • TiO$_2$ is a potential genotoxic agent for blood cells	Turkez and Geyikoglu (2007)

Table 1 (*Continued*)

Type	Crystal phase	Size and characteristics	Animal or cell type	Concentration	Assay	Results	Reference
8 • DegussaTiO$_2$ • Nanocrystalline synthetic TiO$_2$ (nano-TiO$_2$)	• Anatase/rutile = 80/20 • Anatase • Anatase/rutile = 60/40 • Rutile	• ~21 nm • 10.1 ± 1.0 nm • 3.2 ± 0.34 nm • 5.2 ± 0.65 nm	Human lung epithelial cell line (A549)	3 µg/mL to 30 mg/mL	*In vitro* bioassays 1. Viability 2. Live/dead staining 3. LDH release 4. MTT assay	• Cytotoxicity and inflammation observed over 100 µg/mL concentration • Reactive oxygen generation results in increased cytotoxicity • Anatase TiO$_2$ produced the most ROS thus was 100 times more cytotoxic compared to rutile under light conditions	Sayes et al. (2006)
9 TiO$_2$ microspheres	Anatase	• Average 1 µm spheres made up of sub-20 nm TiO$_2$ • SEM, TEM sizing	• Murine brain microglia (BV2) • Rat adrenal pheochromocytoma (PC12) • human neuroblastoma (SH-SY5Y)	• <1 µg/µL • 6 h to 6 days	*In vitro* bioassays 1.WST-1 assay 2. Endocytosis	• Non-cytotoxic up to 10 µg per 10^4 initial cells • Toxicity was observed for Co doped TiO$_2$	Suh et al. (2006b)
10 Degussa P25	Anatase/rutile = 70/30	• ~30 nm/826 nm to 2368 nm aggregates	• Murine brain microglia (BV2)	• 2.5–120 ppm • 6–18 h	*In vitro* bioassays 1. CellTiter-Glo assay 2. ROS assays	• Stimulate microglia to produce ROS • Neurotoxicity implication	Long et al. (2006)
11 NanoTiO$_2$	Rutile	NanoTiO$_2$ (19–21 nm) microparticles (180–250 nm)	• THP-1 cell lines • A549 cell lines	0.1 or 0.5 mg (intratracheal)	Immunostaining TUNEL staining	Pulmonary inflammatory response from 20 nm TiO$_2$	Chen et al. (2006a)
12 Flame synthesized	N/A	8 nm	• Human mesothelioma • Rodent fibroblast cell lines (3T3)	30 ppm for 3 days	*In vitro* bioassays MTT assay total DNA measurement DNA Hoechst assay	• Non-toxic up to 30 ppm for fibroblast • Some toxicity shown for mesothelioma cell	Brunner et al. (2006)
13 • Pigment-grade TiO$_2$ • Ultrafine TiO$_2$ (Degussa P25)	Rutile PG-TiO$_2$	• PG-TiO$_2$ (200–300 nm) • Ultrafine TiO$_2$ (10–20 nm)	Rats, mice and hamsters	• PG-TiO$_2$: 0, 10, 50, 250 mg/m^3 • UF-TiO$_2$: 0, 0.5, 2,10 mg/m^3	Lung burden	High clearance rates (hamsters)	Hext et al. (2005)
14 Ultrafine TiO$_2$	Anatase, rutile	Anatase-sized (20 nm)	Human bronchial epithelial cell lines (BEAS-2B)	0.01, 0.1, 1, 10 µg/mL for 3 days	*In vitro* bioassays MTT assay	Induce hydrogen peroxide (rutile-sized 200 nm)	Gurr et al. (2005)
15 Commercial (Altair)	N/A	40 nm	Rat liver derived Cell lines (BRL3A)	10, 50, 100, 250 µg/mL	*In vitro* bioassays MTT assay LDH assay glutathione levels	• No measurable effect (10–50 µg/mL) • Toxic at high conc.(100–250 µg/mL)	Hussain et al. (2005)

16 Commercial (Neturen, Ishihara Techno Corp.)	Anatase, rutile, mixture	• TiO$_2$-spherical: 30–50 nm • TiO$_2$-spindly: 10–20 nm × 50–100 nm • TiO$_2$–dendritic: 40–70 nm × 200–300 nm	• Murine fibroblast (L929) • Murine macrophage (J774A.1)	Assays probed by varying number, surface area, and volume of the particles	In vitro bioassays Colony formation assay	• Macrophage cells predict cytotoxicity better • Non-spherical TiO$_2$ lower cell viability	Yamamoto et al. (2004)
17 N/A	N/A	1–7 µm (longitudinal length)	Human lymphoblast (U937)	0.125, 0.25, 0.5, 1, 2 mg/well	In vitro bioassays LDH assay	• TiO$_2$ particles are the least toxic • SiO$_2$ > metal alloy > Al$_2$O$_3$ > TiO$_2$	Yoshida et al. (2003)
18 TiO$_2$/hydroxyapatite coated titania	N/A	N/A	Primary rat osteoblasts	TiO$_2$/HA ratio: 0.5, 1, 2	In vitro bioassays MTT assay	Non-cytotoxic	Ramires et al. (2002)
19 • fTiO$_2$ (Degussa) • ufTiO$_2$ (Degussa)		• 220 nm • 20 nm	• Primary alveolar macrophages from beagle dogs (BD-AM), • Macrophages (J774A.1)	10–320 µg UFP/mL/10^6 cells up to 24 h	Apoptosis and necrosis	Fine TiO$_2$ did not show any effects (cytoskeletal dysfunction)	Moller et al. (2002)
20 Commercial (Sigma Chemical Co.)	N/A	~1 µrn	Pulmonary Alveolar Macrophages	0.1, 0.5, 1, 5 mg/mL	In vitro bioassays MTT assay	Significantly lowered cell viability (0.5–5 mg/mL)	Kim et al. (1999)
21 Ultrafine TiO$_2$		Sub-20 nm	• Alveolar macrophages (AM) • Peripheral red blood cells (RBC) of rat	5 mg; single intratracheal	• Lipid peroxidation (LPO) • Glutathione peroxidase (GPx)	• Induction of H$_2$O$_2$ is maximum with crocidolite followed by chrysotile and minimum with UF-TiO$_2$ • Comparison to both the asbestos fibers, UF-TiO$_2$ induced far less toxicity	Afaq et al. (1998a)
22 Ultrafine TiO$_2$		Sub-30 nm	Rat alveolar macrophages (AMs), cell-free lavage fluid	2 mg per rat; single intratracheal	Lactate dehydrogenase	• Increased activities of LDH • Induction of antioxidant enzymes by these cells for self-protection is not sufficient to cope against the toxic action of UF-TiO$_2$, which may lead to oxidative stress	Afaq et al. (1998b)
23 • Degussa P25(UFI) • UV-TITAN Ml60 (UF2) • Pigmentary TiO$_2$ Kemira AFDC	• Uncoated anatase • Rutile coated • Uncoated anatase	• 20 nm • 20 nm • 170 nm	Rat liver epithelial cell lines	0, 5, 10, 50, 100, 200 µg/cm^2	Multinuclei assay (measure the inhibition of cell growth)	Ultrafine TiO$_2$ samples not toxic to cells at the concentration range of 5–200 µg/cm^2	Linnainmaa et al. (1997)
24 TiO$_2$-hexachloroethane and Zn-hexachloroethane pyrotechnic mixtures	N/A		Female rats	• Concentration of smoke was varied (acute inhalation) • Exposed to smoke for 1.25, 2.5, 5 or 10 min	• Histological evaluation • Smoke particle analysis	• The acute inhalation toxicity of TiO$_2$-HC smoke was much lower than the Zn-HC smoke • The animals survived exposure to TiO$_2$-HC smoke, even at relatively high smoke conc.	Karlsson et al. (1986)

Table 2
SiO$_2$ nanotoxicology.

Type	Crystal phase	Size and characteristics	Animal or cell type	Concentration	Assay	Results	Reference
1 Mesoporous SiO$_2$	Amorphous	• 130 nm by SEM, TEM • Amine and phosphate functionalized • Hexagonal and 2 nm pores	Cancer cells (e.g. PANC-1, AsPC-1)	• 6.4, 64 mg/mL, 6.4, 64 g/mL • 1 day	*In vitro* bioassays • WST assay • Apoptosis assay • Necrosis assay	• Non-toxic without cancer agent camptothecin • Toxic to cancer cells with cancer agent	Lu et al. (2007b)
2 Mesoporous and luminescent SiO$_2$	Amorphous	• 100–120 nm by TEM • 780–1050 m^2/g surface area • Rhodamine B incorporated • Hexagonal and 2–3 nm pores • (+) and (−) charged surfaces	• Adipocytes (3T3-L1) • Human mesenchymal stem cells (hMSCs)	• 0.1 mg/mL, 3 h (cytotoxicity) • 0.1 mg/mL, 1 day (proliferation)	*In vitro* bioassays • MTT assay	• Non-toxic regardless of surface charge • Adipogenic and osteogenic differentiation unaffected • Uptake efficient regardless of surface charge	Chung et al. (2007)
3 Multifunctional and luminescent SiO$_2$	Amorphous	• sub-50 nm by SEM, TEM • Amine/carboxylate/Gadolinium functionalized • Luminescent (Ru(bipy)$_3$$^{2+}$)	Monocyte cell (bone marrow progenitor cells from C57BL/6 mice)	• 0.012, 0.123, 1.23, 12.3, 123 μg/5000 cells • 1 day	*In vitro* bioassays • Cell viability assay	• Non-toxic	Rieter et al. (2007a,b)
4 Polymer and protein functionalized luminescent SiO$_2$	Amorphous	• 20 nm by TEM • Luminescent (Ru(bipy)$_3$$^{2+}$) • Polymer and protein coated	Jarkat T luekemia cell	• Concentration enough for fluorescence microscopy • 1, 3, 6 h	*In vitro* bioassays • Necrosis assay • Apoptosis assay	• Non-toxic • Apoptotic, necrotic profile same as nontreated	Bottini et al. (2007)
5 Organically modified SiO$_2$	Amorphous	• 20 nm by TEM • Porphyrin incorporating • ORMOSIL	Tumor cells (e.g. Colon-26, RIF-1)	• 0.5 μM/well • 0–8 J/cm^2 irradiation	*In vitro* bioassays • Photosensitization assay	• Non-toxic without light • Toxic to tumor cells with increasing light dosage	Ohulchanskyy et al. (2007)
6 Silicon nanowires	Silicon	• 90 nm in diameter • 6 μm height	• Murine embryonic stem cell • Kidney cell (HEK293T)	• N/A (grown on Si wafer) • Several days	*In vitro* bioassays • Cell incubation	• Murine stem cells survive for several days interfaced to silicon nanowires with 100 nm diameter	Kim et al. (2007c)
7 Synthetic SiO$_2$	Amorphous	• SiO$_2$ from Na$_2$SiO$_3$ 15–25 nm (SEM)/177–200 nm (DLS) • SiO$_2$ from TEOS 65–95 nm (SEM)/230–243 nm (DLS) • SiO$_2$-chitosan composite 10–15 nm (SEM)/153–177 nm (DLS)	• Fibroblast cells • Epithelial cells	0.21–0.667 mg/mL for 2 days	*In vitro* bioassays • MTT assay • LDH assay	• SiO$_2$-chitosan composite has less toxicity • Silica is more lethal to fibroblast cells • Longer the cell doubling time, the more cytotoxic	Chang et al. (2007)
8 Silica shell with quantum dot core	• Amorphous shell • CdSe/ZnS core • Amine termination	• 15–20 nm overall size	• Leukemia cells (Jurkat, K-562) • Lymphocytes	• 5 μM QD core concentration • 0.5, 3, 24, 48 h • 5 × 10^5 cell/well	*In vitro* bioassays • Flow cytometry	• Non-toxic up to 5 μM QD core concentration, 2 day, no light exposure • Slightly cytotoxic with UV irradiation (ROS, radical generation probable) • Intracellular delivery possible	Zhelev et al. (2006)

9 Multifunctional silica nanotubes	Amorphous walls	• 50 nm diameter • 200 and 500 nm lengths • No surface modification • Magnetite incorporated and amine functionalized (+ charge)	• Human metastatic breast cancer cell (MDA-MB-231) • Normal human umbilical vein endothelial cells	• 0.005, 0.05, 0.5, 5 μg/mL	*In vitro* bioassays • MTT assay	• Non-toxic only at low concentrations (below 0.5 μg/mL) • Toxicity is length independent but dose-dependent • (+) Charged 200 nm long SiO_2 nanotubes are toxic, especially for normal cell lines	Son et al. (2006)
10 Flame engineered SiO_2	• Amorphous • Crystalline	14 nm	Human mesothelioma rodent fibroblast cell lines (3T3)	15 ppm for 6 days	*In vitro* bioassays • MTT assay • Total DNA measurement • DNA Hoechst assay	Non-toxic	Brunner et al. (2006)
11 N/A	Amorphous	0.5–4 μm/1–12 μm	Human leukemic monocyte lymphoma (U937) used differentiated	0.125–1 mg/well	*In vitro* bioassays • LDH assay	• SiO_2 particles are the most toxic • SiO_2 > metal alloy > Al_2O_3 > TiO_2	Yoshida et al. (2003)
12 • 15 nm SiO_2 • 46 nm SiO_2 • Crystalline silica (Min-U-Sil 5)	• Amorphous (15, 46 nm) • Crystalline (Min-U-Sil 5)	• 15 nm SiO_2 (15 ± 5 nm) • 46 nm SiO_2 (46 ± 12 nm) • Min-U-Sil 5 (629 ± 272 nm)	Human lung cancer cells (A549)	• 10, 50, 100 μg/mL for 48 h for GSH, MDA, and LDH (1×10^4 cell/well; T75) • 10, 50, 100 μg/mL for 48 h for SRB (1×10^4 cell/well; 24 well) • 48 h for ROS	*In vitro* bioassays • Sulforhodamine B assay • LDH assay • Intercellular ROS • GSH measurement • MDA measurement • Protein assay	• 15, 46 nm SiO_2 particles are toxic which is dose-dependent and time-dependent at 10–100 μg/mL • Amorphous was more toxic than crystalline SiO_2 for cultures involving human bronchoalveolar carcinoma-derived cells	Lin et al. (2006a)

Table 3
Iron oxide nanotoxicology.

Type	Crystal phase	Size and characteristics	Animal or cell type	Concentration	Assay	Results	Reference
1 Iron oxide (Fe_2O_3) nanoparticles	N/A	Diameter: 5 and 12 nm • Sized by TEM	Rat pheochromocytoma cell line (PC 12)	0.15–15 mM	• Fluorescent Live/dead cell staining • Calcein AM and ethylidium homodimer-1 • Neurite morphometry • Alterations in cytoskeletal structure	Exposure to increasing concentrations of anionic magnetic nanoparticles results in a dose-dependent diminishing ability of PC12 cells to differentiate in response to nerve growth factor	Pisanic et al. (2007)
2 Fe_2O_3 (flame synthesized)	N/A	• Larger mode: 45 nm • Small mode: 5 nm • Sized by SMPS (Scanning Mobility Particle Sizer) and TEM	Human aortic endothelial cells (HAECs)	0.001–50 μg/mL direct exposure	• Measured mRNA level • Measured protein levels of the inflammatory markers • Trypan blue exclusion assay	Fe_2O_3 nanoparticles fail to provoke an inflammatory response in HAECs at any of the concentrations tested	Gojova et al. (2007)
3 • β-FeOOH nanorods • Polymercoated β-FeOOH nanorods (four-layers of polyelectrolytes (PAA/PEI/PAA/PEI))	Akaganeite (β-FeOOH)	• Diameter: 38 ± 5 nm lengths: 480 ± 45 nm (sizing by TEM) • BET surface area: 45.96 m^2/g • Pore size distribution: 2–20 nm	Human cervical carcinoma cells (HeLa)	• 0.1 ng/mL and 100 mg/mL • 5000 cells/well	*In vitro* bioassays • WST-1 assay	• As-prepared and polymer coated iron oxide nanorods were non-toxic at the concentrations between 0.1 ng/mL and 100 mg/mL for HeLa cells • Porous nanorods were uptaken within 15 min and dyes were released into the cytosol and then to the nucleus within 1 day	Wu et al. (2007)
4 Amino-functionalized superparamagnetic iron oxide nanoparticles (SPION)	Fe_3O_4	10–15 nm	Human liver cancer lines (SMMC-7721)	N/A	*In vitro* bioassays • MTT colorimetric assay	• Amine functionalized SPION can be [188]Re labeled • [188]Re labeled immuno-magnetic nanoparticles (IMN) can markedly kill SMMC 7721 liver cancer cells with right dosage	Liang et al. (2007)
5 Fe_2O_3 (flame synthesized)		12–50 nm	• Human mesothelioma (MSTO) • Rodent fibroblast cell lines (3T3)	30 ppm for 3 days	*In vitro* assays • MTT assay • Total DNA measurement • DNA Hoechst assay	• Cytotoxic for MSTO cells for both MTT and DNA (level was same as asbestos; lethal above 7.5 ppm) • Iron ion concentration coupled with nanoparticle uptake may be the cause of increased toxicity • Fairly non-cytotoxic for 3T3 cells (MTT and DNA)	Brunner et al. (2006)

| 6 SPIO (Ferumoxtran-10) (or AMI 7227) | N/A | 30 nm | Rats, rabbits, dogs, and monkeys (lymph nodes) | 2, 13, 40, 126, 400 (mg Fe/kg) | • Pharmacokinetic, safety pharmacology
• Single and repeated dose study
• Reproduction toxicity
• Genotoxicity toxicity | • Toxic at high iron conc. with repeated injections
• Not mutagenic but teratogenic in rats and rabbits | Bourrinet et al. (2006) |
7 Fe$_3$O$_4$	N/A	30, 47 nm	Rat liver derived cell line (BRL3A)	• 10, 50, 100, 250 μg/mL • 24 h	*In vitro* assays • MTT assay • LDH assay	• No measurable toxic effect between 10–50 μg/mL • Toxic at high conc. of 100–250 μg/mL	Hussain et al. (2005)
8 Ferumoxides-poly-L-lysine (PLL) (ferumoxide is commercially sold by Berlex Laboratories which is now Bayer HealthCare Pharmaceuticals as Feridex I.V.)	N/A	• FDA approved iron oxide • PLL = 38.8 kD	• Human mesenchymal stem cells • Human cervical carcinoma cells (HeLa)	25 μg/mL per 5000 cells (for 96 well assays)	*In vitro* bioassays • MTT assay • ROS measurement • Apoptosis assay	• Long-term viability, growth rate, and apoptotic indices of the labeled cells were unaffected by the endosomal incorporation of SPIO • Nonsignificant transient increase in reactive oxygen species • Magnetic cellular labeling with the ferumoxides-PLL complex had no short- or long-term toxic effects on tumor or mesenchymal stem cells	Arbab et al. (2003)
9 SPIO (AMI-25)	N/A	80 nm	Rats, beagle dogs	• Acute toxicity: 500 μmol Fe/kg (28 mg Fe/kg) or 3000 μmol Fe/kg (168 mg Fe/kg) • Subacute toxicity: 0–250 μmol Fe/kg (0–14 mg Fe/kg) • Mutagenicity (Ames test): 0–2140 μmol Fe/kg (0.008–12 mg Fe/kg)	• Acute toxicity • Subacute toxicity: mortality, morbidity, body weight, or food consumption; histology • Mutagenicity (Ames test)	• Acute toxicity: no adverse effects • Subacute toxicity: all within normal ranges; no tissue damages • Mutagenicity (Ames test): non-toxic	Weissleder et al. (1989)

Table 4
CeO$_2$ nanotoxicology.

Type	Crystal phase	Size and characteristics	Animal or cell type	Concentration	Assay	Results	Reference
1 Cerium oxide nanoparticles via microemulsion method	N/A	2–5 nm	• Neuronal and glial cells from adult rat spinal cord • Isolated spinal cord cells	• 1000 cells (2 cells/mm^2 density) • Single dose of 10 nM • 15 and 30 day cultures for live–dead cell assays • 100 mM H$_2$O$_2$ for 1 h	*In vitro* assays • Live–dead cell assays • Neuron–glial cell assay • Hydrogen peroxide-induced oxidative injury assay	• Nano-ceria treated cultures lived longer for both 15, 30 days • Neuronal cells survived significantly higher vs. controls • Protection against hydrogen peroxide-induced oxidative injury is observed for nano-ceria treated cultures	Das et al. (2007)
2 Ceria nanoparticles (commercial NanoActive)	N/A	7 nm in diameter	• MCP-1 transgenic mice (MCP mice) • Wild-type FVB/N mice (WT mice) • 5 weeks old; 20–25 g body weight • Sacrificed at 6 months of age *MCP = monocyte chemoattractant protein	• 15 nmol via intravenous administration • Twice a week for 2 weeks	*In vivo* • Myocardial histology • Expression of cytokines • ER stress-associated genes evaluation	• Cardiac dysfunction slowed while myocardial oxidative stress and ER stress was attenuated using nano-ceria • Cytokine (TNF-α, IL-1β, and IL-6) production decreased for myocardium in MCP mice via nano-ceria treatment • Circulating MCP-1 and CRP levels reduced (likely due to anti-inflammatory effects of CeO$_2$) • Nano-ceria is a potent autoregenerative antioxidant	Niu et al. (2007)
3 Cerium-based compound Envirox™ (commercial catalyst from Oxonica, UK)	N/A	• 70–90 nm • 2% nano-ceria in a mixed aliphatic/cyclo-aliphtic fluid (Envirox™ is a fuel additive to reduce particulate matter (PM) emission in diesel engines	Rat lung slices	N/A	*In vitro* assays • Cell viability (ATP, intracellular Glutathione) • Proinflammatory reaction (TNF alpha) • Anti-oxidant enzyme activity (total GPX, Mn SOD, catalase)	• No impact on lung tissue viability, glutathione dependent metabolism, superoxide dismutase activity, proinflammatory reaction • Cellular defense can take over without harmful consequences	Fall et al. (2007)
4 CeO$_2$ oxide (commercial, Rhodia)	N/A	• 7 nm • 400 m^2/g surface area • IEP = 10.5	Gram-negative bacteria (*Escherichia coli*)	4, 15 mg/L	Counting colony forming units (CFU) on LB petri dishes	• Adsorption and reduction of ceria nanoparticles lead to significant bacterial cytotoxicity • Nano-ceria adsorbs onto the *E. coli* outer membrane	Thill et al. (2006)
5 La$_{0.7}$Sr$_{0.3}$MnO$_3$ (LSMO) nanoparticles doped with cerium	Perovskite	50–300 nm according to cited paper	• Human skin carcinoma (A-431) • Human fibrosarcoma cell lines (HT-1080)	5–100 μg/mL	*In vitro* assays Tetrazolium salt XTT assay	• Cerium-doped LSMO samples and reduced La/Sr ratios resulted in extremely low cytotoxicity • Pure LSMO particles are toxic but cerium doping (~3%) reduced the toxicity level	Kale et al. (2006)
6 Cerium oxide (CeO$_2$) nanoparticles via sol–gel synthesis	N/A	6, 12 nm, and 1 μm sizes	• Hippocampal nerve cell line (HT22) • Murine macrophage cell line (RAW164)	0.01, 0.1, 1, 10, 100 μg/mL per 2.5×10^3 initial cell seeding	*In vitro* assays • MTT assay • Reactive oxygen species (ROS) measurement	• One micron ceria particles show toxicity over 20 μg/mL • Ceria and yttria show antioxidant properties that promote cell survival under conditions of oxidative stress	Schubert et al. (2006)

Table 4 (*Continued*)

Type	Crystal phase	Size and characteristics	Animal or cell type	Concentration	Assay	Results	Reference
7 Ceria nanoparticles via room temperature homogeneous nucleation method	N/A	17–23 nm (by TEM and gas surface analysis)	Human bronchoalveolar carcinoma derived cell line (A549)	• 3.5, 10.5, 23.3 μg/mL • 1–3 days for SRB assays • 1 day for ROS measurement • 3 days for LDH assay	*In vitro* assays • Sulforhodamine B assay • Intracellular ROS measurement • LDH assay • GSH, MDA, α-tocopherol measurement • Total protein concentration assay	• 20 nm ceria particle reduce human lung cancer cell viability • Free radicals are generated to cause oxidative stress and reduce GSH and α-tocopherol levels • Toxicity correlates well to both dose and time exposure • Oxidative stress led to increased LDH, MDA release which are indicators of lipid peroxidation and membrane damage	Lin et al. (2006b)
8 Cerium oxide nanoparticles (CeO_2-NP)	N/A	N/A	Neonatal rat brain cell (astrocytes, neurons, microglia)	• 10 nM, single dose • 24 h on day 10 *in vitro*	*In vitro* assays • Cell damage measured by propidium iodide • Inflammatory activation in microglia	• Reduced free radical mediated cell damage • Decreased NO release • Decreased microglial activation	Strawn et al. (2006) (meeting abstract)
9 Ceria nanoparticles	N/A	• 3–5 nm (non-agglomerated) (by HRTEM and XRD) • Mixed valence states of Ce^{3+} and Ce^{4+} (by XPS)	• Human breast carcinoma cell lines (MCF-7) • Normal breast epithelial cell lines (CRL8798)	0–5 μM	*In vitro* assays • Radiation (0–10 Gy) experiments • MTT assay • TUNEL (apoptosis) staining	• Toxic to cancer cells at concentrations greater than 50 nM • Normal cells are protected against radiation damage	Tarnuzzer et al. (2005)
10 Ceria nanoparticles via flame spray synthesis	N/A	• Size fraction I (20–50 nm) • Size fraction II (40–80 nm) • Size fraction III (80–150 nm) • Size fraction IV (250–500 nm)	Human lung fibroblast (MRC-9)	100 ng/g and 1 μg/g of fluid (100 ppb to 100 ppm)	Uptake *in vitro* assays Analyzed by different sizes, concentrations, and exposure times	• Ceria particle size dictates toxicity • The biological uptake processes on the surface of the cell are faster than the physical transport to the cell • Particle uptake rate is dominated indirectly by particle size while primary particle number conc. and surface area are minor factors	Limbach et al. (2005)

Table 5
Multifunctional nanoparticle systems (MFNPS).

No.	Schematic	Size (nm)	Matrix	Component 1	Component 2	Component3	Surface chemistry	Application(s)	Reference(s)
1		30–40	SiO_2	Gd^{3+} + ligand (MR agent)	$[Ru(bipy)_3]^{2+}$ (fluorescent)	N/A	Si–OH	Target-specific contrast agents for optical and MR imaging of rheumatoid arthritis in mice	Rieter et al. (2007a); Kim et al. (2007a)
2		70–90	PLGA	Fe_3O_4 (MR agent)	DOX (drug molecule)	HER (targeting agent)	–OH	Diagnosis of breast cancer; detection and treatment	Yang et al. (2007)
3		35–45	SiO_2	Gd^{3+} + ligand (MR agent)	$[Ru(bipy)_3]^{2+}$ (fluorescent)	Negatively charged polymer	K_7RGD (positively charged oligomer)	Layer-by-layer assembly method to construct multifunctional nanoparticles; cancer cell targeted imaging	Kim et al. (2007a)
4		40 × (short axis) 100–125 (long axis)	SiO_2	Lanthanide (Eu^{3+}, Gd^{3+}, Tb^{3+}) doped metal-organic-framework (MOF)	Tb^{3+} + ligand	N/A	–OH/–COOH/–NR$_2$/ –NHC(O)	Controlled release of small molecules (drug delivery); detection of small molecules; MR imaging	Rieter et al. (2007b); Rieter et al. (2006)
5		<200 nm	SiO_2	Fe_3O_4 (MR agent)	CdSe/ZnS (fluorescent)	Ibuprofen (drug molecule)	Si–OH	Drug delivery; magnetic susceptibility measurement; fluorescence imaging	Kim et al. (2006b)

#		Size (nm)	Matrix	Component 1	Component 2	Component 3	Functionality	Application	Reference
6		115 × (short axis) 160 (long axis)	SiO_2	Fe_3O_4 (MR agent)	FITC (fluorescent)	Mesopore	−OH	Cell tracking and drug delivery	Lin et al. (2006c)
7		45	SiO_2	Fe_3O_4 (MR agent)	Fluorescent	N/A	$-NH_2/-SH/-OH$	Imaging neuroblastoma	Lee et al. (2006b)
8		Comp. 1 = 10, Comp. 2 = 6	N/A	Au (optical probe)	FePt (MR imaging)	Biomolecule (targeting; e.g. antibody)	N/A	Biochip sensing; molecular MR imaging of cancer cells	Choi et al., 2006
9		9–12	Fe_3O_4	Cy5.5 (near-IR fluorescent)	Chlorotoxin (targeting agent)	PEG (biocompatible stealth coat)	Biomolecules	MR imaging and fluorescence microscopy on rat glioma (brain tumor) cell and rat cardiomyocytes	Veiseh et al. (2005)
10		100	SiO_2	Gd^{3+} + ligand (MR agent)	$[Ru(bipy)_3]^{2+}$ (fluorescent)	$Si(CH_2)_3NH_2$ (for bioconjugation)	$-NH_2/-PCH_3OO^-$	MR and fluorescence imaging possible; radio-opaque (via X-ray fluoroscopy)	Santra et al. (2005a,b)
11		11–17, QD = 3	SiO_2	Gd^{3+} + ligand (MR agent)	CdS:Mn@ ZnS (fluorescent)	$Si(CH_2)_3NH_2$ (for bioconjugation)	$-NH_2/-PCH_3OO^-$	MR and fluorescence imaging possible; TAT peptide conjugation and rat brain labeling studies	Yang et al., 2006a; Santra et al., 2005b,c

Table 5 (*Continued*)

No.	Schematic	Size (nm)	Matrix	Component 1	Component 2	Component3	Surface chemistry	Application(s)	Reference(s)
12		10–20 nm	Magnetic core (magnetic attraction)	Oxide layer (functionalization)	Ligand or functionality to bind His (stabilization)	N/A	Stabilizing agent/ bound functional group/unbound-OH	Magnetic separation of Histidine modified biomolecules such as proteins from cell lysates	Lee et al. (2006a); Xu et al. (2004)
13		100 (diameter) × 200 (two 100 nm segments)	Matrix 1 = Ni, Matrix 2 = Au	Cationic linker (to harness negatively charged biomolecules)	Biomolecule (e.g. negatively charged plasmid; to bind with cationic linker)	Fluorescent tagged biomolecule with thiol functionality (to bind with Au)	Attached biomolecule	*In vitro* and *in vivo* gene delivery in mammalian systems	Salem et al. (2003)
14		100–120	SiO₂	Rhodamine (fluorescent)	Mesopore	N/A	(+) and (−) examples	Differentiation of human mesenchymal stem cells or cancer drug delivery	Chung et al. (2007); Lu et al. (2007b)
15		50 (diameter) × 200–500 or longer (length)	SiO₂	Fe₃O₄ (MR agent)	Antibody (bioconjugation)	Cargo space or Ab	Biomolecules + –OH/hydrophobic interior	Biodetection and controlled release of small molecules	Son et al. (2006)
16		>20 nm (diameter) × 12 μm (length)	Matrix 1 = Au, Matrix 2 = Ni	Au (protecting group; functionality via thiol chemistry)	Ni (magnetic domain; His-tag binding domain)	N/A	PEG (thiol linked molecules)	Magnetic separation of histidine tagged biomolecules	Lee et al. (2004b)

The illustrations were prepared based on the data, schemes, and figures provided in the references in the table with permission from the respective publishers.

organisms integrate themselves readily with engineered nanomaterials their toxic potential as a nanocomposite material could increase which makes probing and understanding nanomaterial's role in controlling and affecting cellular level biological processes (events 1–8 in Fig. 5) very important to investigate and understand. Toxicology arising from such nanobiocomposites will give new meaning to nanotoxicology and, in fact, will be key issues to consider for neuroscientists wanting to use nanotechnology with focuses on neuronal cell systems, brain implantations, and dementia research such as Alzheimer's disease since mycoplasma detection is not trivial and implications have been made on their possible role in human disease action including CNS diseases (Candler and Dale, 2004; Casserly et al., 2007; Daxboeck, 2006; Daxboeck et al., 2003, 2005; Narita et al., 2005; Pellegrini et al., 1996; Tsiodras et al., 2005; Waites and Talkington, 2004).

3.2.3. Titanium dioxide (TiO$_2$)

Titania (TiO$_2$) has received much attention in materials sciences and engineering due to its optoelectronic properties (Hashimoto et al., 2005). For example, TiO$_2$ has been utilized as photocatalysts for photochemical hydrogen production and for self-cleaning windows. In the cosmetic industry, titania is the main ingredient in many commercial sunscreens along side ZnO due to its property of UV absorption.

The phase mainly responsible for titania's photocatalytic properties is anatase. Other known phases are rutile and brookite. Evaluating and comparing TiO$_2$ toxicology has been the theme of many research groups and the investigations involved assaying for size, content and ROS production. Recent efforts have been focused on engineered nanomaterial toxicology and here we represent few excerpts within the past several years. Yoshida et al. (2003) have reported that LDH (lactate dehydrogenase) assay revealed TiO$_2$ to be the least toxic material from sub-100 nm up to 1 μm. According to their studies toxicology assessed using cell membrane damage assays, metal oxides are toxic in the following order: TiO$_2$ < Al$_2$O$_3$ < SiO$_2$ regardless of size under 1 μm. This study, however, does not probe different types of TiO$_2$. For an overview study of cell toxicology in relation to TiO$_2$ particle size and crystal phase, Sayes et al. (2006) and Warheit et al. (2006) have done studies with dermal fibroblasts and human lung epithelial cells as well as with rats which suggest that photoactivation of anatase TiO$_2$ will increase cytotoxicity but concentrations over 100 mg/mL will be significant enough to cause any ill effects. Soto et al. (2005, 2007) have also done a correlation study between particle size, aggregation and toxicology using cellular experimental protocols. In these studies TEM is extensively used to analyze the particle sizes and the results suggest that TiO$_2$ are much less cytotoxic compared to other types of nanomaterials such as carbon nanotubes and SiO$_2$. In a unique synthesis, Suh et al. (2006b) have produced anatase phase TiO$_2$ microspheres that have nanometer features and also showed that TiO$_2$ is biocompatible. The cause for concern in TiO$_2$ toxicity studies are in the cases where researchers showed genotoxicity (Turkez and Geyikoglu, 2007; Wang et al., 2007a) associated with titania and with particles that are non-spherical (Yamamoto et al., 2004). Table 1 summarizes TiO$_2$ nanotoxicology in recent years with a minimum focus on *in vivo* inhalation toxicology and a focus on cellular level toxicity studies. Utilizing nanotechnology in neuroscience will likely not involve inhalation of particles compared to injection and installation of the nanostructured materials either as injectable devices or implantable machines and tools.

Prosthetic devices including neuroprosthetics require well-defined device characteristics such as mechanical and chemical properties. Titanium based materials have been the choice of many for implants. In a recent study, Palmieri et al. (2007) have

investigated into comparing the effects of nano-sized synthetic anatase TiO$_2$ (prepared via the sol–gel route surface) coated onto surfaces against osteoblast-like cells (MG63) for their role in gene regulation using microRNA (miRNA) microarray analyses. miRNAs are small 19–23 nucleotide noncoding RNAs and play a crucial role in the post-transcriptional regulatory process. miRNAs regulate the expression of other types of genes by repressing or cleaving translation of their messenger RNA targets and they have been shown to be an intricate part of neurobiologically important pathways (Kosik, 2006; Kosik and Krichevsky, 2005). The number of known miRNA's are limited to approximately 500, considering this and the shown roles of miRNA it may be an important molecular level screening method that has become available for any type of nanoscience-related neuroscience projects. Interestingly within the past two years, Gao and researchers have utilized nanotechnology to electrochemically detect miRNA at the pM to fM range (Fan et al., 2007; Gao and Yang, 2006) and the Corn group used nanoparticle amplified optical detection methods which allowed the detection lower limit to reach attomolar concentrations (Fang et al., 2006). Recent advances involving nanotechnology and miRNA will foster new and exciting interdisciplinary research linking biology and physical sciences.

3.2.4. Silicon dioxide (SiO$_2$)

In comparison to TiO$_2$, silica (SiO$_2$) has been studied more widely due to an occupational lung disease called silicosis which is linked to crystalline phase silica (Brunner et al., 2006; Jovanovic et al., 2006). Unlike TiO$_2$, however, research involving SiO$_2$ in the field of nanotechnology deals mainly with amorphous phase silica (Bharali et al., 2005; Chowdhury and Akaike, 2005; Gemeinhart et al., 2005). Here we will introduce few good examples of SiO$_2$ nanostructured materials with a focus on recent synthetic particles that have multifunctionality (see Section 4.2). SiO$_2$ sub-50 nm silica nanoparticles incorporating a fluorophore and an MRI agent were synthesized and cell viability was checked with a one day colorimetric tetrazolium assay using monocyte cells which revealed the non-toxic nature of that particular multifunctional particle (Rieter et al., 2007a). Mesoporous SiO$_2$ spheres have been prepared and utilized in several biological applications in the past few years including drug delivery studies (Slowing et al., 2007). In a recent anti-cancer drug delivery study done by UCLA (Lu et al., 2007b), approximately 130 nm amine group functionalized mesoporous SiO$_2$ spheres were formed and surface modified with alkyl phosphate groups. Cytotoxicity tests on several different cancer cell lines (e.g. PANC-1, AsPC-1) revealed practically no toxicity unless the anti-cancer drug was loaded and subsequently released over time. In another protein, polymer functionalized SiO$_2$, luminescent nanobeads of approximately 20 nm were tested for its cytotoxicity (< 6 h) via apoptosis and necrosis assays (flow cytometry) (Bottini et al., 2007). Organically modified 20 nm SiO$_2$ with an incorporated hydrophobic photosensitizer (e.g. porphyrin) were tested for its toxicity levels with tumor cells and showed no apparent toxicity unless irradiated with light to product ROS (Ohulchanskyy et al., 2007). Generally, amorphous SiO$_2$ nanoparticles are considered highly biocompatible and non-cytotoxic unless engineered to be otherwise.

3.2.5. Iron oxide

Iron in the presence of an oxidant (e.g. air) will become iron oxide (i.e. rust). There are several phases of iron oxides which include Haematite (α-Fe$_2$O$_3$), Magnetite (Fe$_3$O$_4$), Maghemite (γ-Fe$_2$O$_3$), β-Fe$_2$O$_3$, ϵ-Fe$_2$O$_3$, Wüstite (FeO) (Cornell and Schwertmann, 1996). Among them, magnetite (Fe$_3$O$_4$) nanoparticles have been the subject of research for many years in hopes of using them for biomedical research (Bulte et al., 2001; Caruthers et al., 2007;

Fig. 4. Contents of DMEM vs. 10 nm nanoparticle. Red chemical structures (first three rows) represent amino acids, black chemical structures (fourth row) represent inorganic salts, and blue structures (rows 5–8) represent vitamins and other small organic molecules. The contents information of DMEM (Dulbecco's Modified Eagle's Medium) were readily available on-line at various biochemical vendor websites such as HyClone and Sigma–Aldrich.

Dunning et al., 2004; Gupta and Gupta, 2005; Mornet et al., 2004; Pankhurst et al., 2003; Simberg et al., 2007; Sykova and Jendelova, 2007; Thorek et al., 2006; Weissleder and Mahmood, 2001; Xu and Sun, 2007). Sub-10 nm Fe_3O_4 nanoparticles have been particularly useful as a superparamagnetic MRI probe that can be made to target-specific cells and tissues inside the body. It is straightforward to synthesize iron oxides especially magnetite nanoparticles: iron salt, surfactant, base, solvent and heat. Compared to TiO_2 and SiO_2, iron oxides are partially soluble in acidic media containing chelating agents such as siderophores (Kraemer, 2004).

For this very reason, *in vitro* neurotoxicity of iron oxides was implicated by researchers from UCSD (Pisanic et al., 2007). In this study, iron oxide nanoparticles affected PC12 cells' ability to differentiate in response to nerve growth factors (NGF) in a concentration dependent manner. For instance, Western blotting revealed that growth associated protein GAP-43 level decreased dramatically when the NGF concentration went from 0.15 to 1.5 mM then 15 mM which alerted the researchers to re-evaluate their efforts in using iron oxide nanoparticles for neurobiological applications. Iron oxides are negatively charged in physiological pH conditions. This good example shows how surface chemistry and its electronic states control bioprocesses in a detrimental manner. Any use of nanotechnology in biological applications should accompany stringent biocompatibility studies of not only in short-term effects but also effects from chronic exposure. Case-by-case approach to probe nanotoxicology is a must especially when bioprocess control over neurological systems is strongly desired. Table 3 lists several good examples of research groups around the world that have researched into both *in vitro* and *in vivo* toxicology of iron oxides.

On a slightly different note, Ruoslahti and co-workers (Simberg et al., 2007) have utilized 50 nm iron oxide nanopaticles as tumor homing vehicles that has been conjugated to a tumor targeting peptide CREKA (Cys-Arg-Glu-Lys-Ala). CREKA allows the nanoparticle to recognize clotted plasma proteins and bind to vessel walls and tumor stroma. Interestingly, these nanoparticles accumulate in tumor vessels; induce blood clotting which increases binding sites for additional particles to home in to. This type of controlled and targeted toxicity is a new state-of-the-art use of iron oxide nanoparticles in comparison to their sole use as image contrast agents. It will be beneficial for the neuroscience community to bench mark such efforts from the cancer research

Fig. 5. Cell and particle interactions. Toxicological effects of nanomaterials can be simplified into eight events as shown in the illustration above but limiting the interaction between a nanoparticle and a cell to eight events is an over simplification and the details of actual phenomena that are happening at the interfaces are very difficult to analyze and understand. (1) Reactive oxygen species products such as superoxide ($^{\bullet}O_2^-$) and hydroxyl radical ($^{\bullet}OH$) whether it is inside or outside can be key factors in nanostructured materials toxicological effects (Nel et al., 2006). Cell membrane integrity leading to cell survivability will be affected by ROS produced by a nanoparticle smaller than a cell (red particle) as shown. (2) Event 2 represents the situation where a nanoparticle is internalized and then creates ROS products (Nel et al., 2006). (3) Particle dissolution affecting cellular function after nanoparticle internalization is event 3 (Borm et al., 2006). (4) Event 4 represents any mechanical damage to sub-cellular units such as the lysosome, endoplasmic reticulum, and nucleus (Yamamoto et al., 2004). (5) Different functional groups and surface electronic structures arising from different nanostructured materials will determine the level of interaction between the nanoparticles and their surroundings which is represented by event 5 (Karakoti et al., 2006; Kostarelos et al., 2007). (6) Overall size of the particle can play an important role as represented by event 6 since large particles can potentially induce permanent damage to the cell membrane while small particles can pass through the membrane and do harm inside cell (Yoshida et al., 2003). (7) Non-spherical particles, on the other hand, might have a different biological response compared to the spherical nanoparticles which is shown as event 7 (Geng et al., 2007). (8) Event 8 represents dissolution characteristics of the nanomaterials outside the cell which can affect the cell in various ways (event 8) (Borm et al., 2006).

community and follow the biological target based approaches and implement them to known targets in neurological disorders.

3.2.6. Cerium oxide: neuroprotecting agent

CeO_2 is a very potent oxidation catalyst which promotes chemical reactions such as CO oxidation in automobile catalytic

Fig. 6. Nanobiocomposite formed from a nanoparticle (sub-micron) and a nanobacteria (e.g. mycoplasma; sub-500 nm). This event is probable to happen under biogenic conditions where polyelectrolytes (e.g. peptide) and soluble ionic species (e.g. Ca^{2+}, Na^+) are readily available. Sub-micron engineered nanoparticles can form new composite materials with mycoplasma and the new nanobiocomposite material can have vastly different chemistries and physical properties which will lead to different biological properties.

converters (Guzman et al., 2005; Trovarelli, 1996). In the last few years, several works involving ceria nanoparticles on their ability to offer cellular level protection have been reported (Das et al., 2007; Niu et al., 2007; Schubert et al., 2006; Singh et al., 2006a). Nano-ceria nanoparticles prevented increases in reactive oxygen species (alternatively coined reactive oxygen intermediates) *in vitro* and *in vivo*. Light-induced degeneration of photoreceptor cells leading to vision loss was reduced. These findings suggest that therapeutics developed based on nano-CeO_2 may effectively decrease any ill effects arising from ROS related degeneration, diseases and ailments (Chen et al., 2006b). In an earlier study, radiation studies were done and it was found that normal cells pretreated with nano-ceria did not die where as untreated cancer cells did. The nature of these types of protective effect comes from the oxidation–reduction (redox) chemistry between Ce^{4+} and Ce^{3+} and the fact that the inorganic structure of ceria can tolerate defects via oxygen vacancies in CeO_{2-x} (Mogensen et al., 2000). Surface charge effects of nano-ceria were investigated in several different pHs and synthesis conditions. As expected, protein adsorption (e.g. BSA) increased as a function of zeta potential increase and negatively charged CeO_2 internalized preferentially in cellular uptake experiments. Synthesis methods strongly affected the IEP of nano-ceria: microemulsion method gave 4.5 and hydrothermal method gave 9.5 (Patil et al., 2007). IEP differences arising from synthesis details being different might be a key issue when utilizing nanostructured materials for biological applications. Biological screening of cerium oxide with a focus in nanotoxicology has been conducted only within the last few years and we have summarized those efforts in Table 4.

3.2.7. Carbon materials

Among carbon-based materials, carbon nanotubes have been well utilized in recent biological applications. Excellent review papers already exist for CNT's (Dai, 2002; Dai et al., 2003; Harrison and Atala, 2007; Pagona and Tagmatarchis, 2006) and C_{60} fullerenes (Diederich and Gomez-Lopez, 1999; Fiorito et al., 2006; Hirsch, 1995; Jensen et al., 1996; Ke and Qiao, 2007; Prato, 1997; Satoh and Takayanag, 2006) so we will focus on new types of spherical and non-tubular forms of carbon that was developed for biological applications (Fig. 7). The first example is carbon nanohorns by Iijima and co-workers (Ajima et al., 2005; Isobe et al., 2006; Matsumura et al., 2007; Miyawaki et al., 2006; Murakami et al., 2004). Processed in a similar fashion as CNT's, researchers were able to synthesize high surface area carbon materials that have tube-like carbon sticking outward but in a spherical overall shape and are approximately 100 nm in size. Cytotoxic assays show practically no toxicity. The second one is carbon nanodots (sub-10 nm) which were strongly two-photon active and emit in the visible range (Cao et al., 2007). *In vitro* tests

suggest that the carbon nanodots can be internalized into mammalian cells and fluorescent microscopy imaging was possible. A third recent class is (fluorescent) diamond nanoparticles (Fu et al., 2007; Yu et al., 2005) which were found to be non-cytotoxic and were used as single-particle biomarkers on mammalian cells.

3.2.8. Zeolites and clays

Recent development in utilizing porous zeolite materials for biomedical application has focused on two main areas. One is in hemostatic agents which induces blood clotting upon treatment and the other in antibacterial agent development (Sakaguchi et al., 2005). Quikclot® (QC) developed by Z-Medica has been a key agent utilized by the military to reduce deaths in the field by blood loss. This agent is very effective but also induces local dehydration and causes *in situ* cauterization. Instead of zeolite based porous materials either mesoporous bioglass (Ostomel et al., 2006a,b) or clays (Baker et al., 2007) can be a highly effective blood clotting agent. Both of these materials, in fact, avoid causing burns to the user. A much more recent product, Quikclot Sport® Silver™, which incorporated silver in the matrix alleviated the negative factors in QC and Z-Medica now offers a burn-free, antibacterial dressing for external wounds (Z-Medica). This later examples clearly demonstrates how a single metal ion source can greatly affect the materials' overall interaction with biological systems such as the blood clotting cascade.

Tailoring inorganic nanostructures by their composition and surface electronics might further allow researchers to invent a porous system where one can control the rate of blood clotting by either engineering the isoelectric point (Ostomel et al., 2007; Sakaguchi et al., 2005) or by incorporating biologically relevant entities into the nanostructured base material (Ostomel et al., 2006c). In essence, there is no extensive mammalian toxicology study done on zeolites but their use as blood clotting agents and related clinical studies have proven that their use on animals and human beings are reasonable within the scope of allowed practices of medicine. We expect to see more work on blood clotting and antibacterial agents using zeolite and other types of porous metal oxides. Studying such controllable systems might offer insights into targeting internal head injuries and other types of internal wounds and clots and allow researchers to directly deal with such medical issues.

3.2.9. Metal and semiconductor nanoparticles

Utilization of metal and semiconductor nanoparticles in biomedical applications has been demonstrated very well by many research groups (Daniel and Astruc, 2004; Fu et al., 2005; Jun et al., 2006; Medintz et al., 2005; Michalet et al., 2005; Tang and Kotov, 2005). Reviews for these two classes of materials exist in multiples and we do not want to repeat what others have done. For metal nanoparticles such and Au and Ag, however, we would like to introduce molecular imaging via (surface) plasmon resonance coupling (Campbell and Xia, 2007; Haes et al., 2004, 2005a,b). Aaron et al. have shown that 25-nm gold nanoparticles when conjugated with anti-EGF (epidermal growth factor) receptor monoclonal antibodies can be efficiently used as *in vivo* targeting agents for imaging cancer markers, specifically epidermal growth factor receptors. The Au nanoparticles results in a dramatic increase in signal contrast compared to other antibody-fluorescent dye targeting agents.

Semiconductor nanoparticles such as CdSe/ZnS nanoparticles have been utilized heavily for bioimaging applications (Michalet et al., 2005). The biggest challenge with this type of material is the potential of high toxicological effect caused by heavy metal dissociation (Chang et al., 2006; Derfus et al., 2004; Kirchner et al., 2005; Sinani et al., 2003; Voura et al., 2004; Zhang et al., 2006).

Fig. 7. Spherical and non-tubular carbon nanomaterials. Sub-100 nm carbon nanoparticles that are other than C_{60} or carbon nanotubes will offer another set of tools for neuroscientist as well as other biologists. Illustrations were prepared based on data, schemes, and figures appearing in the references with permission from the publisher.

carbon nanohorn — 80–100 nm

carbon nanodots — <10 nm

diamond nanoparticles — <100 nm

Fig. 8. Controlling cell function by microscale patterns and nanowires. Details are provided for the top three illustrations in the maintext. Making sub-micron patterns as well as functionalizing the sub-patterns with unique nanostructures such as wires and pores will be very interesting to utilize in neuroscience, especially studying interacting neurons and neuronal implants *in vivo*.

Many *in vitro* and *in vivo* toxicological studies were conducted and interesting studies have been done and in recent years the effect of nanoparticles on microbial species and in the environment has received notable attention (Adams et al., 2006; Bhattacharya and Gupta, 2005; Dreher, 2004; Guzman et al., 2006; Liu, 2006; Maynard and Kuempel, 2005; Wigginton et al., 2007). It is particularly interesting that certain microbial species interact extraordinarily with nanomaterials or in certain instances even synthesize nanostructured materials (Gericke and Pinches, 2006; He et al., 2007; Konishi et al., 2006, 2007; Marshall et al., 2006; Moreau et al., 2007; Shankar et al., 2003). Combining efforts from environmental and biological sciences not necessarily related to medicine could eventually help us understand how different biological systems react cooperatively or uncooperatively with certain types of nanostructured materials regardless of their overall size and content. Moreau et al. (2007), for instance, have shown that extracellular proteins from microbial species can promote biomineralization of metal-bearing nanoparticles and suggested that such an event can lead to limiting nanoparticulate dispersion in the environment.

4. Nanomaterials for biomedical research: opportunities in neuroscience

4.1. Nanowires and patterned surfaces

Patterned surfaces, particularly, created with PDMS (poly (dimethylsiloxane)) elastomer have been of high interest to many for cell attachment studies both for eukaryotic (Aizenberg et al., 1998; Chen et al., 1998, 2005; Kane et al., 1999; Mrksich and Whitesides, 1996; Takayama et al., 1999; Whitesides and Lamantia, 1995; Zhang et al., 1999) and prokaryotic (Weibel et al., 2007) systems (Fig. 8a). Whitesides and co-workers have shown that micro- and nanoscale patterns on flexible substrates can be excellent tools to study cell mechanics and function. In fact, multitudes of projects now involve the use of soft lithography techniques (based on cleanroom microtechnology used to make electronic materials and circuits) which allow facile creation of highly reproducible surface patterns and subsequent systematic analysis of biological systems. Jeon and co-workers at UC Irvine have successfully engineered lab-on-chip systems (made out of PDMS and slide glass) which allow neuronal cell bodies to be spatially separated from the out-growing neurites and axons (Park et al., 2006; Taylor et al., 2005). Microtechnology have also been well utilized by Bhatia and co-workers at MIT to control cellular level microenvironments which allowed three-dimensional cell cultures and high-throughput screening of biomolecules such as extracellular matrix proteins possible (Albrecht et al., 2006; Flaim et al., 2005; Hui and Bhatia,

2007; Khetani and Bhatia, 2008; Underhill and Bhatia, 2007). Lithography techniques also allowed the development of lab-on-chip devices (or platforms) which led to long-term low cell density (nano-liter volumes) postnatal rat primary hippocampal neuron cultures as demonstrated by Millet et al. (2007) at the University of Illinois. The June 2007 issue of Lab on a Chip journal published a special issue on 'Cell and Tissue Engineering in Microsystems' which covers a variety of research efforts involving cell biology investigation on microdevices and patterned surfaces (Bhatia and Chen, 2007) and with the advancement of single cell analysis techniques (Jo et al., 2007; Jurchen et al., 2005; Kruse and Sweedler, 2003; Monroe et al., 2005; Northen et al., 2007; Rubakhin et al., 2000, 2003; Rubakhin and Sweedler, 2007), long-term cell culture experiments with precisely controlled microenvironments can be done in a facile manner in conjunction with high resolution real-time analysis of cellular products.

Nanowires with sub-micron diameters have also been utilized to study cell biology. Yang and co-workers at UC Berkeley have recently reported that sub-100 nm (diameter) silicon nanowires (SiNW) can be integrated into live cells without causing detrimental affects (Kim et al., 2007c). Basically, they were allowed to grow mouse embryonic stem cells on the SiNW and also use them as nanoscale needles to deliver biological materials such as GFP (green fluorescent protein) plasmid (Fig. 8b) into cells. At almost the same time, Bertozzi and co-workers have reported the use of a modified nanosized AFM (atomic force microscopy) tip to favorably deliver fluorescent nanoparticles such as CdS (Chen et al., 2007) (Fig. 8c). The diameter of the AFM tip was sub-10 nm and it proved that length scales much smaller than the cell was very important for the survival and subsequent delivery of materials inside the cell. Making sub-micron patterns of biomolecules as well as functionalizing the sub-patterns with inorganic nanowires and nanopores which can incorporate biological materials will offer additional key functions to any device that may incorporate such sub-units. For neuroscience research, microdevices with sub-cellular (sub-micron) features, patterns, and functional surfaces can eventually aid in carrying out nanosurgeries to cells linked to the CNS and also in studying the interface that is created between neurons and neuronal implants *in vitro* and *in vivo*.

4.2. Multifunctional nanoparticle

Recent trends in nanoparticles engineered for biomedical applications involve nanoparticles having multiple components in the nanomaterial (Fig. 9). In most cases, as depicted in the schematic, a multifunctional nanoparticle system (MFNPS) would be comprised of four main components: a matrix which is few

Fig. 9. Multifunctional nanoparticle systems (MFNPS) for biomedical applications. MFNPSs can be divided into four distinctive types. Type 1 is non-porous but spherical SiO$_2$ based sub-100 nm nanoparticles with two or more components. Type 2 is sub-200 nm spherical nanoparticles that is either porous or can incorporate and, in time, release small molecules such as drug molecules. Type 3 is sub-20 nm nanoparticles with functionalizable ligands or biomolecules stabilized (passivated) onto the nanoparticles and are, in most cases, first synthesized in organic conditions which offer good size control and then phase exchanged to become dispersable in aqueous media. Finally, type 4 is non-spherical nanoparticle systems that have multiple components such as fluorescent tags and antibodies. Illustrations were prepared based on data, schemes, and figures appearing in the references of Table 5 with permission.

hundred nanometers in size or smaller, a magnetic domain (e.g. Fe$_3$O$_4$) for MR imaging, an optical probe (usually fluorescent such as FITC) for microscopy, and pores or functionality that allows the incorporation of a small molecule (i.e. therapeutic agent) or a biomolecule (i.e. antibody). MFNPSs can have four distinctive types. Type 1 is non-porous but spherical SiO$_2$ based sub-100 nm nanoparticles with two or more components. Type 2 is sub-200 nm spherical nanoparticles that is either porous or can incorporate and, in time, release small molecules such as drug molecules. Type 3 is sub-20 nm nanoparticles with functionalizable ligands or biomolecules stabilized (passivated) onto the nanoparticles and are, in most cases, first synthesized in organic conditions and then phase exchanged. Finally, type 4 is non-spherical nanoparticle

systems that have multiple components such as fluorescent tags and antibodies. (Fig. 9) This last type 4 MFNPs will essentially have very different biological responses compared to spherical systems. According to a recent study by Discher and co-workers (Geng et al., 2007) showed that particle flow and subsequent delivery of drugs are affected by shape *in vivo*. Filament (non-spherical) type particles resided approximately ten times longer than spherical particles and due to their prolonged existence drug delivery was more effective as well. Cell uptake efficiencies also differed.

Multiple examples of MFNPS exist that have small molecule therapeutic agents incorporated (Josephson et al., 2002; Kim et al., 2006b, 2007a; Lee et al., 2004b, 2006c; Levy et al., 2002; Lin et al., 2006c; Pellegrino et al., 2005; Rieter et al., 2006, 2007a,b; Santra

et al., 2005a,b,c). The overall theme for MFNPS is very straightforward but finding a balance between rationally designing the system and, at the same time, practically screening will be key issues in the development of MFNPS for biomedical application.

In contrast to inorganic based systems, biodegradable polymers such as poly(L-lactic acid) (PLLA), poly(lactide-co-glycolide) (PLGA), BSA (bovine serum albumin) have been in existence for a while now and is widely used for the controlled delivery of drugs and proteins in the form of microspheres or nanospheres (Giovagnoli et al., 2005; Ibrahim et al., 2005; Langer, 1990; Song et al., 1997; Suslick and Grinstaff, 1990; Wei et al., 2004, 2006; Yeo and Park, 2004). Based on these types of degradable polymeric systems, antibody conjugated magnetic PLGA nanoparticles were reported recently for the diagnosis and treatment of cancer (Yang et al., 2007). The drug molecule incorporated into this PLGA nanoparticle was doxorubicin (DOX) which is very similar in structure with minocycline (Choi et al., 2007) (Fig. 9) which has recently been shown to have potent anti-Alzheimer's disease effect. In fact, although not a multifunctional particle, Huperzine A was encapsulated in PLGA in its microspherical form and was used in the treatment of memory impaired rodents (Chu et al., 2007; Gao et al., 2007). Microemulsion methods have also been used to deliver pharmaceuticals, specifically metal chelators to treat CNS related diseases (Cui et al., 2005b). Veiseh et al. (2005) have reported that multifunctional nanoprobes which contained glioma cell targeting functions were also capable of being detected via MRI and fluorescent microscopy methods. This multifunctional nanoparticle is made up of iron oxide and poly(ethylene glycol) with dual functional groups.

With just single-component nanoparticles, researchers have used the nanoparticles to aid in their quest to find a cure for dementia related diseases such as Alzheimer's disease and Parkinson's disease. Nanostructured gold materials have been used to promote/suppress local protein aggregations such as Aβ (Kogan et al., 2006). In an earlier study, silver nanoparticles were utilized to study the interaction between amyloid β-derived diffusible ligand (ADDL) and the anti-ADDL antibody (Haes et al., 2004, 2005a).

In summary, tailoring the size, contents, and surface electronic properties through chemistry and physical methods within sub-200 nm nanoparticles will be key factors in the quest of using MFNPS (multifunctional nanoparticles) for the treatment and diagnosis of brain related abnormalities. Many review papers (Cornford and Hyman, 1999; Liu et al., 2005a; Lockman et al., 2002; Roney et al., 2005) have been written in recent years that talk about size being a key issue in drug delivery to the brain past the blood–brain barrier (BBB). That is very true in cases where spherical morphologies are observed in the nanomaterials but it raises a big question about particles of different shapes such as carbon nanotubes (Geng et al., 2007). In addition, although not in the field of neuroscience, lessons learned from blood related research using inorganics (Baker et al., 2007; Boettcher et al., 2007; Ostomel et al., 2006a,b,c, 2007) might help to improve particle design, synthesis and final usage as therapeutic or diagnostic agents in CNS related disorders.

We would like to end this section by providing a table listing various multifunctional nanoparticles (shown in Fig. 9) that have been developed in the past several years. This table is aimed to give a straightforward component and characteristic analysis thus providing unfamiliar neuroscientists (or any other biologist) to pick and choose what they think might improve their current research. In majority of the cases, as outlined in Fig. 9, the particles are comprised of a matrix and two or more sub-components that can be detected using fluorescence microscopy or magnetic resonance imaging. The key structural differences arise from

varying formulations among these three main contents but biological functions are more strongly affected by the surface chemistry which is not always straightforward to analyze. The ability to control the size and contents within a multifunctional nanoparticle system seems to have been explored to a much greater extent which focuses on bioimaging rather than actually using them to control specific biological functions. Expanding the state-of-the-art research represented in Table 5 to control bioprocesses involved in various biological systems and functions such as directing neuronal growth and influencing stem cell differentiation seems to be the next logical step in nanobiotechnology utilizing MFNPS.

4.3. Nanoscale imaging

Imaging techniques have improved dramatically over the years, especially the ones that involve nanometer level resolution. Electron microscopy (EM) have been well utilized in many science and engineering fields but such techniques involve the samples to be highly dehydrated since the imaging can only be done under vacuum (Allen et al., 2007; Graham and Orenstein, 2007; Kiseleva et al., 2007). Atomic force microscopy, however, has been the more sample-friendly technique for imaging nanoscale biological and bioinspired materials which is done under atmospheric pressure (Dufrene, 2008; Friedbacher et al., 1991; Hansma, 2001; Hansma et al., 1992, 1996, 1997). Another instrument that biologists and environmental scientists have increased usages of is the ESEM (environmental scanning electron microscope) which can analyze hydrated samples (Bogner et al., 2007; Muscariello et al., 2005; Priester et al., 2007) and is now frequently used to analyze biofilms. Fig. 10 shows characterization tools categorized by type of analysis based on composition (elemental), size (resolution) and type of biological sample analysis which can be linked to contents in Fig. 1. It is important to note that most of the high resolution instrumentation techniques require the samples to be under high vacuum which complicates the sample preparation process especially for biological and wet-samples; hence AFM is the method of choice when relatively unaltered (excluding the fixation process) sample imaging analysis is desirable. For instance, studying protein interactions on surfaces can be best done using AFM and when coupled with time and optical data, the dynamics of protein folding and unfolding can be imaged, tracked and analyzed. In fact, physical scientists have developed analysis platforms that couple together an AFM with a confocal microscope which is now commercially available (Blow, 2008).

Protein misfolding and formation of aggregations have been linked to several neurodegenerative diseases which include Parkinson's, Alzheimer's diseases and Down's syndrome (Bross and Gregersen, 2003). Research efforts focused on understanding the structural variables dictating the ultimate abnormalities linked with such diseases have been done using imaging techniques including AFM (Braga and Ricci, 2004). Suh and co-workers have recently shown that Aβ peptide agglomeration characteristics influence the proliferation and differentiation of murine adult neural stem cells (Heo et al., 2007). The nanoimaging technique which the researchers utilized was AFM as shown in Fig. 11a and d and under atmospheric pressure morphologically distinctive forms of Aβ peptide are formed; oligomeric or fibrillar. Various other groups have utilized AFM to conduct morphological characterization studies related to amyloid beta peptide and other proteineous species linked to neurological disorders such as α-synuclein and tau (Lyubchenko et al., 2006). Not only in biology but also synthetic inorganic nanomaterials can have distinctive morphologies as shown in Fig. 11b and e which are made up of essentially the same material (i.e. Ti and O). This is why associating structural factors to

Fig. 10. Analysis of a cell. Sub-components of a cell include (but not exclusive) nucleic acids, membrane fractions, proteins (e.g. secreted, surface displaying, localized), ion channels, and cytoskeletal components. Considering the nature of such sub-cellular components and products three categories of analyses can be drawn: (1) cell content (elemental) analysis, (2) chemical bond/functional group analysis, (3) imaging (morphology, structure, localization) analysis.

understand different outcomes in biological systems will be highly important when nanotechnology and biotechnology are adjoined together. For direct cell imaging, Lal et al. (1995) used AFM to image neurite outgrowth and cytoskeletal reorganization in real-time using rat fibroblast cells (NIH/3T3) and rat tumor cells (PC-12) *in vitro*. More recently, efforts of cell imaging using AFM have extended to other eukaryotic and prokaryotic species to reveal nanoscale features under ambient conditions (Dufrene, 2008; Kada et al., 2008).

Analyzing and understanding the toxic potentials of nano-structured beta amyloids vs. similar proteineous structures in microbial organisms (i.e. bacterial toxins) have been one of the latest developments in the efforts to understand the nature of structural and functional factors giving rise to unique but detrimental properties in the CNS (Fowler et al., 2007; Lashuel and Lansbury, 2006). Whether it is the fibrillar or oligomeric or porous (channel like) forms of Aβ or α-synuclein, the underling theme is that different nanostructures at different time-domains will affect neurogenesis in a dynamic and complex manner. As mentioned above, nanomaterials of metal oxides (Fig. 11b and e) can be engineered to mimic the structures of Aβ (as shown in Fig. 11a and d) and have well-defined isoelectric points by utilizing constituent engineering via synthetic chemistry methods.

Biochemical and molecular biology analyses can be performed to further elucidate and understand the structural effects that different nanoparticles will have on living system (i.e. cells) at the sub-100 nm domain which is at a length scale where important cellular functions (i.e. transcription, translation) are carried out. However, as mentioned in Section 3.2, the level of understanding of association between cytotoxicity and structural and physicochemical properties of nanomaterials is still not well established. On top of this unresolved complexity, there are various examples and forms of protein aggregation and misfolding that occurs naturally that is linked with neurodegeneration so a step-wise and systemic (high) throughput approach (Shaw et al., 2008; Weissleder et al., 2005) will be helpful. Cellular level activities involving small ion and molecular trafficking (i.e. Ca^{2+} signaling and gene imaging *in vivo*) have received much attention as of late which focuses on nanometer level resolution and manipulation (Atanasijevic and Jasanoff, 2007; Atanasijevic et al., 2006; Palmer et al., 2004). As mentioned in Section 2.3, gene transcription has been imaged in the brain of mice after delivery of antisense nucleic acid decorated

15–20 nm superparamagnetic iron oxide nanoparticles (also fluorescent) *in vivo* using magnetic resonance imaging (Liu et al., 2007b; Masotti et al., 2008). Specific sequences for the antisense single-stranded phosphorothioate-modified oligodeoxynucleotides (sODNs) were complementary to *c-fos* and *β-actin* mRNA and avidin-biotin complexation method was crucial in the formation of the imaging probe. Coupling multiple analysis tools (Fig. 10) to establish a well-defined understanding of sub-100 nm activities associated with cell biology will be invaluable in the further development of nanobiotechnology.

4.4. Gene delivery

4.4.1. DNA based nanotechnology

DNA based nanotechnology, in many ways, has been one of the most heavily studied fields that involves the use and the creation of bioinspired materials for highly selective biosensing, nanoarchitecture engineering and nanoelectronics (Ito and Fukusaki, 2004; Lu and Liu, 2006, 2007; Seeman, 2005; Shamah et al., 2008; Stoltenburg et al., 2007; Wernette et al., 2008). Biologically, nucleic acid delivery *in vitro* and *in vivo* has been well studied and lipid based gene delivery has become a common and essential methodology for neuroscientists and biologists. Transfection techniques, for mammalian cells, are primarily divided into non-viral and viral techniques and for many nanotech research groups investigating gene and drug delivery methodologies, the focus is on the non-viral particle based systems (Dobson, 2006; Labhasetwar, 2005; Li and Szoka, 2007) but increasing number of nanotech projects are investigating and manipulating viruses (Kovacs et al., 2007; Loo et al., 2007; Radloff et al., 2005; Sun et al., 2007).

For DNA delivery and utilization of DNA to study the dynamics of nanostructures, Au nanoparticles (Daniel and Astruc, 2004) and silica nanoparticles have been the choice of materials since there surface chemistries, physicochemical and optoelectronic properties are well established (Hench and West, 1990; Livage et al., 1988; Yan et al., 2007). Nucleic acid hybridization via base pairing (hydrogen bonding) and Au-thiol chemistry (Bain et al., 1989; Laibinis et al., 1991; Love et al., 2005), for the most part, offered a unique opportunity for investigating assembly of DNA functionalized gold nanoparticles which lead to the development of novel sensing technologies (Sassolas et al., 2008) for detecting small molecules (Liu and Lu, 2004b, 2006b; Liu et al., 2006), biomolecules

Fig. 11. Nanoscale imaging of biomolecules and inorganic materials. (Top row) high aspect ratio nanomaterials (e.g. fibrillar, tubular, and rod shaped); (bottom row) low aspect ratio nanostructures (e.g. oligomeric, spherical, and sub-100 nm nanoparticles). (a) AFM image of Aβ, tubular form. (b) TEM image of titanium oxide nanotubes. (c) Illustration representing crystallization schemes for high aspect ratio nanomaterials. (d) AFM image of Aβ, oligomeric form. (e) TEM image of titanium oxide nanoparticles. (f) Illustration representing crystallization schemes of spherical nanomaterials. (a) and (d) (the AFM data) were adapted from reference Heo et al. (2007) with permission from the publisher.

(Cao et al., 2002; Hill et al., 2007; Lee et al., 2004a; Tansil and Gao, 2006) and metal ions (Liu and Lu, 2003, 2004a, 2005, 2006a; Lu and Liu, 2007; Wernette et al., 2008) and nanoassembly/architecture projects (Mirkin, 2000; Park et al., 2004, 2008). Gene delivery using Au nanoparticles have well been demonstrated by Mirkin and co-workers on several occassions (Rosi et al., 2006; Seferos et al., 2007). Surface modified (multifunctional) silica nanoparticles have also been well utilized to deliver or detect DNAs (Bharali et al., 2005; Fuller et al., 2008; Gemeinhart et al., 2005; Klejbor et al., 2007; Kneuer et al., 2000a,b; Radu et al., 2004; Torney et al., 2007).

4.4.2. RNA interference

RNA interference (RNAi) and targeting the translation process which occurs in the cytosol, in rapid manner, paved the way to developing novel pathways to alter protein synthesis by the break down of mRNAs using small interfering RNAs (siRNAs) (Hannon, 2002). Along with siRNAs, microRNAs (miRNAs) are used by the genome of various organisms to carry out similar regulatory assignments which stops the translation process and recent research shows that miRNAs play critical roles in various neuronal pathways and stem cell biology (Hebert and De Strooper, 2007;

Fig. 12. RNA interference vehicles. Various shapes and forms are used as tools to deliver RNA that will selectively silence gene translation; examples include dendrimers, copolymers, nucleic acid decorated Au NPs, nanocomposite spheres, multifunctional QDs, carbon nanotube arrays, and nanocircular RNAs. Illustrations were prepared based on data, schemes, and figures appearing in the references with permission from the publisher.

Kosik, 2006; Kosik and Krichevsky, 2005). The use of chemistry and nanotechnology based tools in discovering new types of therapeutics based on non-viral carrier systems to deliver oligonucleotides into the cytosol to control the translation process have increased over the years (Baigude et al., 2007; Guo, 2005; Heidel et al., 2007; Howard et al., 2006; Schiffelers et al., 2004; Yuan et al., 2006). In this section we would like to review some of the latest developments in the area of RNA interference and DNA delivery using synthetic nanomaterials from polymeric systems to inorganic systems (Fig. 12). The basic scheme, to highlight the state-of-the-art, is to penetrate the cell membrane, deliver binding agents, stop the target gene expression pathway but without damaging or killing the target cells.

Keller and researchers thoroughly investigated several different lipid based carrier systems (liposomal systems as mentioned in the paper) in relation to their protein downregulation efficiency and overall *in vitro* cell toxicity (Spagnou et al., 2004). Variety of commercially available lipid based nucleic acid delivery methods were investigated and compared for silencing the β-Gal reporter gene in two cancer cell lines (HeLa and IGROV-1). The conclusion was that cationic lipid based delivery of plasmid DNA vs. siRNA have distinctive differences which warrant optimization of formulation for increased delivery efficiencies with low toxicities. Related research efforts involving the use of inorganic nanomaterials as gene delivery vehicles can readily utilize the nanotoxicology information reviewed (and tabulized) in this review in Section 3.

Rana and co-workers used a non-toxic and cationically charged poly(lysine) based dendrimer (spherical and oligomeric) nanoparticle with unsaturated hydrocarbon side chains (Baigude et al., 2007). The target gene was apoB and the mRNA expression silencing efficiency was, first, investigated *in vitro* using mouse liver cells (FL83B) and the results were comparable to Lipofectamine 2000 which is an industrial standard for gene delivery into cells. The *in vivo* silencing efficiency was highest at 1 mg/kg (reasonable dosage to be used in a therapeutic application) but did not increase past that concentration. Results of this study suggest that using both the cationically charged dendrimer and the chemically modified siRNA most efficiently silences the oligonucleotide.

Amine terminated or functionalized nanocarriers with PEGylated sub-units within the polymeric species were previously designed for complexation and delivery of siRNA to a human hepatoma cell line (HuH-7 cells) to knockdown transfected luciferage genes as well as the endogeneous Lamin A/C gene with excellent efficiencies (Itaka et al., 2004). Three amine variations were tested and compared; the dipropylene triamine moiety instilled supramolecular nanocarrier provided the best gene silencing ability. The other two were poly(L-lysine) and poly(3-dimethylamino)propyl aspartamide containing nanocarriers. The carrier with the dipropylene triamine has pKa values of 9.9 and 6.4 which allow facile siRNA complexation and sufficient buffering capabilities inside the endosome. In addition, the PEG unit within the dipropylene triamine nanocarrier allowed stable complexes to form with siRNAs even under 50% serum conditions and, in fact, the siRNA-nanocarrier complex even suppressed the endogeneous gene of Lamin A/C, a cytoskeletal protein abundantly expressed in the cell. Kataoka and co-workers, furthermore, introduced a bioconjugate which covalently links siRNA with lactosylated PEG via an acid-labile linkage (size between 90–145 nm with approximately 36 PEG repeats) based on the fact that endosomes have a pH of about 5.5 and internalization of the conjugate will release the siRNA (Oishi et al., 2005, 2007). It is worth noting that PEGylation provides prolonged circulation time *in vivo* (Ogris et al., 1999) and has since emerged as one of the key functionalization tools for developing pharmaceuticals and nanobiocomposites for biomedical usages

(Ballou et al., 2004; Brocchini et al., 2006; Harris and Chess, 2003; Kostiainen et al., 2007; Mishra et al., 2004; Petersen et al., 2002; Tang et al., 2003; Tu and Tirrell, 2004).

Inorganic based nanoparticles have also been utilized successfully for siRNA delivery and analysis. Bakalova and Ohba with fellow researchers utilized a synthetic inorganic core–shell and fluorescent nanoparticle made out of CdSe/ZnS (quantum dots; QD) to multifunctionalize and screen for siRNA sequences. FRET (fluorescence resonance energy transfer) was the main tool for RNA analysis which was done after hybridizing the prepared QD-siRNA probe with Cy5 labeled target mRNA (isolated from K-562 leukemia cells) (Kubo et al., 2008). In an earlier study by Bhatia and co-workers, commercially available QDs that were PEGylated were further functionalized with tumor-homing peptides and siRNA and then used to silence gene(s) after targeting a specific cell (Derfus et al., 2007). Calcium phosphate nanoparticles (approximately 100 nm in size) were also effective in silencing the EGFP gene in HeLa cells in conjunction with siRNAs (Sokolova et al., 2007). In addition, gold nanoparticle (sized approximate 13 nm) decorated with thiol-modified oligonucleotides (i.e. antisense and locked nucleic acid) were also shown to be very effective in entering the target cell and stopping a specific translational process in a non-toxic and controlled manner by the Mirkin group (Rosi et al., 2006; Seferos et al., 2007).

McKnight and co-workers have demonstrated a non-particle based system for RNA interference by using vertically aligned carbon nanofibers to deliver multiple genes (i.e. small hairpin RNA (shRNA) vector and YFP marker gene) which will silence the cyan fluorescent protein (CFP) synthesis in the presence of tetracycline in Chinese hamster ovary cells (CHO-K1) (Mann et al., 2008). Previously, similar platform of materials were utilized to delivery DNA into living cells with good efficiency (McKnight et al., 2003; McKnight et al., 2004). This is very similar to the approach mentioned earlier in the review which highlights the work by Kim et al. (2007c) where GFP plasmid DNA is delivered using silicon nanowires.

RNA dumbbells or nanocircular RNAs (Fig. 12) consisting of 23 base pairs (firefly luciferase gene) and two 9-mer loops were designed and utilized as siRNA precursors after they were processed by the Dicer enzyme inside the cell (Abe et al., 2007). The stem-loop (design) combination allows the RNA dumbbells to be resistant to nucleases and provide a slow-acting RNAi profile. Design concept of this kind will allow the development of well-defined RNAi systems that will effectively silence gene expressions in a highly controllable and non-toxic manner.

5. Conclusions

Size means everything in linking nanotechnology together with biotechnology. Much biotechnology relies heavily on biomolecules such as proteins and DNA. Research in the field of neuroscience will definitely benefit with the advent of chemical and materials synthesis (e.g. multifunctional nanoparticle systems) that allows incorporation of these biomolecules to nanostructured inorganic and organic materials. The foremost areas are likely to involve bioimaging, biomedical-diagnostics, drug delivery, tissue engineering, and neuronal (network) systems studies. Most particularly, studies involving stem cell differentiation and transplantation, neural implants, targeted drug delivery with real-time monitoring capabilities, *in vivo* RNAi will prove very attractive. Multidisciplinary approaches will allow these sorts of projects to be successful research efforts and eventually lead to innovations that will ultimately help mankind. Close collaborations among researchers with different backgrounds will succeed best when nanostrutures are created and characterized by chemists and materials scientists and implementation of

nanomaterials in specific biomedical applications are done by neuroscientists and clinicians. Most importantly, the roles of scientists trained and having experience working at the interface of biotechnology and nanotechnology will play increasingly important roles in the new wave of biomedical research and application. The scientific language and the way research is conducted, valued and evaluated between scientific disciplines have subtle differences which can slow down and even act as sources of deterrents in the road to a successful collaboration. Nanobiotechnology (or bionanotechnology) has advanced significantly now that synthesis and implication of applications need to be followed by practical and realistic usages. New advances, especially in neuroscience, will arise from systematic investigations starting from synthesis to application where the central efforts are probing and understanding events occurring at the nano–bio interface.

Acknowledgments

References

Aaron, J., Nitin, N., Travis, K., Kumar, S., Collier, T., Park, S.Y., Jose-Yacaman, M., Coghlan, L., Follen, M., Richards-Kortum, R., Sokolov, K., 2007. Plasmon resonance coupling of metal nanoparticles for molecular imaging of carcinogenesis *in vivo*. J. Biomed. Opt. 12, 034007.

Abe, N., Abe, H., Ito, Y., 2007. Dumbbell-shaped nanocircular RNAs for RNA interference. J. Am. Chem. Soc. 129, 15108–15109.

Adams, L.K., Lyon, D.Y., Alvarez, P.J.J., 2006. Comparative eco-toxicity of nanoscale TiO_2, SiO_2, and ZnO water suspensions. Water Res. 40, 3527–3532.

Afaq, F., Abidi, P., Matin, R., Rahman, Q., 1998a. Activation of alveolar macrophages and peripheral red blood cells in rats exposed to fibers/particles. Toxicol. Lett. 99, 175–182.

Afaq, F., Abidi, P., Matin, R., Rahman, Q., 1998b. Cytotoxicity, pro-oxidant effects and antioxidant depletion in rat lung alveolar macrophages exposed to ultrafine titanium dioxide. J. Appl. Toxicol. 18, 307–312.

Ahn, S.H., Jeon, S.H., Tsuruo, T., Shim, C.K., Chung, S.J., 2004. Pharmacokinetic characterization of dehydroevodiamine in the rat brain. J. Pharmacol. Sci. 93, 283–292.

Aizenberg, J., Black, A.J., Whitesides, G.M., 1998. Controlling local disorder in self-assembled monolayers by patterning the topography of their metallic supports. Nature 394, 868–871.

Ajima, K., Yudasaka, M., Murakami, T., Maigne, A., Shiba, K., Iijima, S., 2005. Carbon nanohorns as anticancer drug carriers. Mol. Pharmaceutics 2, 475–480.

Akerman, M.E., Chan, W.C.W., Laakkonen, P., Bhatia, S.N., Ruoslahti, E., 2002. Nanocrystal targeting *in vivo*. Proc. Natl. Acad. Sci. U.S.A. 99, 12617–12621.

Alam, H.B., Burris, D., DaCorta, J.A., Rhee, P., 2005. Hemorrhage control in the battlefield: role of new hemostatic agents. Milit. Med. 170, 63–69.

Albrecht, D.R., Underhill, G.H., Wassermann, T.B., Sah, R.L., Bhatia, S.N., 2006. Probing the role of multicellular organization in three-dimensional microenvironments. Nat. Methods 3, 369–375.

Alfredsson, V., Keung, M., Monnier, A., Stucky, G.D., Unger, K.K., Schuth, F., 1994. High-resolution transmission electron-microscopy of mesoporous MCM-41 type materials. J. Chem. Soc. -Chem. Commun. 921–922.

Allen, T.D., Rutherford, S.A., Murray, S., Sanderson, H.S., Gardiner, F., Kiseleva, E., Goldberg, M.W., Drummond, S.P., 2007. A protocol for isolating Xenopus oocyte nuclear envelope for visualization and characterization by scanning electron microscopy (SEM) or transmission electron microscopy (TEM). Nat. Protoc. 2, 1166–1172.

Allen, T.M., Cullis, P.R., 2004. Drug delivery systems: entering the mainstream. Science 303, 1818–1822.

Arap, W., Pasqualini, R., Ruoslahti, E., 1998. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377–380.

Arbab, A.S., Bashaw, L.A., Miller, B.R., Jordan, E.K., Bulte, J.W.M., Frank, J.A., 2003. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation 76, 1123–1130.

Atanasijevic, T., Jasanoff, A., 2007. Preparation of iron oxide-based calcium sensors for MRI. Nat. Protoc. 2, 2582–2589.

Atanasijevic, T., Shusteff, M., Fam, P., Jasanoff, A., 2006. Calcium-sensitive MRI contrast agents based on superparamagnetic iron oxide nanoparticles and calmodulin. Proc. Natl. Acad. Sci. U.S.A. 103, 14707–14712.

Baigude, H., McCarroll, J., Yang, C.S., Swain, P.M., Rana, T.M., 2007. Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem. Biol. 2, 237–241.

Bain, C.D., Troughton, E.B., Tao, Y.T., Evall, J., Whitesides, G.M., Nuzzo, R.G., 1989. Formation of monolayer films by the spontaneous assembly of organic thiols from solution onto gold. J. Am. Chem. Soc. 111, 321–335.

Baker, S.E., Sawvel, A.M., Zheng, N., Stucky, G.D., 2007. Controlling bioprocesses with inorganic surfaces: layered clay hemostatic agents. Chem. Mater. 19, 4390–4392.

Baker, S.E., Sawvel, A.M., Fan, J., Shi, Q., Strandwitz, N.C., Stucky, G.D., 2008. Blood clot initiation by mesocellular foams: dependence on nanopore size and enzyme immobilization. Langmuir 24, 14254–14260.

Balbus, J.M., Maynard, A.D., Colvin, V.L., Castranova, V., Daston, G.P., Denison, R.A., Dreher, K.L., Goering, P.L., Goldberg, A.M., Kulinowski, K.M., Monteiro-Riviere, N.A., Oberdorster, G., Omenn, G.S., Pinkerton, K.E., Ramos, K.S., Rest, K.M., Sass, J.B., Silbergeld, E.K., Wong, B.A., 2007. Meeting report: hazard assessment for nanoparticles—report from an interdisciplinary workshop. Environ. Health Perspect. 115, 1654–1659.

Ballou, B., Lagerholm, B.C., Ernst, L.A., Bruchez, M.P., Waggoner, A.S., 2004. Non-invasive imaging of quantum dots in mice. Bioconj. Chem. 15, 79–86.

Barone, P.W., Baik, S., Heller, D.A., Strano, M.S., 2005. Near-infrared optical sensors based on single-walled carbon nanotubes. Nat. Mater. 4, 86–92.

Beck, J.S., Vartuli, J.C., Roth, W.J., Leonowicz, M.E., Kresge, C.T., Schmitt, K.D., Chu, C.T.W., Olson, D.H., Sheppard, E.W., McCullen, S.B., Higgins, J.B., Schlenker, J.L., 1992. A new family of mesoporous molecular-sieves prepared with liquid-crystal templates. J. Am. Chem. Soc. 114, 10834–10843.

Bergna, H.E. Colloid chemistry of silica. An overview. DuPont, Wilmington, DE, USA. Advances in Chemistry Series (1994), vol. 234 (Colloid Chemistry of Silica). American Chemical Society, pp. 1–47, CODEN: ADCSAJ, ISSN: 0065-2393.

Berkeley, 2006. Manufactured Nanoparticle Health and Safety Disclosure – Berkeley Ordnance. www.calcupa.net/programs/business/Berkeley_Ordinance.pdf.

Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E., 2000. The protein data bank. Nucleic Acids Res. 28, 235–242.

Bharali, D.J., Klejbor, I., Stachowiak, E.K., Dutta, P., Roy, I., Kaur, N., Bergey, E.J., Prasad, P.N., Stachowiak, M.K., 2005. Organically modified silica nanoparticles: a nonviral vector for *in vivo* gene delivery and expression in the brain. Proc. Natl. Acad. Sci. U.S.A. 102, 11539–11544.

Bhatia, S.N., Chen, C., 2007. Special issue on cell and tissue engineering in microsystems. Lab Chip 7, 666–1666.

Bhattacharya, D., Gupta, R.K., 2005. Nanotechnology and potential of microorganisms. Crit. Rev. Biotechnol. 25, 199–204.

Blow, N., 2008. Nanotechnology: could it be a small world after all? Nature 452, 901–906.

Blumen, S.R., Cheng, K., Ramos-Nino, M.E., Taatjes, D.J., Weiss, D.J., Landry, C.C., Mossman, B.T., 2007. Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells. Am. J. Respir. Cell Mol. Biol. 36, 333–342.

Boettcher, S.W., Fan, J., Tsung, C.K., Shi, Q.H., Stucky, G.D., 2007. Harnessing the sol–gel process for the assembly of non-silicate mesostructured oxide materials. Acc. Chem. Res. 40, 784–792.

Bogner, A., Jouneau, P.H., Thollet, G., Basset, D., Gauthier, C., 2007. A history of scanning electron microscopy developments: towards "wet-STEM" imaging. Micron 38, 390–401.

Borm, P., Klaessig, F.C., Landry, T.D., Moudgil, B., Pauluhn, J., Thomas, K., Trottier, R., Wood, S., 2006. Research strategies for safety evaluation of nanomaterials. Part V. Role of dissolution in biological fate and effects of nanoscale particles. Toxicol. Sci. 90, 23–32.

Borm, P.J.A., Kreyling, W., 2004. Toxicological hazards of inhaled nanoparticles—potential implications for drug delivery. J. Nanosci. Nanotech. 4, 521–531.

Bottini, M., Cerignoli, F., Mills, D.M., D'Annibale, F., Leone, M., Rosato, N., Magrini, A., Pellecchia, M., Bergamaschi, A., Mustelin, T., 2007. Luminescent silica nanobeads: characterization and evaluation as efficient cytoplasmatic transporters for T-lymphocytes. J. Am. Chem. Soc. 129, 7814–7823.

Bourrinet, P., Bengele, H.H., Bonnemain, B., Dencausse, A., Idee, J.M., Jacobs, P.M., Lewis, J.M., 2006. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest. Radiol. 41, 313–324.

Braga, P.C., Ricci, D., 2004. Atomic Force Microscopy: Biomedical Methods and Applications. Humana Press, Totowa, NJ.

Brocchini, S., Balan, S., Godwin, A., Choi, J.W., Zloh, M., Shaunak, S., 2006. PEGylation of native disulfide bonds in proteins. Nat. Protoc. 1, 2241–2252.

Bross, P., Gregersen, N., 2003. Protein Misfolding and Disease: Principles and Protocols. Humana Press, Totowa, NJ.

Brunner, T.J., Wick, P., Manser, P., Spohn, P., Grass, R.N., Limbach, L.K., Bruinink, A., Stark, W.J., 2006. In vitro cytotoxicity of oxide nanoparticles: comparison to asbestos, silica, and the effect of particle solubility. Environ. Sci. Tech. 40, 4374–4381.

Bulte, J.W.M., Douglas, T., Witwer, B., Zhang, S.C., Strable, E., Lewis, B.K., Zywicke, H., Miller, B., van Gelderen, P., Moskowitz, B.M., Duncan, I.D., Frank, J.A., 2001. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat. Biotechnol. 19, 1141–1147.

Burghard, M., 2003. Carbon nanotubes by quantitative solid-state conversion of an organometallic precursor. Angew. Chem. Int. Ed. 42, 5929–5930.

Campbell, C.T., 1997. Ultrathin metal films and particles on oxide surfaces: structural, electronic and chemisorptive properties. Surf. Sci. Rep. 27, 1–111.

Campbell, D.J., Olson, J.A., Calderon, C.E., Doolan, P.W., Mengelt, E.A., Ellis, A.B., Lisensky, G.C., 1999. Chemistry with refrigerator magnets: from modeling of nanoscale characterization to composite fabrication. J. Chem. Educ. 76, 1205–1211.

Campbell, D.J., Xia, Y., 2007. Plasmons: why should we care? J. Chem. Educ. 84, 91–96.

Candler, P.M., Dale, R.C., 2004. Three cases of central nervous system complications associated with Mycoplasma pneumoniae. Pediatr. Neurol. 31, 133–138.

Cao, L., Wang, X., Meziani, M.J., Lu, F.S., Wang, H.F., Luo, P.J.G., Lin, Y., Harruff, B.A., Veca, L.M., Murray, D., Xie, S.Y., Sun, Y.P., 2007. Carbon dots for multiphoton bioimaging. J. Am. Chem. Soc. 129, 11318–11319.

Cao, Y.W.C., Jin, R.C., Mirkin, C.A., 2002. Nanoparticles with Raman spectroscopic fingerprints for DNA and RNA detection. Science 297, 1536–1540.

Carrado, K.A., Macha, S.M., Tiede, D.M., 2004. Effects of surface functionalization and organo-tailoring of synthetic layer silicates on the immobilization of cytochrome c. Chem. Mater. 16, 2559–2566.

Carrero-Sanchez, J.C., Elias, A.L., Mancilla, R., Arrellin, G., Terrones, H., Laclette, J.P., Terrones, M., 2006. Biocompatibility and toxicological studies of carbon nanotubes doped with nitrogen. Nano Lett. 6, 1609–1616.

Caruthers, S.D., Wickline, S.A., Lanza, G.M., 2007. Nanotechnological applications in medicine. Curr. Opin. Biotechnol. 18, 26–30.

Casserly, G., Barry, T., Tourtellotte, W.W., Hogan, E.L., 2007. Absence of mycoplasma-specific DNA sequence in brain, blood and CSF of patients with multiple sclerosis (MS): a study by PCR and real-time PCR. J. Neurol. Sci. 253, 48–52.

Cengelli, F., Maysinger, D., Tschudi-Monnet, F., Montet, X., Corot, C., Petri-Fink, A., Hofmann, H., Juillerat-Jeanneret, L., 2006. Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J. Pharmacol. Exp. Ther. 318, 108–116.

Chai, G.S., Yoon, S.B., Yu, J.S., Choi, J.H., Sung, Y.E., 2004. Ordered porous carbons with tunable pore sizes as catalyst supports in direct methanol fuel cell. J. Phys. Chem. B 108, 7074–7079.

Chan, K.C., Patri, A.K., Veenstra, T.D., McNeil, S.E., Issaq, H.J., 2007. Analysis of fullerene-based nanomaterial in serum matrix by CE. Electrophoresis 28, 1518–1524.

Chang, E., Thekkek, N., Yu, W.W., Colvin, V.L., Drezek, R., 2006. Evaluation of quantum dot cytotoxicity based on intracellular uptake. Small 2, 1412–1417.

Chang, J.S., Chang, K.L.B., Hwang, D.F., Kong, Z.L., 2007. In vitro cytotoxicitiy of silica nanoparticles at high concentrations strongly depends on the metabolic activity type of the cell line. Environ. Sci. Tech. 41, 2064–2068.

Charache, P., Macleod, C.M., White, P., 1962. Effects of silicate polymers on erythrocytes in presence and absence of complement. J. Gen. Physiol. 45, 1117–1143.

Chen, C.S., Jiang, X.Y., Whitesides, G.M., 2005. Microengineering the environment of mammalian cells in culture. MRS Bull. 30, 194–201.

Chen, C.S., Mrksich, M., Huang, S., Whitesides, G.M., Ingber, D.E., 1998. Micropatterned surfaces for control of cell shape, position, and function. Biotechnol. Prog. 14, 356–363.

Chen, H.W., Su, S.F., Chien, C.T., Lin, W.H., Yu, S.L., Chou, C.C., Chen, J.J.W., Yang, P.C., 2006a. Titanium dioxide nanoparticles induce emphysema-like lung injury in mice. FASEB J. 20, 2393–2395.

Chen, J.P., Patil, S., Seal, S., McGinnis, J.F., 2006b. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat. Nanotechnol. 1, 142–150.

Chen, X., Kis, A., Zettl, A., Bertozzi, C.R., 2007. A cell nanoinjector based on carbon nanotubes. Proc. Natl. Acad. Sci. U.S.A. 104, 8218–8222.

Chen, X.C., Chang, L.J., 2005. Mycoplasma-mediated alterations of in vitro generation and functions of human dendritic cells. J. Biomed. Sci. 12, 31–46.

Choi, J.S., Jun, Y.W., Yeon, S.I., Kim, H.C., Shin, J.S., Cheon, J., 2006. Biocompatible heterostructured nanoparticles for multimodal biological detection. J. Am. Chem. Soc. 128, 15982–15983.

Choi, Y., Kim, H.-S., Shin, K.Y., Kim, E.-M., Kim, M., Kim, H.-S., Park, C.H., Jeong, Y.H., Yoo, J., Lee, J.-P., Chang, K.-A., Kim, S., Suh, Y.-H., 2007. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32, 2393–2404.

Chowdhury, E.H., Akaike, T., 2005. Bio-functional inorganic materials: an attractive branch of gene-based nano-medicine delivery for 21st century. Curr. Gene Ther. 5, 669–676.

Chu, D.F., Tian, J.W., Liu, W.H., Li, Z., Li, Y.X., 2007. Poly(lactic-co-glycolic acid) microspheres for the controlled release of huperzine A: in vitro and in vivo studies and the application in the treatment of the impaired memory of mice. Chem. Pharm. Bull. 55, 625–628.

Chung, T.H., Wu, S.H., Yao, M., Lu, C.W., Lin, Y.S., Hung, Y., Mou, C.Y., Chen, Y.C., Huang, D.M., 2007. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 28, 2959–2966.

Cobo, F., Cortes, J.L., Cabrera, C., Nieto, A., Concha, A., 2007. Microbiological contamination in stem cell cultures. Cell Biol. Int. 31, 991–995.

Cobo, F., Stacey, G.N., Hunt, C., Cabrera, C., Nieto, A., Montes, R., Cortes, J.L., Catalina, P., Barnie, A., Concha, A., 2005. Microbiological control in stem cell banks: approaches to standardisation. Appl. Microbiol. Biotech. 68, 456–466.

Colvin, V.L., 2003. The potential environmental impact of engineered nanomaterials. Nat. Biotechnol. 21, 1166–1170.

Corma, A., 1997. From microporous to mesoporous molecular sieve materials and their use in catalysis. Chem. Rev. 97, 2373–2419.

Cornell, R.M., Schwertmann, U., 1996. The Iron Oxides: Structure, Properties, Reactions, Occurrence and Uses. VCH, Weinheim, New York.

Cornford, E.M., Hyman, S., 1999. Blood–brain barrier permeability to small and large molecules. Adv. Drug Deliv. Rev. 36, 145–163.

Cui, D.X., Tian, F.R., Ozkan, C.S., Wang, M., Gao, H.J., 2005a. Effect of single wall carbon nanotubes on human HEK293 cells. Toxicol. Lett. 155, 73–85.

Cui, Z.R., Lockman, P.R., Atwood, C.S., Hsu, C.H., Gupte, A., Allen, D.D., Mumper, R.J., 2005b. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm. 59, 263–272.

Cushing, B.L., Kolesnichenko, V.L., O'Connor, C.J., 2004. Recent advances in the liquid-phase syntheses of inorganic nanoparticles. Chem. Rev. 104, 3893–3946.

Center for Biological and Environmental Nanotechnology (CBEN). http://cben.rice.edu/.

Dai, H.J., 2002. Carbon nanotubes: synthesis, integration, and properties. Acc. Chem. Res. 35, 1035–1044.

Dai, L.M., He, P.G., Li, S.N., 2003. Functionalized surfaces based on polymers and carbon nanotubes for some biomedical and optoelectronic applications. Nanotechnology 14, 1081–1097.

Daniel, M.C., Astruc, D., 2004. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem. Rev. 104, 293–346.

Das, M., Patil, S., Bhargava, N., Kang, J.F., Riedel, L.M., Seal, S., Hickman, J.J., 2007. Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons. Biomaterials 28, 1918–1925.

Daxboeck, F., 2006. Mycoplasma pneumoniae central nervous system infections. Curr. Opin. Neurol. 19, 374–378.

Daxboeck, F., Khanakah, G., Bauer, C., Stadler, M., Hofmann, H., Stanek, G., 2005. Detection of Mycoplasma pneumoniae in serum specimens from patients with mycoplasma pneumonia by PCR. Int. J. Med. Microbiol. 295, 279–285.

Daxboeck, F., Krause, R., Wenisch, C., 2003. Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin. Microbiol. Infect. 9, 263–273.

Decker, M., 2005. Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine. Eur. J. Med. Chem. 40, 305–313.

Delatte, N.J., 2001. Lessons from Roman cement and concrete. J. Prof. Issues Eng. Educ. Pract. 127, 109–115.

Derfus, A.M., Chan, W.C.W., Bhatia, S.N., 2004. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett. 4, 11–18.

Derfus, A.M., Chen, A.A., Min, D.H., Ruoslahti, E., Bhatia, S.N., 2007. Targeted quantum dot conjugates for siRNA delivery. Bioconj. Chem. 18, 1391–1396.

Diebold, U., 2003. The surface science of titanium dioxide. Surf. Sci. Rep. 48, 53–229.

Diederich, F., Gomez-Lopez, M., 1999. Supramolecular fullerene chemistry. Chem. Soc. Rev. 28, 263–277.

Dobrovolskaia, M.A., McNeil, S.E., 2007. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2, 469–478.

Dobson, J., 2006. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther. 13, 283–287.

Donaldson, K., Aitken, R., Tran, L., Stone, V., Duffin, R., Forrest, G., Alexander, A., 2006. Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. Toxicol. Sci. 92, 5–22.

Dosa, P.I., Erben, C., Iyer, V.S., Vollhardt, K.P.C., Wasser, I.M., 1999. Metal encapsulating carbon nanostructures from oligoalkyne metal complexes. J. Am. Chem. Soc. 121, 10430–10431.

Dreher, K.L., 2004. Health and environmental impact of nanotechnology: toxicological assessment of manufactured nanoparticles. Toxicol. Sci. 77, 3–5.

Dufrene, Y.F., 2008. Atomic force microscopy and chemical force microscopy of microbial cells. Nat. Protoc. 3, 1132–1138.

Dumortier, H., Lacotte, S., Pastorin, G., Marega, R., Wu, W., Bonifazi, D., Briand, J.P., Prato, M., Muller, S., Bianco, A., 2006. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett. 6, 1522–1528.

Dunning, M.D., Kettunen, M.I., Constant, C.F., Franklin, R.J.M., Brindle, K.M., 2006. Magnetic resonance imaging of functional Schwann cell transplants labelled with magnetic microspheres. Neuroimage 31, 172–180.

Dunning, M.D., Lakatos, A., Loizou, L., Kettunen, M., ffrench-Constant, C., Brindle, K.M., Franklin, R.J.M., 2004. Superparamagnetic iron oxide-labeled Schwann cells and olfactory ensheathing cells can be traced in vivo by magnetic resonance imaging and retain functional properties after transplantation into the CNS. J. Neurosci. 24, 9799–9810.

Dutta, D., Sundaram, S.K., Teeguarden, J.G., Riley, B.J., Fifield, L.S., Jacobs, J.M., Addleman, S.R., Kaysen, G.A., Moudgil, B.M., Weber, T.J., 2007. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol. Sci. 100, 303–315.

Eddaoudi, M., Moler, D.B., Li, H.L., Chen, B.L., Reineke, T.M., O'Keeffe, M., Yaghi, O.M., 2001. Modular chemistry: secondary building units as a basis for the design of highly porous and robust metal-organic carboxylate frameworks. Acc. Chem. Res. 34, 319–330.

Edwards, P.P., Thomas, J.M., 2007. Gold in a metallic divided state—from Faraday to present-day nanoscience. Angew. Chem. Int. Ed. 46, 5480–5486.

El Hamaoui, B., Zhi, L.J., Wu, J.S., Kolb, U., Mullen, K., 2005. Uniform carbon and carbon/cobalt nanostructures by solid-state thermolysis of polyphenylene dendrimer/cobalt complexes. Adv. Mater. 17, 2957–2960.

Ellis-Behnke, R.G., Liang, Y.X., You, S.W., Tay, D.K.C., Zhang, S.G., So, K.F., Schneider, G.E., 2006. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc. Natl. Acad. Sci. U.S.A. 103, 5054–5059.

Faber, C., Zahneisen, B., Tippmann, F., Schroeder, A., Fahrenholz, F., 2007. Gradient-Echo and CRAZED imaging for minute detection of Alzheimer plaques in an APP_{V717I} x $ADAM10$-dn mouse model. Mag. Reson. Med. 57, 696–703.

Fall, M., Guerbet, M., Park, B., Gouriou, F., Dionnet, F., Morin, J.-P., 2007. Evaluation of cerium oxide and cerium oxide based fuel additive safety on organotypic cultures of lung slices. Nanotoxicology 1, 227–234.

Fan, Y., Chen, X.T., Trigg, A.D., Tung, C.H., Kong, J.M., Gao, Z.Q., 2007. Detection of microRNAs using target-guided formation of conducting polymer nanowires in nanogaps. J. Am. Chem. Soc. 129, 5437–5443.

Fang, S.P., Lee, H.J., Wark, A.W., Corn, R.M., 2006. Attomole microarray detection of microRNAs by nanoparticle-amplified SPR imaging measurements of surface polyadenylation reactions. J. Am. Chem. Soc. 128, 14044–14046.

Faraday, M., 1847. The Bakerian lecture: experimental relations of gold (and other metals) to light. Philos. Trans. R. Soc. Lond. Ser. 147, 145–181.

Fiorito, S., Serafino, A., Andreola, F., Togna, A., Togna, G., 2006. Toxicity and biocompatibility of carbon nanoparticles. J. Nanosci. Nanotech. 6, 591–599.

Fischer, T.H., Thatte, H.S., Nichols, T.C., Bender-Neal, D.E., Bellinger, D.A., Vournakis, J.N., 2005. Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber-mediated hemostasis. Biomaterials 26, 5433–5443.

Flaim, C.J., Chien, S., Bhatia, S.N., 2005. An extracellular matrix microarray for probing cellular differentiation. Nat. Methods 2, 119–125.

Fowler, D.M., Koulov, A.V., Balch, W.E., Kelly, J.W., 2007. Functional amyloid—from bacteria to humans. Trends Biochem. Sci. 32, 217–224.

Freund, H.J., Kuhlenbeck, H., Staemmler, V., 1996. Oxide surfaces. Rep. Prog. Phys. 59, 283–347.

Friedbacher, G., Hansma, P.K., Ramli, E., Stucky, G.D., 1991. Imaging powders with the atomic force microscope—from biominerals to commercial materials. Science 253, 1261–1263.

Fu, A.H., Gu, W.W., Larabell, C., Alivisatos, A.P., 2005. Semiconductor nanocrystals for biological imaging. Curr. Opin. Neurobiol. 15, 568–575.

Fu, C.C., Lee, H.Y., Chen, K., Lim, T.S., Wu, H.Y., Lin, P.K., Wei, P.K., Tsao, P.H., Chang, H.C., Fann, W., 2007. Characterization and application of single fluorescent nanodiamonds as cellular biomarkers. Proc. Natl. Acad. Sci. U.S.A. 104, 727–732.

Fuller, J.E., Zugates, G.T., Ferreira, L.S., Ow, H.S., Nguyen, N.N., Wiesner, U.B., Langer, R.S., 2008. Intracellular delivery of core–shell fluorescent silica nanoparticles. Biomaterials 29, 1526–1532.

Gao, P., Xu, H., Ding, P.T., Gao, Q.Z., Sun, J.Y., Chen, D.W., 2007. Controlled release of huperzine A from biodegradable microspheres: in vitro and in vivo studies. Int. J. Pharm. 330, 1–5.

Gao, Z.Q., Yang, Z.C., 2006. Detection of microRNAs using electrocatalytic nanoparticle tags. Anal. Chem. 78, 1470–1477.

Garibaldi, S., Brunelli, C., Bavastrello, V., Ghiglotti, G., Nicolini, C., 2006. Carbon nanotube biocompatibility with cardiac muscle cells. Nanotechnology 17, 391–397.

Garnett, M.C., Kallinteri, P., 2006. Nanomedicines and nanotoxicology: some physiological principles. Occup. Med. (Oxford) 56, 307–311.

Gemeinhart, R.A., Luo, D., Saltzman, W.M., 2005. Cellular fate of a modular DNA delivery system mediated by silica nanoparticles. Biotechnol. Prog. 21, 532–537.

Geng, Y., Dalhaimer, P., Cai, S., Tsai, R., Tewari, M., Minko, T., Discher, D.E., 2007. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2, 249–255.

Gericke, M., Pinches, A., 2006. Biological synthesis of metal nanoparticles. Hydrometallurgy 83, 132–140.

Giovagnoli, S., Luca, G., Casaburi, I., Blasi, P., Macchiarulo, G., Ricci, M., Calvitti, M., Basta, G., Calafiore, R., Rossi, C., 2005. Long-term delivery of superoxide dismutase and catalase entrapped in poly(lactide-co-glycolide) microspheres: in vitro effects on isolated neonatal porcine pancreatic cell clusters. J. Control. Release 107, 65–77.

Gojova, A., Guo, B., Kota, R.S., Rutledge, J.C., Kennedy, I.M., Barakat, A.I., 2007. Induction of inflammation in vascular endothelial cells by metal oxide nanoparticles: effect of particle composition. Environ. Health Perspect. 115, 403–409.

Graham, L., Orenstein, J.M., 2007. Processing tissue and cells for transmission electron microscopy in diagnostic pathology and research. Nat. Protoc. 2, 2439–2450.

Gref, R., Minamitake, Y., Peracchia, M.T., Trubetskoy, V., Torchilin, V., Langer, R., 1994. Biodegradable long-circulating polymeric nanospheres. Science 263, 1600–1603.

Guo, P.X., 2005. RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy. J. Nanosci. Nanotech. 5, 1964–1982.

Gupta, A.K., Gupta, M., 2005. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26, 3995–4021.

Gurr, J.-R., Wang, A.S.S., Chen, C.-H., Jan, K.-Y., 2005. Ultrafine titanium dioxide particles in the absence of photoactivation can induce oxidative damage to human bronchial epithelial cells. Toxicology 213, 66–73.

Guzman, J., Carrettin, S., Corma, A., 2005. Spectroscopic evidence for the supply of reactive oxygen during CO oxidation catalyzed by gold supported on nano-crystalline CeO_2. J. Am. Chem. Soc. 127, 3286–3287.

Guzman, K.A.D., Taylor, M.R., Banfield, J.F., 2006. Environmental risks of nanotechnology: national nanotechnology initiative funding, 2000–2004. Environ. Sci. Tech. 40, 1401–1407.

Haes, A.J., Chang, L., Klein, W.L., Van Duyne, R.P., 2005a. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J. Am. Chem. Soc. 127, 2264–2271.

Haes, A.J., Hall, W.P., Chang, L., Klein, W.L., Van Duyne, R.P., 2004. A localized surface plasmon resonance biosensor: first steps toward an assay for Alzheimer's disease. Nano Lett. 4, 1029–1034.

Haes, A.J., Haynes, C.L., McFarland, A.D., Schatz, G.C., Van Duyne, R.R., Zou, S.L., 2005b. Plasmonic materials for surface-enhanced sensing and spectroscopy. MRS Bull. 30, 368–375.

Han, Y., Lee, S.S., Ying, J.Y., 2007. Spherical siliceous mesocellular foam particles for high-speed size exclusion chromatography. Chem. Mater. 19, 2292–2298.

Han, Y.J., Stucky, G.D., Butler, A., 1999. Mesoporous silicate sequestration and release of proteins. J. Am. Chem. Soc. 121, 9897–9898.

Han, Y.J., Watson, J.T., Stucky, G.D., Butler, A., 2002. Catalytic activity of mesoporous silicate-immobilized chloroperoxidase. J. Mol. Catal. B: Enzym. 17, 1–8.

Handy, R.D., Shaw, B.J., 2007. Toxic effects of nanoparticles and nanomaterials: implications for public health, risk assessment and the public perception of nanotechnology. Health Risk Soc. 9, 125–144.

Hannon, G.J., 2002. RNA interference. Nature 418, 244–251.

Hansma, H.G., 2001. Surface biology of DNA by atomic force microscopy. Annu. Rev. Phys. Chem. 52, 71–92.

Hansma, H.G., Kim, K.J., Laney, D.E., Garcia, R.A., Argaman, M., Allen, M.J., Parsons, S.M., 1997. Properties of biomolecules measured from atomic force microscope images: a review. J. Struct. Biol. 119, 99–108.

Hansma, H.G., Revenko, I., Kim, K., Laney, D.E., 1996. Atomic force microscopy of long and short double-stranded, single-stranded and triple-stranded nucleic acids. Nucleic Acids Res. 24, 713–720.

Hansma, H.G., Vesenka, J., Siegerist, C., Kelderman, G., Morrett, H., Sinsheimer, R.L., Elings, V., Bustamante, C., Hansma, P.K., 1992. Reproducible imaging and dissection of plasmid DNA under liquid with the atomic force microscope. Science 256, 1180–1184.

Hardman, R., 2006. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ. Health Perspect. 114, 165–172.

Harris, J.M., Chess, R.B., 2003. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214–221.

Harrison, B.S., Atala, A., 2007. Carbon nanotube applications for tissue engineering. Biomaterials 28, 344–353.

Hashimoto, K., Irie, H., Fujishima, A., 2005. TiO_2 photocatalysis: a historical overview and future prospects. Jpn. J. Appl. Phys. Part 1: Regul. Pap. Brief Commun. Rev. Pap. 44, 8269–8285.

Hayashi, T., Hirono, S., Tomita, M., Umemura, S., 1996. Magnetic thin films of cobalt nanocrystals encapsulated in graphite-like carbon. Nature 381, 772–774.

He, S.Y., Guo, Z.R., Zhang, Y., Zhang, S., Gu, J.W.N., 2007. Biosynthesis of gold nanoparticles using the bacteria Rhodopseudomonas capsulata. Mater. Lett. 61, 3984–3987.

Hebert, S.S., De Strooper, B., 2007. miRNAs in neurodegeneration. Science 317, 1179–1180.

Heidel, J.D., Yu, Z.P., Liu, J.Y.C., Rele, S.M., Liang, Y.C., Zeidan, R.K., Kornbrust, D.J., Davis, M.E., 2007. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U.S.A. 104, 5715–5721.

Heller, D.A., Baik, S., Eurell, T.E., Strano, M.S., 2005. Single-walled carbon nanotube spectroscopy in live cells: towards long-term labels and optical sensors. Adv. Mater. 17, 2793–2799.

Heller, D.A., Jeng, E.S., Yeung, T.K., Martinez, B.M., Moll, A.E., Gastala, J.B., Strano, M.S., 2006. Optical detection of DNA conformational polymorphism on single-walled carbon nanotubes. Science 311, 508–511.

Hench, L.L., West, J.K., 1990. The sol–gel process. Chem. Rev. 90, 33–72.

Heo, C., Chang, K.A., Choi, H.S., Kim, H.S., Kim, S., Liew, H., Kim, J.A., Yu, E., Ma, J., Suh, Y.H., 2007. Effects of the monomeric, oligomeric, and fibrillar $A\beta_{42}$ peptides on the proliferation and differentiation of adult neural stem cells from subventricular zone. J. Neurochem. 102, 493–500.

Hext, P.M., Tomenson, J.A., Thompson, P., 2005. Titanium dioxide: inhalation toxicology and epidemiology. Ann. Occup. Hyg. 49, 461–472.

Hill, H.D., Vega, R.A., Mirkin, C.A., 2007. Nonenzymatic detection of bacterial genomic DNA using the bio bar code assay. Anal. Chem. 79, 9218–9223.

Hirsch, A., 1995. Addition-reactions of buckminsterfullerene (C_{60}). Synthesis 895–913.

Hodes, G., 2007. When small is different: some recent advances in concepts and applications of nanoscale phenomena. Adv. Mater. 19, 639–655.

Hofer, R., Textor, M., Spencer, N.D., 2001. Alkyl phosphate monolayers, self-assembled from aqueous solution onto metal oxide surfaces. Langmuir 17, 4014–4020.

Howard, K.A., Rahbek, U.L., Liu, X.D., Damgaard, C.K., Glud, S.Z., Andersen, M.O., Hovgaard, M.B., Schmitz, A., Nyengaard, J.R., Besenbacher, F., Kjems, J., 2006. RNA interference *in vitro* and *in vivo* using a chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476–484.

Hu, J.T., Odom, T.W., Lieber, C.M., 1999. Chemistry and physics in one dimension: synthesis and properties of nanowires and nanotubes. Acc. Chem. Res. 32, 435–445.

Huber, D.L., 2005. Synthesis, properties, and applications of iron nanoparticles. Small 1, 482–501.

Huh, Y.M., Jun, Y.W., Song, H.T., Kim, S., Choi, J.S., Lee, J.H., Yoon, S., Kim, K.S., Shin, J.S., Suh, J.S., Cheon, J., 2005. *In vivo* magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J. Am. Chem. Soc. 127, 12387–12391.

Hui, E.E., Bhatia, S.N., 2007. Micromechanical control of cell–cell interactions. Proc. Natl. Acad. Sci. U.S.A. 104, 5722–5726.

Humphrey, W., Dalke, A., Schulten, K., 1996. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33–38.

Huo, Q.S., Margolese, D.I., Ciesla, U., Feng, P.Y., Gier, T.E., Sieger, P., Leon, R., Petroff, P.M., Schuth, F., Stucky, G.D., 1994. Generalized synthesis of periodic surfactant inorganic composite-materials. Nature 368, 317–321.

Hussain, S.M., Hess, K.L., Gearhart, J.M., Geiss, K.T., Schlager, J.J., 2005. *In vitro* toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol. In Vitro 19, 975–983.

Hyeon, T., 2003. Chemical synthesis of magnetic nanoparticles. Chem. Commun. 927–934.

International Council on Nanotechnology. http://icon.rice.edu (accessed April 2007).

Intercampus Effort to Study Nanotoxicology. http://www.bren.ucsb.edu/news/press/nanotoxicology.htm (accessed July 2007).

Institute of Bioengineering and Nanotechnology (IBN). http://www.ibn.a-star.edu.sg/ (accessed April 2007).

Ibrahim, M.A., Ismail, A., Fetouh, M.I., Gopferich, A., 2005. Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J. Control. Release 106, 241–252.

Ideker, T., Galitski, T., Hood, L., 2001. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. 2, 343–372.

Iijima, S., 1991. Helical microtubules of graphitic carbon. Nature 354, 56–58.

Iijima, S., Yudasaka, M., Yamada, R., Bandow, S., Suenaga, K., Kokai, F., Takahashi, K., 1999. Nano-aggregates of single-walled graphitic carbon nano-horns. Chem. Phys. Lett. 309, 165–170.

Ishiyama, M., Tominaga, H., Shiga, M., Sasamoto, K., Ohkura, Y., Ueno, K., 1996. A combined assay of cell viability and *in vitro* cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol. Pharmac. Bull. 19, 1518–1520.

Isobe, H., Tanaka, T., Maeda, R., Noiri, E., Solin, N., Yudasaka, M., Iijima, S., Nakamura, E., 2006. Preparation, purification, characterization, and cytotoxicity assessment of water-soluble, transition-metal-free carbon nanotube aggregates. Angew. Chem. Int. Ed. 45, 6676–6680.

Itaka, K., Kanayama, N., Nishiyama, N., Jang, W.D., Yamasaki, Y., Nakamura, K., Kawaguchi, H., Kataoka, K., 2004. Supramolecular nanocarrier of siRNA from PEG-based block catiomer carrying diamine side chain with distinctive pK(a) directed to enhance intracellular gene silencing. J. Am. Chem. Soc. 126, 13612–13613.

Ito, Y., Fukusaki, E., 2004. DNA as a 'nanomaterial'. J. Mol. Catal. B: Enzym. 28, 155–166.

Iyer, V.S., Vollhardt, K.P.C., Wilhelm, R., 2003. Near-quantitative solid-state synthesis of carbon nanotubes from homogeneous diphenylethynecobalt and -nickel complexes. Angew. Chem. Int. Ed. 42, 4379–4383.

Jan, E., Kotov, N.A., 2007. Successful differentiation of mouse neural stem cells on layer-by-layer assembled single-walled carbon nanotube composite. Nano Lett. 7, 1123–1128.

Jeng, E.S., Moll, A.E., Roy, A.C., Gastala, J.B., Strano, M.S., 2006. Detection of DNA hybridization using the near-infrared band-gap fluorescence of single-walled carbon nanotubes. Nano Lett. 6, 371–375.

Jensen, A.W., Wilson, S.R., Schuster, D.I., 1996. Biological applications of fullerenes. Bioorg. Med. Chem. 4, 767–779.

Jeong, U., Teng, X.W., Wang, Y., Yang, H., Xia, Y.N., 2007. Superparamagnetic colloids: controlled synthesis and niche applications. Adv. Mater. 19, 33–60.

Jia, G., Wang, H.F., Yan, L., Wang, X., Pei, R.J., Yan, T., Zhao, Y.L., Guo, X.B., 2005. Cytotoxicity of carbon nanomaterials: single-wall nanotube, multi-wall nanotube, and fullerene. Environ. Sci. Tech. 39, 1378–1383.

Jiao, J., Seraphin, S., Wang, X.K., Withers, J.C., 1996. Preparation and properties of ferromagnetic carbon-coated Fe, Co, and Ni nanoparticles. J. Appl. Phys. 80, 103–108.

Jo, K., Heien, M.L., Thompson, L.B., Zhong, M., Nuzzo, R.G., Sweedler, J.V., 2007. Mass spectrometric imaging of peptide release from neuronal cells within microfluidic devices. Lab Chip 7, 1454–1460.

Josephson, L., Kircher, M.F., Mahmood, U., Tang, Y., Weissleder, R., 2002. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconj. Chem. 13, 554–560.

Jovanovic, A.V., Flint, J.A., Varshney, M., Morey, T.E., Dennis, D.M., Duran, R.S., 2006. Surface modification of silica core–shell nanocapsules: biomedical implications. Biomacromolecules 7, 945–949.

Jun, Y.W., Huh, Y.M., Choi, J.S., Lee, J.H., Song, H.T., Kim, S., Yoon, S., Kim, K.S., Shin, J.S., Suh, J.S., Cheon, J., 2005. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J. Am. Chem. Soc. 127, 5732–5733.

Jun, Y.W., Jang, J.T., Cheon, J., 2006. Nanocrystals and their biomedical applications. Bull. Korean Chem. Soc. 27, 961–971.

Jurchen, J.C., Rubakhin, S.S., Sweedler, J.V., 2005. MALDI-MS imaging of features smaller than the size of the laser beam. J. Am. Soc. Mass Spectrom. 16, 1654–1659.

Kada, G., Kienberger, F., Hinterdorfer, P., 2008. Atomic force microscopy in bionanotechnology. Nano Today 3, 12–19.

Kale, S.N., Arora, S., Bhayani, K.R., Paknikar, K.M., Jani, M., Wagh, U.V., Kulkarni, S.D., Ogale, S.B., 2006. Cerium doping and stoichiometry control for biomedical use of $La_{0.7}Sr_{0.3}MnO_3$ nanoparticles: microwave absorption and cytotoxicity study. Nanomed. Nanotechnol. Biol. Med. 2, 217–221.

Kam, N.W.S., Jessop, T.C., Wender, P.A., Dai, H.J., 2004. Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into mammalian cells. J. Am. Chem. Soc. 126, 6850–6851.

Kane, R.S., Takayama, S., Ostuni, E., Ingber, D.E., Whitesides, G.M., 1999. Patterning proteins and cells using soft lithography. Biomaterials 20, 2363–2376.

Karakoti, A.S., Hench, L.L., Seal, S., 2006. The potential toxicity of nanomaterials—the role of surfaces. J. Min. Met. Mater. Soc. 58, 77–82.

Karlsson, N., Cassel, G., Fangmark, I., Bergman, F., 1986. A comparative-study of the acute inhalation toxicity of smoke from TiO_2-hexachloroethane and Zn-hexachloroethane pyrotechnic mixtures. Arch. Toxicol. 59, 160–166.

Ke, P.C., Qiao, R., 2007. Carbon nanomaterials in biological systems. J. Phys.: Condes. Matter 19.

Khetani, S.R., Bhatia, S.N., 2008. Microscale culture of human liver cells for drug development. Nat. Biotechnol. 26, 120–126.

Kim, J., Grate, J.W., Wang, P., 2006a. Nanostructures for enzyme stabilization. Chem. Eng. Sci. 61, 1017–1026.

Kim, J., Lee, J.E., Lee, J., Yu, J.H., Kim, B.C., An, K., Hwang, Y., Shin, C.H., Park, J.G., Kim, J., Hyeon, T., 2006b. Magnetic fluorescent delivery vehicle using uniform mesoporous silica spheres embedded with monodisperse magnetic and semiconductor nanocrystals. J. Am. Chem. Soc. 128, 688–689.

Kim, J.K., Lee, W.K., Lee, E.J., Cho, Y.J., Lee, K.H., Kim, H.S., Chung, Y., Kim, K.A., Lim, Y., 1999. Mechanism of silica- and titanium dioxide-induced cytotoxicity in alveolar macrophages. J. Toxicol. Environ. Health A 58, 437–450.

Kim, J.S., Rieter, W.J., Taylor, K.M.L., An, H., Lin, W., Lin, W., 2007a. Self-assembled hybrid nanoparticles for cancer-specific multimodal imaging. J. Am. Chem. Soc. 129, 8962–8963.

Kim, M.I., Kim, J., Lee, J., Jia, H., Bin Na, H., Youn, J.K., Kwak, J.H., Dohnalkova, A., Grate, J.W., Wang, P., Hyeon, T., Park, H.G., Chang, H.N., 2007b. Crosslinked enzyme aggregates in hierarchically-ordered mesoporous silica: a simple and effective method for enzyme stabilization. Biotechnol. Bioeng. 96, 210–218.

Kim, S.W., Son, S.U., Lee, S.I., Hyeon, T., Chung, Y.K., 2000. Cobalt on mesoporous silica: the first heterogeneous Pauson-Khand catalyst. J. Am. Chem. Soc. 122, 1550–1551.

Kim, W., Ng, J.K., Kunitake, M.E., Conklin, B.R., Yang, P.D., 2007c. Interfacing silicon nanowires with mammalian cells. J. Am. Chem. Soc. 129, 7228–7229.

Kimura, Y., Shibasaki, S., Morisato, K., Ishizuka, N., Minakuchi, H., Nakanishi, K., Matsuo, M., Amachi, T., Ueda, M., Ueda, K., 2004. Microanalysis for MDR1 ATPase by high-performance liquid chromatography with a titanium dioxide column. Anal. Biochem. 326, 262–266.

Kirchner, C., Liedl, T., Kudera, S., Pellegrino, T., Javier, A.M., Gaub, H.E., Stolzle, S., Fertig, N., Parak, W.J., 2005. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Lett. 5, 331–338.

Kiseleva, E., Allen, T.D., Rutherford, S.A., Murray, S., Morozova, K., Gardiner, F., Goldberg, M.W., Drummond, S.P., 2007. A protocol for isolation and visualization of yeast nuclei by scanning electron microscopy (SEM). Nat. Protoc. 2, 1943–1953.

Kitano, H., 2002a. Computational systems biology. Nature 420, 206–210.

Kitano, H., 2002b. Systems biology: a brief overview. Science 295, 1662–1664.

Klein, J., 2007. Probing the interactions of proteins and nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 104, 2029–2030.

Klejbor, I., Stachowiak, E.K., Bharali, D.J., Roy, I., Spodnik, I., Morys, J., Bergey, E.J., Prasad, P.N., Stachowiak, M.K., 2007. ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology. J. Neurosci. Methods 165, 230–243.

Kneuer, C., Sameti, M., Bakowsky, U., Schiestel, T., Schirra, H., Schmidt, H., Lehr, C.M., 2000a. A nonviral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro. Bioconj. Chem. 11, 926–932.

Kneuer, C., Sameti, M., Haltner, E.G., Schiestel, T., Schirra, H., Schmidt, H., Lehr, C.M., 2000b. Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA. Int. J. Pharm. 196, 257–261.

Kogan, M.J., Bastus, N.G., Amigo, R., Grillo-Bosch, D., Araya, E., Turiel, A., Labarta, A., Giralt, E., Puntes, V.F., 2006. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett. 6, 110–115.

Kong, G.K.W., Adams, J.J., Harris, H.H., Boas, J.F., Curtain, C.C., Galatis, D., Masters, C.L., Barnham, K.J., McKinstry, W.J., Cappai, R., Parker, M.W., 2007. Structural studies of the Alzheimer's amyloid precursor protein copper-binding domain reveal how it binds copper ions. J. Mol. Biol. 367, 148–161.

Konishi, Y., Ohno, K., Saitoh, N., Nomura, T., Nagamine, S., Hishida, H., Takahashi, Y., Uruga, T., 2007. Bioreductive deposition of platinum nanoparticles on the bacterium Shewanella algae. J. Biotechnol. 128, 648–653.

Konishi, Y., Tsukiyama, T., Ohno, K., Saitoh, N., Nomura, T., Nagamine, S., 2006. Intracellular recovery of gold by microbial reduction of $AuCl_4^-$ ions using the anaerobic bacterium Shewanella algae. Hydrometallurgy 81, 24–29.

Kosik, K.S., 2006. The neuronal microRNA system. Nat. Rev. Neurosci. 7, 911–920.

Kosik, K.S., Krichevsky, A.M., 2005. The elegance of the microRNAs: a neuronal perspective. Neuron 47, 779–782.

Kostarelos, K., Lacerda, L., Pastorin, G., Wu, W., Wieckowski, S., Luangsivilay, J., Godefroy, S., Pantarotto, D., Briand, J.P., Muller, S., Prato, M., Bianco, A., 2007. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat. Nanotechnol. 2, 108–113.

Kostiainen, M.A., Szilvay, G.R., Lehtinen, J., Smith, D.K., Linder, M.B., Urtti, A., Ikkala, O., 2007. Precisely defined protein-polymer conjugates: construction of synthetic DNA binding domains on proteins by using multivalent dendrons. ACS Nano 1, 103–113.

Kovacs, E.W., Hooker, J.M., Romanini, D.W., Holder, P.G., Berry, K.E., Francis, M.B., 2007. Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system. Bioconj. Chem. 18, 1140–1147.

Kraemer, S.M., 2004. Iron oxide dissolution and solubility in the presence of siderophores. Aquat. Sci. 66, 3–18.

Kroto, H.W., Heath, J.R., O'Brien, S.C., Curl, R.F., Smalley, R.E., 1985. C_{60}: Buckminsterfullerene. Nature 318, 162–163.

Kruse, R., Sweedler, J.V., 2003. Spatial profiling invertebrate ganglia using MALDI MS. J. Am. Soc. Mass Spectrom. 14, 752–759.

Kubo, T., Zhelev, Z., Ohba, H., Bakalova, R., 2008. Chemically modified symmetric and asymmetric duplex RNAs: an enhanced stability to nuclease degradation and gene silencing effect. Biochem. Biophys. Res. Commun. 365, 54–61.

Labhasetwar, V., 2005. Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery. Curr. Opin. Biotechnol. 16, 674–680.

Laibinis, P.E., Whitesides, G.M., Allara, D.L., Tao, Y.T., Parikh, A.N., Nuzzo, R.G., 1991. Comparison of the structures and wetting properties of self-assembled monolayers of normal-alkanethiols on the coinage metal-surfaces, Cu, Ag, Au. J. Am. Chem. Soc. 113, 7152–7167.

Lal, R., Drake, B., Blumberg, D., Saner, D.R., Hansma, P.K., Feinstein, S.C., 1995. Imaging real-time neurite outgrowth and cytoskeletal reorganization with an atomic-force microscope. Am. J. Physiol. Cell. Physiol. 38, C275–C285.

Lam, C.W., James, J.T., McCluskey, R., Arepalli, S., Hunter, R.L., 2006. A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Crit. Rev. Toxicol. 36, 189–217.

Lam, C.W., James, J.T., McCluskey, R., Hunter, R.L., 2004. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol. Sci. 77, 126–134.

Langer, R., 1990. New methods of drug delivery. Science 249, 1527–1533.

Lashuel, H.A., Lansbury, P.T., 2006. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q. Rev. Biophys. 39, 167–201.

Lavalley, J.C., 1996. Infrared spectrometric studies of the surface basicity of metal oxides and zeolites using adsorbed probe molecules. Catal. Today 27, 377–401.

Lee, I.S., Lee, N., Park, J., Kim, B.H., Yi, Y.W., Kim, T., Kim, T.K., Lee, I.H., Paik, S.R., Hyeon, T., 2006a. Ni/NiO core/shell nanoparticles for selective binding and magnetic separation of histidine-tagged proteins. J. Am. Chem. Soc. 128, 10658–10659.

Lee, J., Kim, J., Hyeon, T., 2006b. Recent progress in the synthesis of porous carbon materials. Adv. Mater. 18, 2073–2094.

Lee, J.H., Jun, Y.W., Yeon, S.I., Shin, J.S., Cheon, J., 2006c. Dual-mode nanoparticle probes for high-performance magnetic resonance and fluorescence imaging of neuroblastoma. Angew. Chem. Int. Ed. 45, 8160–8162.

Lee, K.B., Kim, E.Y., Mirkin, C.A., Wolinsky, S.M., 2004a. The use of nanoarrays for highly sensitive and selective detection of human immunodeficiency virus type 1 in plasma. Nano Lett. 4, 1869–1872.

Lee, K.B., Park, S., Mirkin, C.A., 2004b. Multicomponent magnetic nanorods for biomolecular separations. Angew. Chem. Int. Ed. 43, 3048–3050.

Lee, S.-M., Cho, S.-N., Cheon, J., 2003. Anisotropic shape control of colloidal inorganic nanocrystals. Adv. Mater. 15, 441–444.

Lei, Z.B., Xiao, Y., Dang, L.Q., Lu, M., You, W.S., 2006. Fabrication of ultra-large mesoporous carbon with tunable pore size by monodisperse silica particles derived from seed growth process. Micropor. Mesopor. Mater. 96, 127–134.

Levy, L., Sahoo, Y., Kim, K.S., Bergey, E.J., Prasad, P.N., 2002. Nanochemistry: synthesis and characterization of multifunctional nanoclinics for biological applications. Chem. Mater. 14, 3715–3721.

Li, W.J., Szoka, F.C., 2007. Lipid-based nanoparticles for nucleic acid delivery. Pharmac. Res. 24, 438–449.

Liang, S., Wang, Y.X., Yu, J.F., Zhang, C.F., Xia, J.Y., Yin, D.Z., 2007. Surface modified superparamagnetic iron oxide nanoparticles: as a new carrier for bio-magnetically targeted therapy. J. Mater. Sci. Mater. Med. 18, 2297–2302.

Limbach, L.K., Li, Y., Grass, R.N., Brunner, T.J., Hintermann, M.A., Muller, M., Gunther, D., Stark, W.J., 2005. Oxide nanoparticle uptake in human lung fibroblasts: effects of particle size, agglomeration, and diffusion at low concentrations. Environ. Sci. Technol. 39, 9370–9376.

Lin, W.S., Huang, Y.W., Zhou, X.D., Ma, Y.F., 2006a. In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol. Appl. Pharmacol. 217, 252–259.

Lin, W.S., Huang, Y.W., Zhou, X.D., Ma, Y.F., 2006b. Toxicity of cerium oxide nanoparticles in human lung cancer cells. Int. J. Toxicol. 25, 451–457.

Lin, Y.S., Wu, S.H., Hung, Y., Chou, Y.H., Chang, C., Lin, M.L., Tsai, C.P., Mou, C.Y., 2006c. Multifunctional composite nanoparticles: magnetic, luminescent, and mesoporous. Chem. Mater. 18, 5170–5172.

Linnainmaa, K., Kivipensas, P., Vainio, H., 1997. Toxicity and cytogenetic studies of ultrafine titanium dioxide in cultured rat liver epithelial cells. Toxicol. In Vitro 11, 329–335.

Liopo, A.V., Stewart, M.P., Hudson, J., Tour, J.M., Pappas, T.C., 2006. Biocompatibility of native and functionalized single-walled carbon nanotubes for neuronal interface. J. Nanosci. Nanotech. 6, 1365–1374.

Liu, C.H., Huang, S.N., Cui, J.K., Kim, Y.R., Farrar, C.T., Moskowitz, M.A., Rosen, B.R., Liu, P.K., 2007a. MR contrast probes that trace gene transcripts for cerebral ischemia in live animals. FASEB J. 21, 3004–3015.

Liu, C.H., Kim, Y.R., Ren, J.Q., Eichler, F., Rosen, B.R., Liu, P.K., 2007b. Imaging cerebral gene transcripts in live animals. J. Neurosci. 27, 713–722.

Liu, G., Garrett, M.R., Men, P., Zhu, X.W., Perry, G., Smith, M.A., 2005a. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim. Biophys. Acta: Mol. Basis Dis. 1741, 246–252.

Liu, J., Lu, Y., 2005. Stimuli-responsive disassembly of nanoparticle aggregates for light-up colorimetric sensing. J. Am. Chem. Soc. 127, 12677–12683.

Liu, J., Lu, Y., 2006a. Preparation of aptamer-linked gold nanoparticle purple aggregates for colorimetric sensing of analytes. Nat. Protoc. 1, 246–252.

Liu, J.W., Lu, Y., 2003. A colorimetric lead biosensor using DNAzyme-directed assembly of gold nanoparticles. J. Am. Chem. Soc. 125, 6642–6643.

Liu, J.W., Lu, Y., 2004a. Accelerated color change of gold nanoparticles assembled by DNAzymes for simple and fast colorimetric Pb^{2+} detection. J. Am. Chem. Soc. 126, 12298–12305.

Liu, J.W., Lu, Y., 2004b. Adenosine-dependent assembly of aptazyme-functionalized gold nanoparticles and its application as a colorimetric biosensor. Anal. Chem. 76, 1627–1632.

Liu, J.W., Lu, Y., 2006b. Fast colorimetric sensing of adenosine and cocaine based on a general sensor design involving aptamers and nanoparticles. Angew. Chem. Int. Ed. 45, 90–94.

Liu, J.W., Mazumdar, D., Lu, Y., 2006. A simple and sensitive "dipstick" test in serum based on lateral flow separation of aptamer-linked nanostructures. Angew. Chem. Int. Ed. 45, 7955–7959.

Liu, W.T., 2006. Nanoparticles and their biological and environmental applications. J. Biosci. Bioeng. 102, 1–7.

Liu, Y.F., Wang, S.P., Lee, J.W., Kotov, N.A., 2005b. A floating self-assembly route to colloidal crystal templates for 3D cell scaffolds. Chem. Mater. 17, 4918–4924.

Livage, J., Henry, M., Sanchez, C., 1988. Sol–gel chemistry of transition-metal oxides. Prog. Solid State Chem. 18, 259–341.

Lockman, P.R., Mumper, R.J., Khan, M.A., Allen, D.D., 2002. Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev. Ind. Pharm. 28, 1–13.

Long, T.C., Saleh, N., Tilton, R.D., Lowry, G.V., Veronesi, B., 2006. Titanium dioxide (P25) produces reactive oxygen species in immortalized brain microglia (BV2): implications for nanoparticle neurotoxicity. Environ. Sci. Tech. 40, 4346–4352.

Loo, L., Guenther, R.H., Lommel, S.A., Franzen, S., 2007. Encapsidation of nanoparticles by Red Clover Necrotic Mosaic Virus. J. Am. Chem. Soc. 129, 11111–11117.

Love, J.C., Estroff, L.A., Kriebel, J.K., Nuzzo, R.G., Whitesides, G.M., 2005. Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chem. Rev. 105, 1103–1169.

Lovric, J., Bazzi, H.S., Cuie, Y., Fortin, G.R.A., Winnik, F.M., Maysinger, D., 2005a. Differences in subcellular distribution and toxicity of green and red emitting CdTe quantum dots. J. Mol. Med. 83, 377–385.

Lovric, J., Cho, S.J., Winnik, F.M., Maysinger, D., 2005b. Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem. Biol. 12, 1227–1234.

Lu, A.H., Li, W.C., Salabas, E.L., Spliethoff, B., Schuth, F., 2006. Low temperature catalytic pyrolysis for the synthesis of high surface area, nanostructured graphitic carbon. Chem. Mater. 18, 2086–2094.

Lu, A.H., Salabas, E.L., Schuth, F., 2007a. Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew. Chem. Int. Ed. 46, 1222–1244.

Lu, A.H., Schuth, F., 2006. Nanocasting: a versatile strategy for creating nanostructured porous materials. Adv. Mater. 18, 1793–1805.

Lu, J., Liong, M., Zink, J.I., Tamanoi, F., 2007b. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3, 1341–1346.

Lu, Y., Liu, J.W., 2006. Functional DNA nanotechnology: emerging applications of DNAzymes and aptamers. Curr. Opin. Biotechnol. 17, 580–588.

Lu, Y., Liu, J.W., 2007. Smart nanomaterials inspired by biology: dynamic assembly of error-free nanomaterials in response to multiple chemical and biological stimuli. Acc. Chem. Res. 40, 315–323.

Luckarift, H.R., Spain, J.C., Naik, R.R., Stone, M.O., 2004. Enzyme immobilization in a biomimetic silica support. Nat. Biotechnol. 22, 211–213.

Lyubchenko, Y.L., Sherman, S., Shlyakhtenko, L.S., Uversky, V.N., 2006. Nanoimaging for protein misfolding and related diseases. J. Cell. Biochem. 99, 53–70.

Mann, D.G.J., McKnight, T.E., McPherson, J.T., Hoyt, P.R., Melechko, A.V., Simpson, M.L., Sayler, G.S., 2008. Inducible RNA interference-mediated gene silencing using nanostructured gene delivery arrays. ACS Nano 2, 69–76.

Manna, S.K., Sarkar, S., Barr, J., Wise, K., Barrera, E.V., Jejelowo, O., Rice-Ficht, A.C., Ramesh, G.T., 2005. Single-walled carbon nanotube induces oxidative stress and activates nuclear transcription factor-kappa B in human keratinocytes. Nano Lett. 5, 1676–1684.

Marris, E., 2007. Four years in Iraq—the war against wounds. Nature 446, 369–371.

Marshall, M.J., Beliaev, A.S., Dohnalkova, A.C., Kennedy, D.W., Shi, L., Wang, Z.M., Boyanov, M.I., Lai, B., Kemner, K.M., McLean, J.S., Reed, S.B., Culley, D.E., Bailey, V.L., Simonson, C.J., Saffarini, D.A., Romine, M.F., Zachara, J.M., Fredrickson, J.K., 2006. c-Type cytochrome-dependent formation of U(IV) nanoparticles by *Shewanella oneidensis*. PLoS. Biol. 4, 1324–1333.

Martin, C.R., Kohli, P., 2003. The emerging field of nanotube biotechnology. Nat. Rev. Drug Discov. 2, 29–37.

Masotti, A., Vicennati, P., Boschi, F., Calderan, L., Sbarati, A., Ortaggi, G., 2008. A novel near-infrared indocyanine dye-polyethylenimine conjugate allows DNA delivery imaging *in vivo*. Bioconj. Chem. 19, 983–987.

Matsumura, S., Ajima, K., Yudasaka, M., Iijima, S., Shiba, K., 2007. Dispersion of cisplatin-loaded carbon nanohorns with a conjugate comprised of an artificial peptide aptamer and polyethylene glycol. Mol. Pharmaceutics 4, 723–729.

Maynard, A.D., Aitken, R.J., Butz, T., Colvin, V., Donaldson, K., Oberdoerster, G., Philbert, M.A., Ryan, J., Seaton, A., Stone, V., Tinkle, S.S., Tran, L, Walker, N.J., Warheit, D.B., 2006. Safe handling of nanotechnology. Nature 444, 267–269.

Maynard, A.D., Baron, P.A., Foley, M., Shvedova, A.A., Kisin, E.R., Castranova, V., 2004. Exposure to carbon nanotube material: aerosol release during the handling of unrefined single-walled carbon nanotube material. J. Toxicol. Environ. Health. A 67, 87–107.

Maynard, A.D., Kuempel, E.D., 2005. Airborne nanostructured particles and occupational health. J. Nanopart. Res. 7, 587–614.

McKnight, T.E., Melechko, A.V., Griffin, G.D., Guillorn, M.A., Merkulov, V.I., Serna, F., Hensley, D.K., Doktycz, M.J., Lowndes, D.H., Simpson, M.L., 2003. Intracellular integration of synthetic nanostructures with viable cells for controlled biochemical manipulation. Nanotechnology 14, 551–556.

McKnight, T.E., Melechko, A.V., Hensley, D.K., Mann, D.G.J., Griffin, G.D., Simpson, M.L., 2004. Tracking gene expression after DNA delivery using spatially indexed nanofiber arrays. Nano Lett. 4, 1213–1219.

Medina, C., Santos-Martinez, M.J., Radomski, A., Corrigan, O.I., Radomski, M.W., 2007. Nanoparticles: pharmacological and toxicological significance. Br. J. Pharmacol. 150, 552–558.

Medintz, I.L., Uyeda, H.T., Goldman, E.R., Mattoussi, H., 2005. Quantum dot bioconjugates for imaging, labelling and sensing. Nat. Mater. 4, 435–446.

Michalet, X., Pinaud, F.F., Bentolila, L.A., Tsay, J.M., Doose, S., Li, J.J., Sundaresan, G., Wu, A.M., Gambhir, S.S., Weiss, S., 2005. Quantum dots for live cells, *in vivo* imaging, and diagnostics. Science 307, 538–544.

Millet, L.J., Stewart, M.E., Sweedler, J.V., Nuzzo, R.G., Gillette, M.U., 2007. Microfluidic devices for culturing primary mammalian neurons at low densities. Lab Chip 7, 987–994.

Mirkin, C.A., 2000. Programming the assembly of two- and three-dimensional architectures with DNA and nanoscale inorganic building blocks. Inorg. Chem. 39, 2258–2272.

Mishra, S., Webster, P., Davis, M.E., 2004. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 83, 97–111.

Miyawaki, J., Yudasaka, M., Imai, H., Yorimitsu, H., Isobe, H., Nakamura, E., Iijima, S., 2006. *In vivo* magnetic resonance imaging of single-walled carbon nanohorns by labeling with magnetite nanoparticles. Adv. Mater. 18, 1010–1014.

Mogensen, M., Sammes, N.M., Tompsett, G.A., 2000. Physical, chemical and electrochemical properties of pure and doped ceria. Solid State Ion 129, 63–94.

Moller, W., Hofer, T., Ziesenis, A., Karg, E., Heyder, J., 2002. Ultrafine particles cause cytoskeletal dysfunctions in macrophages. Toxicol. Appl. Pharmacol. 182, 197–207.

Monica, J.C., Heintz, M.E., Lewis, P.T., 2007. The perils of pre-emptive regulation. Nat. Nanotechnol. 2, 68–70.

Monnier, A., Schuth, F., Huo, Q., Kumar, D., Margolese, D., Maxwell, R.S., Stucky, G.D., Krishnamurty, M., Petroff, P., Firouzi, A., Janicke, M., Chmelka, B.F., 1993. Cooperative Formation of inorganic-organic interfaces in the synthesis of silicate mesostructures. Science 261, 1299–1303.

Monroe, E.B., Jurchen, J.C., Lee, J., Rubakhin, S.S., Sweedler, J.V., 2005. Vitamin E imaging and localization in the neuronal membrane. J. Am. Chem. Soc. 127, 12152–12153.

Monteiro-Riviere, N.A., Nemanich, R.J., Inman, A.O., Wang, Y.Y.Y., Riviere, J.E., 2005. Multi-walled carbon nanotube interactions with human epidermal keratinocytes. Toxicol. Lett. 155, 377–384.

Moore, A., Marecos, E., Bogdanov, A., Weissleder, R., 2000. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214, 568–574.

Moreau, J.W., Weber, P.K., Martin, M.C., Gilbert, B., Hutcheon, I.D., Banfield, J.F., 2007. Extracellular proteins limit the dispersal of biogenic nanoparticles. Science 316, 1600–1603.

Mornet, S., Vasseur, S., Grasset, F., Duguet, E., 2004. Magnetic nanoparticle design for medical diagnosis and therapy. J. Mater. Chem. 14, 2161–2175.

Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival—application to proliferation and cyto-toxicity assays. J. Immunol. Methods 65, 55–63.

Mrksich, M., Whitesides, G.M., 1996. Using self-assembled monolayers to understand the interactions of man-made surfaces with proteins and cells. Annu. Rev. Biophys. Biomol. Struct. 25, 55–78.

Muldoon, L.L., Sandor, M., Pinkston, K.E., Neuwelt, E.A., 2005. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery 57, 785–796.

Murakami, T., Ajima, K., Miyawaki, J., Yudasaka, M., Iijima, S., Shiba, K., 2004. Drug-loaded carbon nanohorns: adsorption and release of dexamethasone *in vitro*. Mol. Pharmaceutics 1, 399–405.

Murray, C.B., Sun, S.H., Doyle, H., Betley, T., 2001. Monodisperse 3d transition-metal (Co, Ni, Fe) nanoparticles and their assembly into nanoparticle superlattices. MRS Bull. 26, 985–991.

Muscariello, L., Rosso, F., Marino, G., Giordano, A., Barbarisi, M., Cafiero, G., Barbarisi, A., 2005. A critical overview of ESEM applications in the biological field. J. Cell. Physiol. 205, 328–334.

Narita, M., Tanaka, H., Togashi, T., Abe, S., 2005. Cytokines involved in CNS manifestations caused by *Mycoplasma pneumoniae*. Pediatr. Neurol. 33, 105–109.

Nel, A., Xia, T., Madler, L., Li, N., 2006. Toxic potential of materials at the nanolevel. Science 311, 622–627.

Neuwelt, E.A., Varallyay, C.G., Manninger, S., Solymosi, D., Haluska, M., Hunt, M.A., Nesbit, G., Stevens, A., Jerosch-Herold, M., Jacobs, P.M., Hoffman, J.M., 2007. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 60, 601–611.

Niu, J.L., Azfer, A., Rogers, L.M., Wang, X.H., Kolattukudy, P.E., 2007. Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathy. Cardiovasc. Res. 73, 549–559.

Norris, D.J., Vlasov, Y.A., 2001. Chemical approaches to three-dimensional semiconductor photonic crystals. Adv. Mater. 13, 371–376.

Northen, T.R., Yanes, O., Northen, M.T., Marrinucci, D., Uritboonthai, W., Apon, J., Golledge, S.L., Nordstrom, A., Siuzdak, G., 2007. Clathrate nanostructures for mass spectrometry. Nature 449, 1033–11033.

Nanotechnology Characterization Laboratory (NCL). http://ncl.cancer.gov/ (accessed April 2007).

Oberdorster, E., 2004. Manufactured nanomaterials (fullerenes, C_{60}) induce oxidative stress in the brain of juvenile largemouth bass. Environ. Health. Perspect. 112, 1058–1062.

Oberdorster, G., Oberdorster, E., Oberdorster, J., 2005. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 113, 823–839.

Odom, T.W., Huang, J.L., Kim, P., Lieber, C.M., 1998. Atomic structure and electronic properties of single-walled carbon nanotubes. Nature 391, 62–64.

Ogris, M., Brunner, S., Schuller, S., Kircheis, R., Wagner, E., 1999. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6, 595–605.

Ohulchanskyy, T.Y., Roy, I., Goswami, L.N., Chen, Y., Bergey, E.J., Pandey, R.K., Oseroff, A.R., Prasad, P.N., 2007. Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer. Nano Lett. 7, 2835–2842.

Oishi, M., Nagasaki, Y., Itaka, K., Nishiyama, N., Kataoka, K., 2005. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. 127, 1624–1625.

Oishi, M., Nagasaki, Y., Nishiyama, N., Itaka, K., Takagi, M., Shimamoto, A., Furuichi, Y., Kataoka, K., 2007. Enhanced growth inhibition of hepatic multicellular tumor spheroids by lactosylated poly(ethylene glycol)-siRNA conjugate formulated in PEGylated polyplexes. ChemMedChem 2, 1290–1297.

Ostomel, T.A., Shi, Q., Stoimenov, P.K., Stucky, G.D., 2007. Metal-oxide surface-charge mediated hemostasis. Langmuir 23, 11233–11238.

Ostomel, T.A., Shi, Q.H., Stucky, G.D., 2006a. Oxide hemostatic activity. J. Am. Chem. Soc. 128, 8384–8385.

Ostomel, T.A., Shi, Q.H., Tsung, C.K., Liang, H.J., Stucky, G.D., 2006b. Spherical bioactive glass with enhanced rates of hydroxyapatite deposition and hemostatic activity. Small 2, 1261–1265.

Ostomel, T.A., Stoimenov, P.K., Holden, P.A., Alam, H.B., Stucky, G.D., 2006c. Host-guest composites for induced hemostasis and therapeutic healing in traumatic injuries. J. Thromb. Thrombol. 22, 55–67.

Pagona, G., Tagmatarchis, N., 2006. Carbon nanotubes: materials for medicinal chemistry and biotechnological applications. Curr. Med. Chem. 13, 1789–1798.

Palmer, A.E., Jin, C., Reed, J.C., Tsien, R.Y., 2004. Bcl-2-mediated alterations in endoplasmic reticulum Ca^{2+} analyzed with an improved genetically encoded fluorescent sensor. Proc. Natl. Acad. Sci. U.S.A. 101, 17404–17409.

Palmieri, A., Brunelli, G., Guerzoni, L., Lo Muzio, L., Scarano, A., Rubini, C., Scapoli, L., Martinelli, M., Pezzetti, F., Carinci, F., 2007. Comparison between titanium and anatase miRNAs regulation. Nanomed. Nanotechnol. Biol. Med. 3, 138–143.

Pankhurst, Q.A., Connolly, J., Jones, S.K., Dobson, J., 2003. Applications of magnetic nanoparticles in biomedicine. J. Phys. D: Appl. Phys. 36, R167–R181.

Park, C.H., Kim, S.H., Choi, W., Lee, Y.J., Kim, J.S., Kang, S.S., Suh, Y.H., 1996. Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa. Planta Med. 62, 405–409.

Park, C.H., Lee, Y.J., Lee, S.H., Choi, S.H., Kim, H.S., Jeong, S.J., Kim, S.S., Suh, Y.H., 2000. Dehydroevodiamine HCl prevents impairment of learning and memory and neuronal loss in rat models of cognitive disturbance. J. Neurochem. 74, 244–253.

Park, J., Bauer, S., von der Mark, K., Schmuki, P., 2007. Nanosize and vitality: TiO$_2$ nanotube diameter directs cell fate. Nano Lett. 7, 1686–1691.

Park, J.W., Vahidi, B., Taylor, A.M., Rhee, S.W., Jeon, N.L., 2006. Microfluidic culture platform for neuroscience research. Nat. Protoc. 1, 2128–2136.

Park, S., Lim, J.-H., Chung, S.-W., Mirkin, C.A., 2004. Self-assembly of mesoscopic metal-polymer amphiphiles. Science 303, 348–351.

Park, S.Y., Lytton-Jean, A.K.R., Lee, B., Weigand, S., Schatz, G.C., Mirkin, C.A., 2008. DNA-programmable nanoparticle crystallization. Nature 451, 553–556.

Patil, S., Sandberg, A., Heckert, E., Self, W., Seal, S., 2007. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials 28, 4600–4607.

Pellegrini, M., Obrien, T.J., Hoy, J., Sedal, L., 1996. *Mycoplasma pneumoniae* infection associated with an acute brainstem syndrome. Acta Neurol. Scand. 93, 203–206.

Pellegrino, T., Kudera, S., Liedl, T., Javier, A.M., Manna, L., Parak, W.J., 2005. On the development of colloidal nanoparticles towards multifunctional structures and their possible use for biological applications. Small 1, 48–63.

Petersen, H., Fechner, P.M., Martin, A.L., Kunath, K., Stolnik, S., Roberts, C.J., Fischer, D., Davies, M.C., Kissel, T., 2002. Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system. Bioconj. Chem. 13, 845–854.

Petropoulos, A.E., Schaffer, B.K., Cheney, M.L., Enochs, S., Zimmer, C., Weissleder, R., 1995. MR-imaging of neuronal transport in the guinea-pig facial-nerve—initial findings. Acta Oto-Laryngol. 115, 512–516.

Pisanic, T.R., Blackwell, J.D., Shubayev, V.I., Finones, R.R., Jin, S., 2007. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 28, 2572–2581.

Prato, M., 1997. [60] Fullerene chemistry for materials science applications. J. Mater. Chem. 7, 1097–1109.

Priester, J.H., Horst, A.M., Van De Werfhorst, L.C., Saleta, J.L., Mertes, L.A.K., Holden, P.A., 2007. Enhanced visualization of microbial biofilms by staining and environmental scanning electron microscopy. J. Microbiol. Methods 68, 577–587.

Radloff, C., Vaia, R.A., Brunton, J., Bouwer, G.T., Ward, V.K., 2005. Metal nanoshell assembly on a virus bioscaffold. Nano Lett. 5, 1187–1191.

Radu, D.R., Lai, C.Y., Jeftinija, K., Rowe, E.W., Jeftinija, S., Lin, V.S.Y., 2004. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. J. Am. Chem. Soc. 126, 13216–13217.

Rajh, T., Chen, L.X., Lukas, K., Liu, T., Thurnauer, M.C., Tiede, D.M., 2002. Surface restructuring of nanoparticles: an efficient route for ligand-metal oxide crosstalk. J. Phys. Chem. B 106, 10543–10552.

Ramires, P.A., Cosentino, F., Milella, E., Torricelli, P., Giavaresi, G., Giardino, R., 2002. *In vitro* response of primary rat osteoblasts to titania/hydroxyapatite coatings compared with transformed human osteoblast-like cells. J. Mater. Sci. Mater. Med. 13, 797–801.

Razin, S., 1978. Mycoplasmas. Microbiol. Rev. 42, 414–470.

Razin, S., Yogev, D., Naot, Y., 1998. Molecular biology and pathogenicity of mycoplasmas. Microbiol. Mol. Biol. Rev. 62, 1094–1156.

Rieter, W.J., Kim, J.S., Taylor, K.M.L., An, H.Y., Lin, W.L., Tarrant, T., Lin, W.B., 2007a. Hybrid silica nanoparticles for multimodal imaging. Angew. Chem. Int. Ed. 46, 3680–3682.

Rieter, W.J., Taylor, K.M.L., An, H., Lin, W., Lin, W., 2006. Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents. J. Am. Chem. Soc. 128, 9024–9025.

Rieter, W.J., Taylor, K.M.L., Lin, W., 2007b. Surface modification and functionalization of nanoscale metal-organic frameworks for controlled release and luminescence sensing. J. Am. Chem. Soc. 129, 9852–9853.

Rinzler, A.G., Liu, J., Dai, H., Nikolaev, P., Huffman, C.B., Rodriguez-Macias, F.J., Boul, P.J., Lu, A.H., Heymann, D., Colbert, D.T., Lee, R.S., Fischer, J.E., Rao, A.M., Eklund, P.C., Smalley, R.E., 1998. Large-scale purification of single-wall carbon nanotubes: process, product, and characterization. Appl. Phys. A 67, 29–37.

Rock, J.P., Parsa, A.T., Rutka, J.T., 2005. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor—comments. Neurosurgery 57, 796–1796.

Roney, C., Kulkarni, P., Arora, V., Antich, P., Bonte, F., Wu, A.M., Mallikarjuana, N.N., Manohar, S., Liang, H.F., Kulkarni, A.R., Sung, H.W., Sairam, M., Aminabhavi, T.M., 2005. Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer's disease. J. Control. Release 108, 193–214.

Rosi, N.L., Giljohann, D.A., Thaxton, C.S., Lytton-Jean, A.K.R., Han, M.S., Mirkin, C.A., 2006. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 312, 1027–1030.

Rottem, S., Barile, M.F., 1993. Beware of mycoplasmas. Trends Biotechnol. 11, 143–151.

Rouquerol, J., Avnir, D., Fairbridge, C.W., Everett, D.H., Haynes, J.H., Pernicone, N., Ramsay, J.D.F., Sing, K.S.W., Unger, K.K., 1994. Recommendations for the characterization of porous solids. Pure Appl. Chem. 66, 1739–1758.

Roy, S.C., Paulose, M., Grimes, C.A., 2007. The effect of TiO$_2$ nanotubes in the enhancement of blood clotting for the control of hemorrhage. Biomaterials 28, 4667–4672.

Rubakhin, S.S., Garden, R.W., Fuller, R.R., Sweedler, J.V., 2000. Measuring the peptides in individual organelles with mass spectrometry. Nat. Biotechnol. 18, 172–175.

Rubakhin, S.S., Greenough, W.T., Sweedler, J.V., 2003. Spatial profiling with MALDI MS: distribution of neuropeptides within single neurons. Anal. Chem. 75, 5374–5380.

Rubakhin, S.S., Sweedler, J.V., 2007. Characterizing peptides in individual mammalian cells using mass spectrometry. Nat. Protoc. 2, 1987–1997.

Sakaguchi, K., Matsui, M., Mizukami, F., 2005. Applications of zeolite inorganic composites in biotechnology: current state and perspectives. Appl. Microbiol. Biotech. 67, 306–311.

Salem, A.K., Searson, P.C., Leong, K.W., 2003. Multifunctional nanorods for gene delivery. Nat. Mater. 2, 668–671.

Samori, B., Zuccheri, G., 2005. DNA codes for nanoscience. Angew. Chem. Int. Ed. 44, 1166–1181.

Sanchez, C., Lebeau, B., Chaput, F., Boilot, J.P., 2003. Optical properties of functional hybrid organic-inorganic nanocomposites. Adv. Mater. 15, 1969–1994.

Sano, N., Akazawa, H., Kikuchi, T., Kanki, T., 2003. Separated synthesis of iron-included carbon nanocapsules and nanotubes by pyrolysis of ferrocene in pure hydrogen. Carbon 41, 2159–2162.

Santra, S., Bagwe, R.P., Dutta, D., Stanley, J.T., Walter, G.A., Tan, W., Moudgil, B.M., Mericle, R.A., 2005a. Synthesis and characterization of fluorescent, radio-opaque, and paramagnetic silica nanoparticles for multimodal bioimaging applications. Adv. Mater. 17, 2165–2169.

Santra, S., Dutta, D., Walter, G.A., Moudgil, B.M., 2005b. Fluorescent nanoparticle probes for cancer imaging. Technol. Cancer Res. Treat. 4, 593–602.

Santra, S., Yang, H.S., Holloway, P.H., Stanley, J.T., Mericle, R.A., 2005c. Synthesis of water-dispersible fluorescent, radio-opaque, and paramagnetic CdS:Mn/ZnS quantum dots: a multifunctional probe for bioimaging. J. Am. Chem. Soc. 127, 1656–1657.

Sarikaya, M., Tamerler, C., Jen, A.K.Y., Schulten, K., Baneyx, F., 2003. Molecular biomimetics: nanotechnology through biology. Nat. Mater. 2, 577–585.

Sassolas, A., Leca-Bouvier, B.D., Blum, L.J., 2008. DNA biosensors and microarrays. Chem. Rev. 108, 109–139.

Satishkumar, B.C., Govindaraj, A., Rao, C.N.R., 1999. Bundles of aligned carbon nanotubes obtained by the pyrolysis of ferrocene-hydrocarbon mixtures: role of the metal nanoparticles produced in situ. Chem. Phys. Lett. 307, 158–162.

Satoh, M., Takayanag, I., 2006. Pharmacological studies on Fullerene(C-60), a novel carbon allotrope, and its derivatives. J. Pharmacol. Sci. 100, 513–518.

Sayes, C.M., Gobin, A.M., Ausman, K.D., Mendez, J., West, J.L., Colvin, V.L., 2005. Nano-C-60 cytotoxicity is due to lipid peroxidation. Biomaterials 26, 7587–7595.

Sayes, C.M., Wahi, R., Kurian, P.A., Liu, Y.P., West, J.L., Ausman, K.D., Warheit, D.B., Colvin, V.L., 2006. Correlating nanoscale titania structure with toxicity: a cytotoxicity and inflammatory response study with human dermal fibroblasts and human lung epithelial cells. Toxicol. Sci. 92, 174–185.

Schiffelers, R.M., Ansari, A., Xu, J., Zhou, Q., Tang, Q.Q., Storm, G., Molema, G., Lu, P.Y., Scaria, P.V., Woodle, M.C., 2004. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, 10.

Schmidt-Winkel, P., Lukens, W.W., Zhao, D.Y., Yang, P.D., Chmelka, B.F., Stucky, G.D., 1999. Mesocellular siliceous foams with uniformly sized cells and windows. J. Am. Chem. Soc. 121, 254–255.

Schubert, D., Dargusch, R., Raitano, J., Chan, S.W., 2006. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem. Biophys. Res. Commun. 342, 86–91.

Seeman, N.C., 2003. DNA in a material world. Nature 421, 427–431.

Seeman, N.C., 2005. From genes to machines: DNA nanomechanical devices. Trends Biochem. Sci. 30, 119–125.

Seferos, D.S., Giljohann, D.A., Rosi, N.L., Mirkin, C.A., 2007. Locked nucleic acid-nanoparticle conjugates. ChemBioChem 8, 1230–1232.

Shamah, S.M., Healy, J.M., Cload, S.T., 2008. Complex target SELEX. Acc. Chem. Res. 41, 130–138.

Shankar, S.S., Ahmad, A., Pasricha, R., Sastry, M., 2003. Bioreduction of chloroaurate ions by geranium leaves and its endophytic fungus yields gold nanoparticles of different shapes. J. Mater. Chem. 13, 1822–1826.

Shaw, S.Y., Westly, E.C., Pittet, M.J., Subramanian, A., Schreiber, S.L., Weissleder, R., 2008. Perturbational profiling of nanomaterial biologic activity. Proc. Natl. Acad. Sci. U.S.A. 105, 7387–7392.

Shvedova, A.A., Castranova, V., Kisin, E.R., Schwegler-Berry, D., Murray, A.R., Gandelsman, V.Z., Maynard, A., Baron, P., 2003. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J. Toxicol. Environ. Health. A 66, 1909–1926.

Silva, G.A., 2005. Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg. Neurol. 63, 301–306.

Silva, G.A., 2006. Neuroscience nanotechnology: progress, opportunities and challenges. Nat. Rev. Neurosci. 7, 65–74.

Simberg, D., Duza, T., Park, J.H., Essler, M., Pilch, J., Zhang, L.L., Derfus, A.M., Yang, M., Hoffman, R.M., Bhatia, S., Sailor, M.J., Ruoslahti, E., 2007. Biomimetic

amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. U.S.A. 104, 932–936.

Simonetti, A.B., Englert, G.E., Campos, K., Mergener, M., de David, C., de Oliveira, A.P., Roehe, P.M., 2007. Nanobacteria-like particles: a threat to cell cultures. Braz. J. Microbiol. 38, 153–158.

Sinani, V.A., Koktysh, D.S., Yun, B.G., Matts, R.L., Pappas, T.C., Motamedi, M., Thomas, S.N., Kotov, N.A., 2003. Collagen coating promotes biocompatibility of semiconductor nanoparticles in stratified LBL films. Nano Lett. 3, 1177–1182.

Singh, N., Liang, C.Y., Rzigalinski, B., 2006a. Antioxidant properties of cerium oxide nanoparticles. Free Radic. Biol. Med. 41, S152–S1152.

Singh, R., Pantarotto, D., Lacerda, L., Pastorin, G., Klumpp, C., Prato, M., Bianco, A., Kostarelos, K., 2006b. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc. Nat. Acad. Sci. 103, 3357–3362.

Slowing, I.I., Trewyn, B.G., Giri, S., Lin, V.S.Y., 2007. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv. Func. Mater. 17, 1225–1236.

Sokolova, V., Kovtun, A., Prymak, O., Meyer-Zaika, W., Kubareva, E.A., Romanova, E.A., Oretskaya, T.S., Heumann, R., Epple, M., 2007. Functionalisation of calcium phosphate nanoparticles by oligonucleotides and their application for gene silencing. J. Mater. Chem. 17, 721–727.

Son, S.J., Bai, X., Nan, A., Ghandehari, H., Lee, S.B., 2006. Template synthesis of multifunctional nanotubes for controlled release. J. Control. Release 114, 143–152.

Song, C.X., Labhasetwar, V., Murphy, H., Qu, X., Humphrey, W.R., Shebuski, R.J., Levy, R.J., 1997. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J. Control. Release 43, 197–212.

Song, H.T., Choi, J.S., Huh, Y.M., Kim, S., Jun, Y.W., Suh, J.S., Cheon, J., 2005. Surface modulation of magnetic nanocrystals in the development of highly efficient magnetic resonance probes for intracellular labeling. J. Am. Chem. Soc. 127, 9992–9993.

Soto, K., Garza, K.M., Murr, L.E., 2007. Cytotoxic effects of aggregated nanomaterials. Acta Biomater. 3, 351–358.

Soto, K.F., Carrasco, A., Powell, T.G., Garza, K.M., Murr, L.E., 2005. Comparative *in vitro* cytotoxicity assessment of some manufactured nanoparticulate materials characterized by transmission electron microscopy. J. Nanopart. Res. 7, 145–169.

Spagnou, S., Miller, A.D., Keller, M., 2004. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43, 13348–13356.

Stoltenburg, R., Reinemann, C., Strehlitz, B., 2007. SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 24, 381–403.

Strawn, E.T., Cohen, C.A., Rzigalinski, B.A., 2006. Cerium oxide nanoparticles increase lifespan and protect against free radical-mediated toxicity. FASEB J. 20, A1356–A11356.

Suh, W.H., Jang, A.R., Lee, C.S., Suh, Y.H., Suslick, K.S., 2006a. Endocytosis of magnetic microspheres into cells. Microsc. Microanal. S-02, 620–621.

Suh, W.H., Jang, A.R., Suh, Y.H., Suslick, K.S., 2006b. Porous, hollow, and ball-in-ball metal oxide microspheres: preparation, endocytosis, and cytotoxicity. Adv. Mater. 18, 1832–1837.

Suh, W.H., Suslick, K.S., Suh, Y.-H., 2005. Therapeutic agents for Alzheimer's disease. Curr. Med. Chem.: Cent. Nerv. Sys. Agen. 5, 259–269.

Suh, Y.H., Checler, F., 2002. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 54, 469–525.

Sui, J., Tleugabulova, D., Brennan, J.D., 2005. Direct and indirect monitoring of peptide-silica interactions using time-resolved fluorescence anisotropy. Langmuir 21, 4996–5001.

Sun, J., DuFort, C., Daniel, M.C., Murali, A., Chen, C., Gopinath, K., Stein, B., De, M., Rotello, V.M., Holzenburg, A., Kao, C.C., Dragnea, B., 2007. Core-controlled polymorphism in virus-like particles. Proc. Natl. Acad. Sci. U.S.A. 104, 1354–1359.

Suslick, K.S., Grinstaff, M.W., 1990. Protein microencapsulation of nonaqueous liquids. J. Am. Chem. Soc. 112, 7807–7809.

Swan, E.E.L., Popat, K.C., Desai, T.A., 2005a. Peptide-immobilized nanoporous alumina membranes for enhanced osteoblast adhesion. Biomaterials 26, 1969–1976.

Swan, E.E.L., Popat, K.C., Grimes, C.A., Desai, T.A., 2005b. Fabrication and evaluation of nanoporous alumina membranes for osteoblast culture. J. Biomed. Mater. Res. Part A 72A, 288–295.

Sykova, E., Jendelova, P., 2007. Migration, fate and *in vivo* imaging of adult stem cells in the CNS. Cell Death Differ. 14, 1336–1342.

Takayama, S., McDonald, J.C., Ostuni, E., Liang, M.N., Kenis, P.J.A., Ismagilov, R.F., Whitesides, G.M., 1999. Patterning cells and their environments using multiple laminar fluid flows in capillary networks. Proc. Natl. Acad. Sci. U.S.A. 96, 5545–5548.

Tang, G.P., Zeng, J.M., Gao, S.J., Ma, Y.X., Shi, L., Li, Y., Too, H.P., Wang, S., 2003. Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. Biomaterials 24, 2351–2362.

Tang, Z.Y., Kotov, N.A., 2005. One-dimensional assemblies of nanoparticles: preparation, properties, and promise. Adv. Mater. 17, 951–962.

Tansil, N.C., Gao, Z.Q., 2006. Nanoparticles in biomolecular detection. Nano Today 1, 28–37.

Tarnuzzer, R.W., Colon, J., Patil, S., Seal, S., 2005. Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage. Nano Lett. 5, 2573–2577.

Taylor, A.M., Blurton-Jones, M., Rhee, S.W., Cribbs, D.H., Cotman, C.W., Jeon, N.L., 2005. A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat. Methods 2, 599–605.

Taylor, J.R., Fang, M.M., Nie, S.M., 2000. Probing specific sequences on single DNA molecules with bioconjugated fluorescent nanoparticles. Anal. Chem. 72, 1979–1986.

Terrones, M., Grobert, N., Olivares, J., Zhang, J.P., Terrones, H., Kordatos, K., Hsu, W.K., Hare, J.P., Townsend, P.D., Prassides, K., Cheetham, A.K., Kroto, H.W., Walton, D.R.M., 1997. Controlled production of aligned-nanotube bundles. Nature 388, 52–55.

Thess, A., Lee, R., Nikolaev, P., Dai, H.J., Petit, P., Robert, J., Xu, C.H., Lee, Y.H., Kim, S.G., Rinzler, A.G., Colbert, D.T., Scuseria, G.E., Tomanek, D., Fischer, J.E., Smalley, R.E., 1996. Crystalline ropes of metallic carbon nanotubes. Science 273, 483–487.

Thill, A., Zeyons, O., Spalla, O., Chauvat, F., Rose, J., Auffan, M., Flank, A.M., 2006. Cytotoxicity of CeO$_2$ nanoparticles for *Escherichia coli*. Physico-chemical insight of the cytotoxicity mechanism. Environ. Sci. Tech. 40, 6151–6156.

Thorek, D.L.J., Chen, A., Czupryna, J., Tsourkas, A., 2006. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann. Biomed. Eng. 34, 23–38.

Tischer, W., Wedekind, F. Immobilized enzymes : methods and applications. Boehringer Mannheim GmbH, Penzberg, Germany. Topics in Current Chemistry (1999), vol. 200 (Biocatalysis: From Discovery to Application), Springer-Verlag, pp. 95–126, CODEN: TPCCAQ, ISSN: 0340-1022.

Tominaga, H., Ishiyama, M., Ohseto, F., Sasamoto, K., Hamamoto, T., Suzuki, K., Watanabe, M., 1999. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal. Commun. 36, 47–50.

Torney, F., Trewyn, B.G., Lin, V.S.Y., Wang, K., 2007. Mesoporous silica nanoparticles deliver DNA and chemicals into plants. Nat. Nanotechnol. 2, 295–300.

Trovarelli, A., 1996. Catalytic properties of ceria and CeO$_2$-containing materials. Catal. Rev.: Sci. Eng. 38, 439–520.

Tsay, J.M., Michalet, X., 2005. New light on quantum dot cytotoxicity. Chem. Biol. 12, 1159–1161.

Tsiodras, S., Kelesidis, I., Kelesidis, T., Stamboulis, E., Giamarellou, H., 2005. Central nervous system manifestations of *Mycoplasma pneumoniae* infections. J. Infect. 51, 343–354.

Tu, R.S., Tirrell, M., 2004. Bottom-up design of biomimetic assemblies. Adv. Drug Deliv. Rev. 56, 1537–1563.

Turkez, H., Geyikoglu, F., 2007. An *in vitro* blood culture for evaluating the genotoxicity of titanium dioxide: the responses of antioxidant enzymes. Toxicol. Ind. Health 23, 19–23.

The Nanotoxicology Research and Training Program. http://www.cnsi.ucla.edu/staticpages/education/nanotox-program (accessed October 2007).

Underhill, G.H., Bhatia, S.N., 2007. High-throughput analysis of signals regulating stem cell fate and function. Curr. Opin. Chem. Biol. 11, 357–366.

Veiseh, O., Sun, C., Gunn, J., Kohler, N., Gabikian, P., Lee, D., Bhattarai, N., Ellenbogen, R., Sze, R., Hallahan, A., Olson, J., Zhang, M.Q., 2005. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett. 5, 1003–1008.

Vlasov, Y.A., Bo, X.Z., Sturm, J.C., Norris, D.J., 2001. On-chip natural assembly of silicon photonic bandgap crystals. Nature 414, 289–293.

Voura, E.B., Jaiswal, J.K., Mattoussi, H., Simon, S.M., 2004. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nature Med. 10, 993–998.

Wadghiri, Y.Z., Sigurdsson, E.M., Sadowski, M., Elliott, J.I., Li, Y.S., Scholtzova, H., Tang, C.Y., Aguinaldo, G., Pappolla, M., Duff, K., Wisniewski, T., Turnbull, D.H., 2003. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 50, 293–302.

Waites, K.B., Talkington, D.F., 2004. *Mycoplasma pneumoniae* and its role as a human pathogen. Clin. Microbiol. Rev. 17, 697–728.

Wang, J., 2005. Nanomaterial-based amplified transduction of biomolecular interactions. Small 1, 1036–1043.

Wang, J.J., Sanderson, B.J.S., Wang, H., 2007a. Cyto- and genotoxicity of ultrafine TiO$_2$ in cultured human lymphoblastoid cells. Mutat. Res.: Genet. Toxicol. Environ. Mutagen. 628, 99–106.

Wang, J.X., Zhou, G.Q., Chen, C.Y., Yu, H.W., Wang, T.C., Ma, Y.M., Jia, G., Gao, Y.X., Li, B., Sun, J., Li, Y.F., Jiao, F., Zhao, Y.L., Chai, Z.F., 2007b. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol. Lett. 168, 176–185.

Wang, Y.X.J., Hussain, S.M., Krestin, G.P., 2001. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol. 11, 2319–2331.

Ware, C.B., Nelson, A.M., Blau, C.A., 2006. A comparison of NIH-approved human ESC lines. Stem Cells 24, 2677–2684.

Warheit, D.B., Webb, T.R., Colvin, V.L., Reed, K.L., Sayes, C.R., 2007. Pulmonary bioassay studies with nanoscale and fine-quartz particles in rats: toxicity is not dependent upon particle size but on surface characteristics. Toxicol. Sci. 95, 270–280.

Warheit, D.B., Webb, T.R., Sayes, C.M., Colvin, V.L., Reed, K.L., 2006. Pulmonary instillation studies with nanoscale TiO$_2$ rods and dots in rats: toxicity is not dependent upon particle size and surface area. Toxicol. Sci. 91, 227–236.

Wei, G.B., Jin, Q.M., Giannobile, W.V., Ma, P.X., 2006. Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. J. Control. Release 112, 103–110.

Wei, G.B., Pettway, G.J., McCauley, L.K., Ma, P.X., 2004. The release profiles and bioactivity of parathyroid hormone from poly(lactic-co-glycolic acid) microspheres. Biomaterials 25, 345–352.

Weibel, D.B., DiLuzio, W.R., Whitesides, G.M., 2007. Microfabrication meets microbiology. Nat. Rev. Microbiol. 5, 209–218.

Weissleder, R., Kelly, K., Sun, E.Y., Shtatland, T., Josephson, L., 2005. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23, 1418–1423.

Weissleder, R., Mahmood, U., 2001. Molecular imaging. Radiology 219, 316–333.

Weissleder, R., Stark, D.D., Engelstad, B.L., Bacon, B.R., Compton, C.C., White, D.L., Jacobs, P., Lewis, J., 1989. Superparamagnetic iron-oxide—pharmacokinetics and toxicity. Am. J. Roentgenol. 152, 167–173.

Wernette, D.P., Liu, J.W., Bohn, P.W., Lu, Y., 2008. Functional-DNA-based nanoscale materials and devices for sensing trace contaminants in water. MRS Bull. 33, 34–41.

What is carbon black? http://carbon-black.org/what_is.html (accessed January 2008).

Whitesides, J.G., Lamantia, A.S., 1995. Distinct adhesive behaviors of neurons and neural precursor cells during regional differentiation in the mammalian forebrain. Dev. Biol. 169, 229–241.

Wiesner, M.R., 2006. Responsible development of nanotechnologies for water and wastewater treatment. Water Sci. Technol. 53, 45–51.

Wigginton, N.S., Haus, K.L., Hochella, M.F., 2007. Aquatic environmental nanoparticles. J. Environ. Monit. 9, 1306–1316.

Wu, P.C., Wang, W.S., Huang, Y.T., Sheu, H.S., Lo, Y.W., Tsai, T.L., Shieh, D.B., Yeh, C.S., 2007. Porous iron oxide based nanorods developed as delivery nanocapsules. Chem. Eur. J. 13, 3878–3885.

Xia, T., Kovochich, M., Brant, J., Hotze, M., Sempf, J., Oberley, T., Sioutas, C., Yeh, J.I., Wiesner, M.R., Nel, A.E., 2006a. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 6, 1794–1807.

Xia, Y.D., Yang, Z.X., Mokaya, R., 2006b. Simultaneous control of morphology and porosity in nanoporous carbon: graphitic mesoporous carbon nanorods and nanotubules with tunable pore size. Chem. Mater. 18, 140–148.

Xu, C.J., Sun, S.H., 2007. Monodisperse magnetic nanoparticles for biomedical applications. Polymer Int. 56, 821–826.

Xu, C.J., Xu, K.M., Gu, H.W., Zhong, X.F., Guo, Z.H., Zheng, R.K., Zhang, X.X., Xu, B., 2004. Nitrilotriacetic acid-modified magnetic nanoparticles as a general agent to bind histidine-tagged proteins. J. Am. Chem. Soc. 126, 3392–3393.

Yamamoto, A., Honma, R., Sumita, M., Hanawa, T., 2004. Cytotoxicity evaluation of ceramic particles of different sizes and shapes. J. Biomed. Mater. Res. Part A 68A, 244–256.

Yamawaki, H., Iwai, N., 2006. Cytotoxicity of water-soluble fullerene in vascular endothelial cells. Am. J. Physiol. Cell. Physiol. 290, C1495–C1502.

Yan, A.H., Lau, B.W., Weissman, B.S., Kulaots, I., Yang, N.Y.C., Kane, A.B., Hurt, R.H., 2006. Biocompatible, hydrophilic, supramolecular carbon nanoparticles for cell delivery. Adv. Mater. 18, 2373–2378.

Yan, J.L., Estevez, M.C., Smith, J.E., Wang, K.M., He, X.X., Wang, L., Tan, W.H., 2007. Dye-doped nanoparticles for bioanalysis. Nano Today 2, 44–50.

Yang, P.D., Deng, T., Zhao, D.Y., Feng, P.Y., Pine, D., Chmelka, B.F., Whitesides, G.M., Stucky, G.D., 1998. Hierarchically ordered oxides. Science 282, 2244–2246.

Yang, H.S., Santra, S., Walter, G.A., Holloway, P.H., 2006a. Gd-III-functionalized fluorescent quantum dots as multimodal imaging probes. Adv. Mater. 18, 2890–2894.

Yang, J., Lee, C.-H., Park, J., Seo, S., Lim, E.-K., Song, Y.J., Suh, J.-S., Yoon, H.-G., Huh, Y.-M., Haam, S., 2007. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J. Mater. Chem. 17, 2695–2699.

Yang, K., Zhu, L.Z., Xing, B.S., 2006b. Adsorption of polycyclic aromatic hydrocarbons by carbon nanomaterials. Environ. Sci. Tech. 40, 1855–1861.

Yeo, Y., Park, K., 2004. A new microencapsulation method using an ultrasonic atomizer based on interfacial solvent exchange. J. Control. Release 100, 379–388.

Ying, J.Y., Mehnert, C.P., Wong, M.S., 1999. Synthesis and applications of supramolecular-templated mesoporous materials. Angew. Chem. Int. Ed. 38, 56–77.

Yoon, S.B., Chai, G.S., Kang, S.K., Yu, J.S., Gierszal, K.P., Jaroniec, M., 2005. Graphitized pitch-based carbons with ordered nanopores synthesized by using colloidal crystals as templates. J. Am. Chem. Soc. 127, 4188–4189.

Yoon, S.B., Sohn, K., Kim, J.Y., Shin, C.H., Yu, J.S., Hyeon, T., 2002. Fabrication of carbon capsules with hollow macroporous core/mesoporous shell structures. Adv. Mater. 14, 19–21.

Yoshida, K., Morita, M., Mishina, H., 2003. Cytotoxicity of metal and ceramic particles in different sizes. JSME Int. J. C: Mech. Syst. 46, 1284–1289.

Yu, S.J., Kang, M.W., Chang, H.C., Chen, K.M., Yu, Y.C., 2005. Bright fluorescent nanodiamonds: no photobleaching and low cytotoxicity. J. Am. Chem. Soc. 127, 17604–17605.

Yuan, X.D., Li, L., Rathinavelu, A., Hao, J.S., Narasimhan, M., He, M., Heitlage, V., Tam, L., Viqar, S., Salehi, M., 2006. siRNA drug delivery by biodegradable polymeric nanoparticles. J. Nanosci. Nanotech. 6, 2821–2828.

Z-Medica QuikClot. http://www.z-medica.com/quikclot/index.asp.

Z-Medica Quikclot Sport™ Silver. http://www.z-medica.com/products/quikclot_-sport.asp.

Zaremba, C.M., Belcher, A.M., Fritz, M., Li, Y.L., Mann, S., Hansma, P.K., Morse, D.E., Speck, J.S., Stucky, G.D., 1996. Critical transitions in the biofabrication of abalone shells and flat pearls. Chem. Mater. 8, 679–690.

Zdravkov, B.D., Cermak, J.J., Sefara, M., Janku, J., 2007. Pore classification in the characterization of porous materials: a perspective. Cent. Eur. J. Chem. 5, 385–395.

Zhang, S.G., Yan, L., Altman, M., Lassle, M., Nugent, H., Frankel, F., Lauffenburger, D.A., Whitesides, G.M., Rich, A., 1999. Biological surface engineering: a simple system for cell pattern formation. Biomaterials 20, 1213–1220.

Zhang, T.T., Stilwell, J.L., Gerion, D., Ding, L.H., Elboudwarej, O., Cooke, P.A., Gray, J.W., Alivisatos, A.P., Chen, F.F., 2006. Cellular effect of high doses of silica-coated quantum dot profiled with high throughput gene expression analysis and high content cellomics measurements. Nano Lett. 6, 800–808.

Zhang, Y.J., Wang, S.P., Eghtedari, M., Motamedi, M., Kotov, N.A., 2005. Inverted-colloidal-crystal hydrogel matrices as three-dimensional cell scaffolds. Adv. Func. Mater. 15, 725–731.

Zhao, D.Y., Feng, J.L., Huo, Q.S., Melosh, N., Fredrickson, G.H., Chmelka, B.F., Stucky, G.D., 1998a. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. Science 279, 548–552.

Zhao, D.Y., Huo, Q.S., Feng, J.L., Chmelka, B.F., Stucky, G.D., 1998b. Nonionic triblock and star diblock copolymer and oligomeric surfactant syntheses of highly ordered, hydrothermally stable, mesoporous silica structures. J. Am. Chem. Soc. 120, 6024–6036.

Zhao, X.J., Zhang, S.G., 2006. Molecular designer self-assembling peptides. Chem. Soc. Rev. 35, 1105–1110.

Zhelev, Z., Ohba, H., Bakalova, R., 2006. Single quantum dot-micelles coated with silica shell as potentially non-cytotoxic fluorescent cell tracers. J. Am. Chem. Soc. 128, 6324–6325.

Zheng, M., Jagota, A., Strano, M.S., Santos, A.P., Barone, P., Chou, S.G., Diner, B.A., Dresselhaus, M.S., McLean, R.S., Onoa, G.B., Samsonidze, G.G., Semke, E.D., Usrey, M., Walls, D.J., 2003. Structure-based carbon nanotube sorting by sequence-dependent DNA assembly. Science 302, 1545–1548.

Zhu, L., Chang, D.W., Dai, L., Hong, Y., 2007. DNA damage induced by multiwalled carbon nanotubes in mouse embryonic stem cells. Nano Lett. 7, 3592–3597.

Zhu, S.Q., Oberdorster, E., Haasch, M.L., 2006. Toxicity of an engineered nanoparticle (fullerene, C-60) in two aquatic species, Daphnia and fathead minnow. Mar. Environ. Res. 62, S5–S9.